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Abstract
Malaria and Human African Trypanosomiasis are vector borne protozoan para-
sitic diseases. Resistance to current treatments is widespread with many historical
treatments becoming obsolete and ineffective or contain impracticable treatment
regimes. N -Myristoyltransferase (NMT) inhibition is being targeted towards such
diseases. This project developed a structure-activity investigation into transition
state mimetic inhibitors of NMT and demonstrated their activity towards T.
brucei and two strains of P. falciparum.
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The initial investigation synthesised a simplified transition state mimetic 108
from myristic acid using protecting group strategies. The hydroxyamine scaffold
contained on hydroxyamine 109 was consequently present in numerous other
derivatives. The structure-activity investigation successfully demonstrated that
the activity towards T. brucei and P. falciparum is due to the key features of the
hydroxyamine 109.
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The project investigated the introduction of fragments from HMG-reductase in-
hibitors into the hydroxyamine scaffold. A cerium acetylide addition reaction
was used to gain access to a series of tertiary alcohol derivatives and reductive
aminations to make the amine derivatives. Early synthetic HMG-reductase in-
hibitors were incorporated to investigate their activity towards T. brucei and P.
falciparum by inhibition of NMT.
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Derivatives were also developed that included alkene and phenoxy variation of the
myristoyl chain, which built on the chemistry used to generate the hydroxyamine
109. However, derivatisation did not improve the selectivity and potency profile
of the parent hydroxyamine 109.
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Chapter 1
Introduction
The inhibition of N -Myristoyltransferase (NMT) is being targeted as treatments
for fungal, protozoan and viral diseases. NMT uses a myristoylated Co-enzyme
A (CoA) substrate during it catalytic cycle. The transition state intermediate
1 present during the catalytic cycle is shown in Figure 1.1. A compound that
mimics 1 would give rise to a new group of inhibitors that combine three aspects
of the intermediate; the peptide, CoA and myristoyl chain. Mimetics of CoA
are known, and have been used in the inhibition of 3-hydroxy-3-methylglutaryl-
CoA (HMG-CoA) reductase to control cholesterol biosynthesis. This led to the
development of the HMG-reductase inhibitors, the statins, that are HMG-CoA
2 mimetics and blockbuster pharmaceutical drugs. Statins (e.g. fluvastatin 3)
contain two regions; a HMG mimetic and a hydrophobic portion that binds into
an area of HMG-CoA reductase where Co-Enzyme A would be located. The
purpose of this project is to develop a NMT transition state mimetic which may
incorporate aspects of the statins and applying them towards the inhibition of
NMT. The hypothetical compound 4 combines critical areas of the myristoyl-
CoA intermediate 1 with fluvastatin. This project will investigate the structure-
activity relationships of compounds such as 4 in relation to activity against T.
brucei and P. falciparum.
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Figure 1.2: The reaction catalysed by NMT and the formation of its
substrate Myristoyl-CoA 5 catalysed by Acyl-CoA synthase
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1.1 N -Myristoyltransferase (NMT)
N -Myristoyltransferases are enzymes responsible for modifying specific proteins
by covalent attachment of myristic acid (Figure 1.2). N -Myristoylation occurs
at the glycinyl N -terminus of specific targeted peptides 8. Myristoyl-CoA, the
NMT substrate, is the product of the substitution reaction between CoA and
Myristic acid, catalysed by Acyl-CoA synthase. NMT catalyses thioester cleav-
age of Myristoyl-CoA 5 and directs the substitution of the peptide substrate.
Although the biological functions of myristoylated peptides are complex, it is
well understood that the hydrophobic myristoyl chain can anchor the peptide
into the lipid bilayer.
NMT exists in all eukaryotic cellular organisms1 and are related to the GCN5
superfamily of enzymes.2,3 Significant genetic variance exists between species ex-
pressing NMT with significant genetic variation depending on the source organ-
ism. As a consequence of genetic variation, NMT inhibitors have been widely
studied in an effort to exploit selectivity towards various therapeutic targets,
without adverse human toxicity. Currently there are no licensed NMT inhibitors
in the clinical domain.
NMT was first isolated from Saccharomyces cerevisiae and its catalytic kinet-
ics were established using reverse phase HPLC.4 Rudnick et al. showed that
myristoyl-CoA binds to NMT prior to the peptide recognition. After catalysis
NMT has little affinity for CoA, releasing it before the myristoylated peptide. The
mechanistic study confirmed the stability of NMT-Myristoyl-CoA complex and
its Bi-Bi ordered mode of action (Figure 1.3). The first three dimensional struc-
ture of Candida albicans NMT (caNMT5) was resolved in 1998 closely followed
by Saccharomyces cerevisiae NMT (scNMT6) and provided the first structural
analysis and mechanistic description of the catalytic mode of action of NMT.
The active site of NMT contains 4 distinct regions that act synergistically (Fig-
ure 1.4A). A deep hydrophobic pocket extends the length of NMT and provides
internalisation and stabilisation of the myristoyl chain. Bhatnagar et al. crystal-
lised ScNMT with S -(2-oxo)pentadecyl-CoA 9 (originally synthesised by Zheng
et al.7) . S -(2-oxo)pentadecyl-CoA 9 has a non-cleavable methylene between car-
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Figure 1.3: Sequential Ordered Bi-Bi Mechanism of
N -myristoyltransferase4
bonyl and sulphur atoms of the thioester contained on myristoyl-CoA and is a
potent inhibitor of NMT (Figure 1.4C). The hydrophobic residues and the dis-
tinctive bent shape of the myristoyl pocket, along with the Co-A portion were
identified by understanding the binding mechanism of S -(2-oxo)pentadecyl-CoA
9 (Figure 1.4C). The selectivity of NMT to C14 fatty acids was attributed to Van
der waals interactions between the Trp 200 and His 201 residues at the end of the
hydrophobic pocket. A conformational change was proposed during the myristoyl
CoA binding event that would enable peptide recognition and catalysis.
ScNMT induces the nucleophilic addition-elimination reaction by carbonyl ac-
tivation of the thioester on myristoyl-CoA, through hydrogen bonding with the
amide groups of Phe 170 and Leu 171 residues within a oxyanion hole (Fig-
ure 1.5A). Bhatnagar et al. also provided evidence of the role of the carboxylate
C-terminus of ScNMT, through activation by deprotonation of the N-terminus of
GLY peptide substrate (Figure 1.5A) and enhancing its reactivity by improving
its nucleophilicity.
ScNMT was widely studied and later Farazi et al. confirmed the mechanism
4
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Figure 1.4: A) A schematic of the active site of NMT; B) Compariason of
Myristoyl-CoA conformation from differant source organisms8 (reproduced);
C) Structural binding mechanism of myristoyl CoA7(reproduced).
by describing an Ab loop conformation change, after the Myristoyl-CoA binding
event.9 This conformational change frees a portion of the peptide binding site,
confirming the Bi-Bi mechanism previously reported. Farazi et al. also expan-
ded that structural mechanism of action by describing the stabilisation effects
caused by residues Asn 169 and Thr 205 after the peptide substrates glycine N-
terminus is activated by deprotonation (Figure 1.5A). Wu et al. later described
the importance of the N-terminus region of NMT though stabilisation effects of
the Ab loop conformation change after myristoyl-CoA binding, and the specific
N-terminus region interactions that ScNMT has with Myristoyl-CoA.10 Several
crystal structures of NMT have been published from different organisms, but even
with significant genetic variations existing between NMT from different organ-
ism little differences are observed in the binding mechanism and conformation of
myristoyl-CoA (Figure 1.4B).
NMT myristoylates numerous peptide substrates which have a wide range of sec-
ondary functions. The NMT-peptide substrate recognition event mechanism is
significantly more complex compared with NMT-myristoyl-CoA recognition and
varies greatly between NMTs from different organisms. Evidence that myris-
toylation is totally selective to the Glycine N-terminus substrate was provided by
5
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Figure 1.5: A) Structural enzymatic mechanism of ScNMT (reproduced9);
B) Crystal structure containing Myristoyl-CoA 5 of ScNMT from 2P6E10;
C) Full describtion of Myristoyl-CoA 5 binding mechanism (reproduced10).
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synthetic octapeptide studies11 and significant genetic similarities exist in NMT
between species in the peptide substrate binding region.12 Peptidic inhibitors
and their mode of action will be discussed in some detail, but full analysis of the
peptide substrate recognition events is outside the scope of this project.
1.2 Applications of preclinical NMT inhibitors
Historically, inhibitors of NMT have been developed as anti-fungal agents. Re-
search has progressed in the development of NMT inhibitors towards a variety of
other targets including, but not limited to protozoan, viral and fungal infections.
Other inhibitors of NMT are beyond the scope of this project. No clinically avail-
able NMT inhibitors are licensed and a new clinically available NMT inhibitor
would be a new class of medicine.
Fungal infections
The kingdom of fungi has been estimated, with significant debate, to contain 1.5
million species.13 Approximately 70,000 species have been formally characterised
with about 300 being virulent to humans14 with risks postulated to increase with
rises in global ambient temperatures.15 Cryptococcal meningitis is caused by the
fungi Cryptococcus and results in 625,000 deaths each year mainly occurring in
sub Saharan Africa.16,17 Histoplasmosis is a opportunistic fungal infection caused
by Histoplasma capsulatum that has a mortality rate of 20 - 40% in immun-
ocompromised patients, often misdiagnosed as tuberculosis.18 Fungal infections
are harder to treat than bacterial as both fungal and human cells are eukaryotic,
often leading to excessive toxicity.
There are four major classes of anti-fungals that are clinically utilised. The
polyenes were developed early and include amphotericin B 10, also active against
Leishmaniasis, which shows activity by disrupting fungi membrane functions.
Naftifine 11 is a member of the allyl amine class of anti-fungals which show
activity by inhibition of the fungal enzyme squalene epoxidase, but toxic meta-
bolites of naftifine limit its use to topical applications. The azoles are the largest
7
Figure 1.6: Left:Cryptococcosis of the lung using mucicarmine stain.
Centre: Candida albicans fungal organisms. Right: Histopathologic changes
associated with a fungal infection with Candida albicans. (reproduced19).
class exemplified by fluconazole 12 which disrupts ergosterol biosynthesis through
inhibition of the 14α-demethylase. Caspofungin 13, within the newly developed
Echinocandin class of anti-fungals, disrupt cell wall biosynthesis through inhib-
ition of the enzyme β-1,3-glucan synthase.20 Early NMT inhibitors have been
demonstrated as anti-fungal agents.
Myristic acid analogues show moderate anti-fungal properties (Table 1.2.1). 4-
Oxatetradecanoic acid 14 was found to have fungicidal properties and its mechan-
ism of action was determined by efficient incorporation into peptides, disrupting
downstream functions.21 2-substituted myristic analogues 15, 16, 17 and 18 were
shown to have anti-fungal activity.22 The mechanism of action was not demon-
strated but competitive inhibition is plausible. 2-Methoxymyristric acid 19 was
also shown to be an anti-fungal agent but its mechanism of action was also never
concluded.23,24
Peptomimetics targeting the peptide binding site were based on the octapeptide
substrate 22.25 A series of NMT inhibitors were developed as anti-fungals with
structures exemplified by the dipeptide 23.26 The dipeptide 23 shows over 200-
fold selectivity to CaNMT compared to HsNMT but had a low in vivo toxicity to-
wards to C. albicans despite nano-molar potency to CaNMT.27 It was postulated
that compounds such as 23 suffered from transport or metabolism difficulties.
The peptidic backbone contained on 23 was modified and 24 was developed.28
The amide 24 reserved the key structural features of 23 and improved its in vivo
activity. Other strategies towards NMT inhibition were also being explored as
anti-fungal agents.
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Figure 1.7: Commonly utilised antifungals amphotericin B10, naftifine 11,
fluconazole 12 and caspofungin 13.
Table 1.2.1: Analogues of myristic acid with anti-fungal properties.22–24
CH3(CH2)9
X OR2
O
R1
Myristic X R1 R2
MIC (mM)
acid analogue C.albicans N.neoforms
14 O H H ND ND
15 CH2 OH H >5 >5
16 CH2 Br H 0.04 0.02
17 CH2 Cl H 0.59 0.04
18 CH2 Br CH3 >5 1.9
19 CH2 OCH3 H 0.11 0.11
20 O OCH3 H 3.5 0.08
21 S OCH3 H 1.24 1.24
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Figure 1.8: Peptomimetic inhibitors of NMT.25,27,28
The benzofuran 25 was discovered through an industry screening of CaNMT in-
hibitors.29 The known beta-blocking activity of 25 was removed by elimination
of its ß-amino alcohol moiety. The new lead 26 had sub micro-molar activity,
excellent in vitro selectivity and showed promising anti-fungal activity against
C.albicans achieving in vitro activities similar to the fluconazole. The crys-
tal structure of CaNMT containing a benzofuran inhibitor was solved and it
linked the importance of the amine containing C4 side chain with specific peptide
residues.30 The low in vivo activity of 26 was attributed to a short half life due
to its hydrolysable ester.31 Swapping the C1 substitution to a non-hydrolysable
ether exemplified in 27 improved the half life and potency. Despite the nano-
molar potency and excellent selectivity 27 showed a modest in vivo anti-fungal
activity with ED50 7.1 mg/kg compared to that fluconazole ED50 of 0.5 mg/kg
in the same rat model.32,33
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Figure 1.9: CaNMT inhibitors developed as antifungal agents.30–33
Protozoan Infections
Human African Trypanosomiasis
Human African Trypanosomiasis (HAT), or sleeping sickness, is a parasitic dis-
ease caused by infection with the protozoa Trypanosoma brucei (T.b) gambiense
or T.b. rhodesiense. HAT occurs in 36 sub-Saharan African countries and T.b
gambiense is responsible 98 % of reported cases.34 The primary vector of the dis-
ease is infection from the bite of an infected tsetse fly. The first clinical symptoms
occur 1-2 years from infection and if left untreated can cause death in about 3
years.35 Recurring outbreaks have occurred in the past century with the most
recent epidemic coming to a end in the late 1990s and in 2009 worldwide cases
dropped below 10 000. The decline in cases was confirmed with only 6314 repor-
ted in 2013.34 Despite the gradual decline in the number of reported cases several
gaps exist in the current clinical strategy for the treatment of HAT.
Stage one treatments, effective before Trypanosoma brucei crosses the blood-brain
barrier, are limited with only suramin 28 effective against T.b. rhodesiense and
Pentamidine 29 against T.b. gambiense. Suramin 28 has excessive toxicity37
and pentamidine 29 is the preferred treatment at the early stages of infection.
Stage two treatments, applied once Trypanosoma brucei crosses the blood-brain
barrier, require alternative clinical strategies. Melarsoprol 30, an arsenic con-
taining compound is the first line treatment against T.b. rhodesiense despite
11
Figure 1.10: Trypanosoma brucei in thin blood smears stained with
giemsa. Center: A close up of a tsetse fly (reproduced36).
excessive toxicity and being fatal in a small number of treatments. Eflornithine
31 is significantly less toxic but is only effective against T.b. gambiense. In 2009,
co-administered intravenous eflornithine 31 with oral nifurtimox 32 (Trypano-
soma cruzi / Chagas treatment) was approved for clinical use. The combination
therapy is now listed on the WHO list of essential medicine and treatment kits
are donated by Sanofi and Bayer. The use of melarsoprol-free treatment has
increased the price of treatment from $30 USD in 2001 to $440 in 2010 which
may hinder treatments in the future.38 Phase 1 trials of acoziborole 33 are com-
plete and are continuing though the development pipeline. Phase 3 clinical trials
of Fexinidazole 34 confirmed it is safe and effective and is currently awaiting
submission to the European Medicines Agency.39
The myristic acid analogue 35 was discovered to have selective toxicity to HAT.40
As a result a further 244 myristic acid analogues were synthesised and revealed
20 with high HAT toxicity.41 A thioether or ether was present in many of the
structures exemplified in compounds 36 and 37 in Figure 1.12. The ether func-
tional group was also present combined with aromatic systems in 38 and 39 and
also as the ester 40.
The mode of action of myristic analogues were unresolved with several complex
mechanisms postulated by Doering.40,41 The analogues may disrupt the action of
Acyl-CoA synthase, the enzymatic step before myristoylation. Another possibility
is the analogues could have activity by disrupting homoeostasis though modified
myristoylation of peptide substrates. Alternatively the myristic acid analogues
could competitively inhibit NMT though improved binding efficiency inside the
hydrophobic pocket. Incorporation of functional groups, into the myristoyl chain,
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Figure 1.12: Early analogues of myristric acid activity against HAT
that aid competitive selective binding to NMT would benefit the inhibitor potency
of a transition state mimetic. A combination of mechanisms of toxicity towards
HAT was not dismissed by Doering. NMT inhibitors that specifically target T.
brucei later reemerged.
The genome of Trypanosoma brucei was sequenced and Trypanosoma brucei NMT
(TbNMT) successfully purified.42 Several anti-fungal NMT inhibitors, exempli-
fied by 42 and 43 in 44 were shown to inhibit T. brucei NMT (TbNMT).43,44
Piggybacking the inhibitory properties from anti-fungal compounds developed at
Pfizer provided starting points for inhibition of TbNMT, as a new potential mech-
anism for clinical treatment of HAT. These hits against TbNMT were interesting
but were never optimised as other more promising novel TbNMT inhibitors as a
potential for HAT treatments evolved.
A focused library of 62000 compounds were used in high throughput screen for
inhibition of TbNMT and many consequently showed T. brucei activity.45 Fig-
ure 1.14 shows the pyrazole sulphonamide 45 which was the initial hit from the
campaign and showed micro molar IC50 TbNMT with promising selectivity. The
hit was optimised to give 46 with nanomolar activity and 100 fold selectivity.46,47
As Trypanosoma brucei crosses the blood brain barrier, 46 was optimised further
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Figure 1.13: Antifungal inhibitors demonstrated to show TbNMT
inhibition and activity towards T.brucei.43
to have bioavailability at the infection site.48 The inhibitor binding mechanism of
47 was proposed by co-crystallisation in Leishmania major NMT (LmNMT) and
confirmed that its binding site was within the peptide binding site area of NMT.
Currently, there are no clinically available TbNMT inhibitors with applications
towards Human African Trypanosomiasis.
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Figure 1.14: TbNMT inhibitors with in vitro activity against T.brucei 45–48
Malaria
Approximately half of the worlds population is at risk from infection of Plas-
modium parasites that cause malaria. There are four species of protozoa; Plas-
modium falciparum, vivax, malariae and ovale that are transmitted though the
bite of the Anopheles mosquitoes. It is estimated that in 2013 about 198 million
cases of malaria occurred worldwide and these led to the deaths of approximately
584 000 people.49
Figure 1.15: Left: Plasmodium falciparum in human host; Centre:
Immature P.Vivax in human host; Right: Feeding female anopheles
quadriannulatus mosquito. (Reproduced19)
There is a wide range of treatments clinically available for treatment (chloroquine
48) and prevention (doxycycline 49) of malaria. The prevalence of parasitic res-
16
istance to chloroquine, and others within its class, lead to the development of
combination therapies such as malerone (atovaquone 50 and proguanil 51). Al-
though malaria is considered preventable and curable, the latest class of antimal-
arials developed from artemisinin 52 are now showing significant geographic pat-
terns of resistances.50,51 Development of new classes of anti-malarials are needed
to combat and treat life threatening multidrug resistant Plasmodium infections.
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Figure 1.16: Examples from the major classes of clinically avaible malaria
treatment including chloroquine 48, doxycycline 49, artemisinin 52 and
malerone (atovaquone 50/proguanil 51).
The benzothiazole 44 is a anti-fungal that showed inhibition of TbNMT (Fig-
ure 1.13).43 Using the same ’piggy-backing’ approach, P. falciparum NMT (PfNMT)
was targeted in vitro.52,53 Industry developed anti-fungals showed in vitro PfNMT
inhibition. The benzothiazole 44 is a selective inhibitor of PfNMT over HsNMT.
Analogues of the benzothiazole 44, namely 53 and 54 showed good potency with
in vitro PfNMT IC50 below 30 µM.54 Piggy-backing structure based activity from
anti-fungals provided evidence for commissioning a screen of CaNMT inhibitors
towards PfNMT.
The benzofuran 26 (RO-09-4609) shows a micro-molar inhibitory activity in
PfNMT. It was developed at Roche as a CaNMT inhibitor which showed low
micromolar anti-fungal activity against C. albicans (Figure 1.18).30–32 The activ-
ity of 26 in PfNMT was significant and led to the synthesis of 55 that con-
tained the 4-piperinol and benzyl oxadiazole systems that improved potency while
conserving selectivity.55 The benzofuran core was modified and consequently 56
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Figure 1.17: PfNMT inhibitors 44, 53 and 5454
showed nanomolar activity.56 Figure 1.18 shows the redevelopment of the CaNMT
anti-fungal inhibitor 26 towards PfNMT and consequently showed sub micro-
molar in vivo activity against P. falciparum.
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Figure 1.18: Sucsessive generations PfNMT benzofuran inhibitors55,56
Compound 57 replaces the benzofuran scaffold of 26 with a benzothiophene scaf-
fold (Figure 1.19).57 The benzothiophene 57 contains the 4-piperinol fragment
found in the later generation benzofuran inhibitor 55 and a child inhibitor 56
shown in Figure 1.18. The 4-piperinol ring is structurally similar to the piperazine
ring contained on HAT inhibitor 46 discussed previously. The inhibitor 46 shows
a nano molar activity against PfNMT. Its 1,3,5-trimethylpyrazole fragment was
incorporated into 58 which also combined the 4-piperinol and oxadiazole frag-
ments of 55 (Figure 1.18) with the benzothiophene scaffold leading to selective
sub micro-molar in vivo activities. The binding mode of 46 and 58 were found ex-
perimentally to be closely related.58 Incorporation of the 1,3,5-trimethylpyrazole,
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developed from a Trypanosome research stream,46–48 was a successful mechanism
for provision of a potent inhibitor of Plasmodium NMT.
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Figure 1.19: Benzothiophene inhibitors of PfNMT.57,58
MRT00057965 59 is a quinoline based inhibitor that shows micro-molar activity
against Plasmodium vivax NMT (PvNMT).59 It was discovered during a HTS
campaign towards protozoa NMT and is structurally different from the benzo-
furan and benzothiophene inhibitors previously discussed. The original hit was
optimised to give 60 by introducing a ester into position 3 of the quinoline back-
bone. Compound 60 is structurally similar to 57 shown in Figure 1.19. It was
shown to be more selective for PvNMT over HsNMT than the lead 59. Incor-
poration of the pyridinyl-3-propylamine fragment contained in 61 showed some
similarities to the anti-fungal 26 shown in Figure 1.18. Nanomolar activity of 61
was achieved but high selectivity compared to HsNMT is yet to be accomplished
on the quinoline series.60
A myristoylation assay was performed using a HTS of Pfizers Global Diverse Rep-
resentative set of 150000 compounds against NMT isolated from P. falciparum,
L. donovani and H.sapien.61 The screen revealed several novel scaffolds as start-
ing points for further medical chemistry campaigns including the PF-03531814
62, PF-02378143 63, PF-03665853 64 and CP-854190 65 (Figure 1.21). 62 is
an azetidinopyrimidine, a class that showed 9 other hits of similar structure and
some having a SAR profile selective to PfNMT over HsNMT. The aminomethyl-
indazole class, represented by 63 had 15 related compounds with selective SAR
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Figure 1.20: Quinoline based PvNMT inhibitors.59,60
PfNMT profiles. The glycinyl 3-aminopyrrolidine 65 showed 30 hits. 64 is a
representative benzimidazolemethylamine, a class which showed 47 hits in the
screen. All represent novel scaffolds requiring further development as potential
selective NMT inhibitors targeting P. falciparum and L. donovani.
Inhibitors that target NMT have been demonstrated to show excellent potential
as a novel class of medicine for clinical treatment of protozoan infections. NMT
inhibitors are not limited to protozoan applications, but this is beyond the scope
of this project. Specifically, the scope of this thesis is in vivo activity towards T.
brucei rhodesience and TM4/8.2 and K1CB1, a sensitive and multi-drug resistant
strains of P. falciparum. The development of NMT inhibitors has been demon-
strated through a piggybacking approach by redesigning the activity of anti-fungal
NMT inhibitors toward P. falciparum. This project will explore piggy backing
the NMT inhibitory activities of fragments from alternative sources, in particular
HMG-CoA reductase inhibitors or the statins.
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Figure 1.21: Novel scaffolds identified from HTS screening against P.
falciparum and T. brucei NMT
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1.3 HMG-CoA reductase and heart disease
Coronary heart disease is characterised by cholesterol rich atherosclerotic arterial
deposits that block blood flow to the heart (Figure 1.22). Heart disease is the
leading cause of death in the US62, UK63 and Australia.64 The primary symp-
toms are angina, heart attacks and heart failure which are life threatening if left
untreated. The major underlying physiological cause of heart disease is an excess
of cholesterol in the bloodstream either from diet or excessive biosynthesis.
Figure 1.22: Atherosclerotic arterial deposits. (reproduced62
Before clinical manifestations of heart disease occur, physicians diagnose heart
disease by measuring levels of Low and High Density Lipoproteins bound cho-
lesterol (LDL/HDL). LDL levels are key indicators of heart disease along with
several other risk factors including cigarette smoking, hypertension, diabetes mel-
litus, obesity, lifestyle and family history. Treatment of coronary heart disease
before clinical intervention includes modification of lifestyle to include regular ex-
ercise, balanced diet, abstaining from smoking and controlling alcohol intake. If
lifestyle changes are not successful then clinical intervention is required to lower
LDL levels.65
Cholesterol is an essential molecule in mammals, helping to regulate cell mem-
brane fluidity. It is also the precursor to the steroid hormones which regulate an
extensive range of biological functions. Cholesterol is a biologically fundamental
molecule, yet high concentration of cholesterol lead to atherosclerotic deposition
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in arteries and consequently increase health risks. Mammals obtain cholesterol
either though ingestion or by biosyntheses from acetyl-CoA. Biosynthesis of cho-
lesterol from acetyl-CoA occurs through a process of more than 20 bio-synthetic
steps (simplified pathway Scheme 1.1).
Acetyl-CoA HMG-CoA Mevalonate IsopentenylPyrophosphate
Farnesyl 
PyrophosphateSqualeneCholesterol
HO
HH
H
H
Regulation
of cell 
fludity
Sterioid 
hormones Heart disease
2 66
67
Scheme 1.1: Simplified cholesterol biosyntheses from acetyl-CoA.
Cholesterol biosynthesis inhibition was demonstrated in the 1960s as an effect-
ive means to lowering plasma cholesterol in mammals.66 Cholesterol biosynthesis
inhibition is today the primary clinical mechanism for the treatment of heart dis-
ease. LDL Cholesterol levels are lowered by inhibiting a single biosynthetic step.
Clinical HMG-reductase inhibitors are known as the statins. By lowering LDL
cholesterol biosynthesis in the blood, it reduces the deposition of cholesterol as
arterial deposits, thus lowering the risk of developing life threatening symptoms.
HMG-reductase inhibitors and the first Statins
Cholesterol synthesis occurs in every cell in the body. The rate limiting step
during biosynthesis is the reduction of HMG-CoA to Mevalonate (Scheme 1.2).
Mammalian HMG-CoA reductase is a 97 kDa glycoprotein anchored to the endo-
plasmic reticulum membrane and contains 8 active sites.67 HMG-CoA reductase
catalyses the reduction of HMG-CoA 2 through stabilisation of the natural sub-
strate, intermediates and guiding two equivalents of NADPH sequentially into the
active site.68–70 Inhibition of HMG-CoA reductase became a target for lowering
cholesterol in the 1960’s.71
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Scheme 1.2: Emzyme catalysed reduction of HMG-CoA
Compactin, 68, was the first HMG-CoA inhibitor pharmacophore discovered in
the early 1970s in broths of Penicillium brevicompactum 72 and Penicillium cit-
rinum.73 Scheme 1.3 shows the prodrug compactin 68 conversion from a lactone
into its active ring open form 69. The active form contains a HMG emulating
hydrophilic moiety (outlined) and a hydrophobic portion which is replacing the
CoA fragment of the natural CoA substrate. Compactin entered clinical trials as
a pro drug in 1978, but was never marketed.74
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Scheme 1.3: Compactin (prodrug) and active form.
Although compactin 68 was clinically unsuccessful it served as a scaffold for the
generation and investigation of structurally similar derivatives. This lead to three
compounds approved for clinical use; lovastatin 70 (1987), pravastatin 72 (1989)
and the semi synthetic simvastatin 71 (1991). The first statins had structures
almost identical to compactin and were clinically and commercially enormously
successful. As a consequence the prescription and world sales of simvastatin 71
reached US$5.9 billion shortly before its patent expired in 2004.75 Competition
from generic manufacturers of simvastatin 71 dropped the price to approximately
24
$361 million in the US alone in the 12 months prior to the 31st March 2010.76
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Figure 1.23: First generation clinical HMG-reductase inhibitors.
Development of the synthetic statins, structural mode of
action and clinical trials
As the early statins were progressing though clinical trials, the development of
synthetic HMG-CoA reductase inhibitors intensified. New analogues based on a
substituted decalin ring structure were difficult to access. Consequently, detailed
development began into fully synthetic inhibitors. Sato et al. demonstrated that
cholesterol biosynthesis could be inhibited using a simple hydrophobic fragment
such as 73 (Figure 1.24).77 This work highlighted that the complexity of the
decalin ring in compactin 68 was not required. Since analogues of the lactone 73
were significantly easier to prepare, it was used as a starting point for numerous
medicinal chemistry campaigns.
The development of synthetic statins progressed by understanding the structural
requirement for binding to HMG-CoA reductase. Nakamura et al.78 described the
inhibition constants of HMG-CoA and several compactin fragments with HMG-
CoA reductase (Table 1.3.1). 74 showed no inhibition of HMG-CoA reductase
and demonstrated the importance of the HMG mimetic fragment. No synergistic
inhibition was observed, indicating that compactin interacted with a single site.
Mevalonate 66 showed activity in the same order of magnitude as dihydroxy-
valerate 75. Nakamura et al. showed the importance of a hydrophobic pocket
close to the binding site of CoA substrate, and adjacent to the HMG binding
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Figure 1.24: A chloresterol biosynthesis inhibitor 73 reported by Sato.77
site. Nakamura et al. reported the structure of 76 which used a 2,4-dichloro-
6-hydroxy phenyl substitution to space-fill the pocket. 76 was demonstrated to
have a dissociation constant on par with compactin.
At the same time Stocker et al. reported the structure activity relationship of the
first generation of synthetic HMG-reductase inhibitors.79 Stocker et al. reported
the inhibition results of lactone 76 with many other derivatives. The suite of
analogues prepared eventually identified key features required for inhibition and
demonstrated that a phenol was not essential. The activity of the styrene 77
which contains a trans-ethylene linker gave similar activity compared to its ethyl
linked derivative 78. The trans-ethylene linker was demonstrated as superior
in companion series and is consequently seen downstream in the development of
further statins. One of the key outcomes of the project was the resolution of
diastereoisomers and enantiomers contained in 77.
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Figure 1.25: The first generation of synthetic HMG-CoA reductase
inhibitors.
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Table 1.3.1: Dissociation constants determined by Nakamura.78
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667574
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Compound Dissociation Constant (M)
74 no inhibition
mixture 74 and DL-3,5-dihydroxyvalerate 75 21 x 10-3
DL-mevalonate 66 4 x 10-3
DL-3,5-dihydroxyvalerate 75 21 x 10-3
HMG-CoA 2 0.6 x 10-6
76 0.28 x 10-9
Compactin 69 0.24 x 10-9
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Scheme 1.4 shows the synthesis of the mixture of diastereoisomers 77 and 79 gen-
erated in 4 steps from 2,4-dichlorobenzaldehyde. The aldol condensation between
acetaldehyde and 2,4-dichlorobenaldehyde 80 was complete in two steps. Under
basic conditions acetaldehyde and the benzaldehyde 80 gave the aldol product,
which was dehydrated using acetic anhydride to give 81 in excellent yield. Methyl
acetoacetate was sequentially deprotonated using NaH and n-BuLi before being
added to the aldehyde 81 to give 82 in near quantitive yield. After reduction
of the ketoalcohol 82 using sodium borohydride, hydrolysis and lactonisation of
the ester 83 generated a mixture of lactone diastereoisomers 77 and 79 which
were separated by chromatography. The two enantiomers of the active diaste-
reoisomer 77 were then separated by chiral amide derivatisation using (R)-(+)-α-
methylbenzylamine and column chromatography. Hydrolysis of individual chiral
amide derivatives 84 and 85 prior to lactone recyclisation gave the enantiomers
86 and 87 respectively. Only 86 was found to be an active HMG-reductase in-
hibitor offering critical information regarding the active site of HMG-reductase.
As the drug discovery process progressed a biphenyl system replaced the simple
aryl ring contained in the lactone 77.80,81 A 4’-methylbiphenyl ring in the lac-
tone 88 led to nanomolar inhibition of HMG reductase, and was later replaced
with a 4’-fluorobiphenyl system contained in the lactone 89. The 4’-fluorophenyl
moiety features in current commercially available synthetic statins. The lactone
90 replaces the chlorine substituents with methyl groups to fill the hydrophobic
pocket in HMG reductase.
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Figure 1.26: The second generation of synthetic HMG-CoA reductase
inhibitors.
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Synthesis of many of the substituted biphenyl analogues, including 89, was per-
formed in 6 steps (Scheme 1.5). The biphenyl system was formed using a CH
activation strategy. The benzyl imine 91 was generated by a condensation reac-
tion between 2,4-dichlorobenzaldehyde 80 and aniline. The newly formed imine
directed the palladium CH insertion to give the palladacycle 92 in quantitative
yield. Reaction with 4-fluorophenylmagnesium bromide then gave the desired bi-
phenyl 93 from which the HMG emulating fragment was installed using the same
strategy described in Scheme 1.4.80
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Scheme 1.5: Formation of the biphenyl system contained on 89.80
The majority of the medicinal chemistry performed during the development of
the synthetic statins remains unreported. Figure 1.27 shows the pyrrole 94 which
has an isopropyl substitution and was reported by Roth et al.82 The isopropyl
substitution is a core feature of many of the clinical synthetic statins marketed
today. Fluvastatin 3 has an 4-fluorophenyl and an isopropyl substituted indole
core with a trans-ethylene linker. Fluvastatin 3 has all of the core features previ-
ously discussed and was commercially licensed as a HMG-reductase inhibitor in
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1993.
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Figure 1.27: Introduction of the isopropyl pyrrole substitution shown in
9482 which is structurally similar to fluvastatin 3.
The process used to manufacture fluvastatin is shown in Scheme 1.6. The key
feature of the synthesis is that it generates the syn-diol of 3 without need for
chromatography and uses fluorobenzene 95 as the starting material. The indole
96 is formed using a Bishler-indole synthesis between 97 and 98. A formylation
of the indole 96 uses N -methyl-N -phenyl-3-aminoacrolein 99 and gives 100 as a
single isomer. Introduction of the HMG emulating fragment was performed using
tert-butyl acetoacetate to give 101 in the same manner as Scheme 1.4. The key
stereoselective reduction uses diethylmethoxyboron as a covalently bound chela-
tion agent to activate the beta ketone and guide the hydride addition to generate
syn-diol 102 in 99:1 syn:anti purity. Hydrolysis of the ester and conversion to
its sodium salt generates fluvastatin in 6 steps.83
The absolute three dimensional shape of the active site of HMG-CoA reductase,
containing its natural substrate HMG-CoA, was not reported until after a large
majority of the statins were approved or in late stage clinical trials.70 The re-
search and development of statins was thus achieved using traditional medicinal
chemistry permutations without a complete understanding of the interactions
with HMG-CoA reductase. Crystallisation of HMG-CoA containing the statins
offered the first complete explanation to the statins mechanism of binding towards
the active site of HMG-CoA reductase.84 Istvan et al. described the hydrophilic
region of HMG-CoA reductase which shared several polar interactions with the
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Scheme 1.6: Commercial manufacture of fluvastatin.
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HMG moiety on the statins exemplified by fluvastatin in Figure 1.28. These inter-
actions include a hydrogen bond network of Glu559 and Asp767 to the O5 hydroxyl
group of fluvastatin and a salt bridge between the terminal carboxylate of the
HMG moiety with Lys735. The second region Istvan et al. described involved the
hydrophobic side chains of residues Leu562, Val683 , Leu853, Ala856 and Leu857, that
participate in Van der Waals interactions with the hydrophobic areas of statins.
Istvan et al. highlighted the importance of the 4’-fluoro position and its polar
interaction with Arg590 and a binding mechanism present in all the synthetic
statins.
Figure 1.28: Crystal structure of fluvastatin bound to HMG-CoA
reductase. (reproduced84)
Figure 1.29 shows the four fully synthetic statins which are clinically available
for treatment of heart disease. All of the statins have similar structural features,
discussed previously, that inhibit HMG-reductase. Widespread scepticism about
cholesterol biosynthesis inhibition and postulated long term side effects remained
long after the first statins were licensed. It was not until large scale phase 4
clinical trials were performed as post marketing surveillance that statins were
finally confirmed to be clinically safe and effective. Scandinavian Simvastatin
Survival Group involved over four thousand patients and linked the use of statins
to the successful lowering of LDL cholesterol resulting in the reduction in heart
attacks without major presence of side effects.85
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Figure 1.29: Commercially available synthetic statins
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1.4 Aims
Incorporation of HMG-CoA reductase inhibitors towards
NMT transition state mimetics
This project will investigate the potential of designing NMT inhibitors, through
synthesis, that include fragments from the HMG-CoA reductase inhibitors. In-
clusion of statin fragments into myristic structures could initiate a novel mode
of inhibition of NMT with potential applications towards T. brucei and P. fal-
ciparum. Similarly the investigation will also include the incorporation of features
developed previously as myristic acid analogs as to explore the structure-activity
dependency of the myristic chain.
The hypothetical NMT inhibitor 107 shows the 4 key aspects to be explored in the
scope of this structure-activity investigation. Firstly 107 contains a non-cleavable
linker housed between the myristic chain and the peptide glycine N-terminus. The
inhibitor 107 also incorporates a fluvastatin fragment. The application of statin
fragments towards NMT is one of the major scientific outcomes to be explored
in this investigation. Lastly 107 contains a myristic chain analog that contains a
phenoxy fragment inspired from a myristic acid analog which has a demonstrated
HAT toxicity (see Figure 1.12). The investigation will approach each segment
individually so to build a clear understanding the structure activity dependency
of the key elements towards T. brucei and P. falciparum.
In Chapter 2, the structure-activity investigation will commence through syn-
thesis of a simplified version of 107. The initial target 108 contains a non
cleavable 3-hydroxy amine system with a glycine substitution. A non-cleavable
myristoyl-CoA analogue was previously demonstrated as a potent NMT inhibitor
(see Figure 1.4). It is postulated that a similar strategy in a transition state mi-
metic may improve potency by resisting metabolism. The intermediate 109 does
not contain a substituted amine or a functionalised myristoyl chain, and thus
provides a baseline toxicity against T. brucei and P. falciparum and an initial
proof of concept. Amine substitutions, generalised in 110, will provide inform-
ation about favourable substitutions that improve the potency and selectivity
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Figure 1.30: The hypothetical inhibitor 107 showing key aspects of the
SAR invesagation.
profiles against T. brucei and P. falciparum.
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Figure 1.31: Inital target 108 from its key intermediate 109 used for
further derivatation.
Synthesis of the key intermediate 109 is proposed from ethyl myristate 111. The
linker length between the hydroxyl and amine functional groups will be explored
though the synthesis of two variations of 109. Synthesis of the C1 hydroxyamine
112 is proposed via the cyanohydrin 113. Conversely, synthesis of the C3 hydroxy
amine 114 is proposed from from its alkyne 115.
36
C13H27
OH
NH2 C13H27
OH
NH2
C13H27
OH
NH2
C13H27 CN
OH
C13H27 O
O
C13H27
OH
NH2
C1 C2 C3
113
112
111
109
115
114
Figure 1.32: Investagation into the structure activity dependency of the
hydroxy-amine linker.
Chapter 3 will investigate the incorporation of statin fragments into NMTmemetic
inhibitors. Baseline activity towards T. brucei and P. falciparum will be provided
by the hydroxyamine 109. The structure activity investigation will then func-
tionalise the hydroxyamine 109 with statin fragments and make an assessment
of the effects towards T. brucei and P. falciparum toxicity. Figure 1.33 illus-
trates two targets 116 and 117 which incorporate a fluvastatin fragment into
109. The target 116 illustrates the structure-activity investigation though the
incorporation of a fluvastatin fragment as a tertiary alcohol. Conversely 117 il-
lustrates another structure-activity investigation strategy by incorporation of the
fluvastatin fragment through an amine substitution. The two targets 116 and
117 illustrate the strategic investigation into the two potential CoA binding areas
of NMT, accessible by adding complexity to the hydroxyamine 109.
The structure-activity investigation will develop two series of compounds. The
first series of compounds will incorporate several increasingly complex statin frag-
ments as tertiary alcohols (Figure 1.34). The second series will investigate the
activities of compounds with the same fragments installed as amine substitutions.
Analysis of the potency and selectivity profiles of each compound set 118 and
119 against T. brucei and P. falciparum, and comparison with the unsubsti-
tuted hydroxy amine 109 will offer information to the dependency of the statin
fragments to binding efficiency with NMT.
Chapter 4 will focus on the structure activity investigation of the myristic chain.
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Figure 1.33: Investagation into the structure activity dependency of statin
fragment.
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Figure 1.34: Introduction of statin fragment to the parent hydroxyamine
109.
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Several myristic acid analogues have been demonstrated to show anti-HAT and
anti-fungal activity. If a myristic acid analogue shows activity though competitive
inhibition, incorporating the chain functionality from the myristic acid analogues
would improve the potency and selectivity profiles of mimetic inhibitors. Two
myristic chain functionalised targets are shown in Figure 1.35. The first target
120 incorporates a phenoxy fragment at the C6 position of myristoyl chain con-
tained on109. The second target 121 incorporates a cis-alkene at the C5 position
of the myristoyl chain. The aim of both targets is to explore whether function-
alisation of the chain leads to improved binding efficiency towards NMT and a
improved potency and/or selectivity profile towards T. brucei and P. falciparum.
OH
NH2
O
OH
NH2
OH
NH2
C8H17
109
120 121
Figure 1.35: Investagation into the structure activity dependency the
myristoyl chain.
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Chapter 2
Myristoyl-Peptide Mimetics
2.1 Linear synthesis of proposed NMT XXXXXXXXXXXX
inhibitor 108
Two targets were envisaged for the proof of concept studies for the proposed
NMT inhibitors, namely the amines 122 and 108. These amines are reminiscent
of the tetrahedral intermediate 123 formed in the reaction catalysed by NMT.
The amines 122 and 108 contain a 13 carbon chain and a charged glycine subunit
mimicking the myristic acid and the peptide chain respectively. A CoA-emulating
moiety was not used initially as to provide baseline activity during biological
assessments for this potential binding motif. The target 108 was favoured over
122, because 122 was thought to be susceptible to glycolytic cleavage in the cell.
Unlike 122, the extra methylene in 108 provided a non-cleavable linker and thus
postulated to reduce metabolic deactivation.
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Figure 2.1: The initial transition state mimetics 122 and 108 and the
transition state of NMT 123
The proposed synthesis of 108 from myristic acid 7 is shown in Scheme 2.1.
40
The esterification of myristic acid 7 followed by a Claisen condensation with
acetonitrile should produce the ketonitrile 124. Reduction of the ketonitrile 124
to the amine 109 could be performed using a metal hydride reduction to give
the hydroxyamine 109. Then attachment of methyl glycine, using 125, would
generate 108 in a relatively short synthesis.
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Scheme 2.1: Proposed synthesis of target 108
Ethyl myristate 111 was prepared using a Fisher esterification (Scheme 2.2).86
A solution of myristic acid and sulphuric acid in ethanol was heated under reflux
for 24 hours to give the ester in good yield after vacuum distillation. After
some experimentation, the conversion of the ester to the ketonitrile 124 was
accomplished. However, to obtain good yields, strict anhydrous conditions were
required (Scheme 2.2). The nucleophile for this reaction was lithioacetonitrile
and was prepared by treating anhydrous acetonitrile with n-butyllithium at -
84°C.87–89 Good yields of 124 were obtained when the ester 111 was treated
with two equivalents of lithioacetonitrile at -45°C. An excess of base was used
as a precaution to ensure the ketonitrile 124 was sequestered as the enolate 126
avoiding significant generation of the double addition product 127, which was
not observed in the reaction (Scheme 2.3).
C13H27 OH
O
C13H27 O
OEtOH, H+
24h, 78°C
79%
C13H27
O
CN
n-BuLi, CH3CN
-45°C, 3h
74%
7 111 124
Scheme 2.2: Generation of the ketonitrile 124
The high solubility of the unreacted starting material 111 and other by-products
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in petrol was exploited in the purification of 124. Trituration of the crude residue
with petrol gave the pure ketonitrile in good yield (Scheme 2.2). The 1H NMR
spectrum of the ketonitrile 124 contained the key singlet at 3.43 ppm (2H) as-
signed to the methylene between the nitrile and carbonyl groups. A triplet at
2.61 ppm (2H) was assigned to the methylene on the alkyl chain adjacent to
the ketone. The 13C NMR spectrum contained the expected 16 signals and the
presence of a ketone and nitrile functional groups confirmed by the signals at
197.7 and 114.0 ppm respectively. The presence of the nitrile and carbonyl was
also confirmed by their respective absorbances at 2259 and 1716 cm-1 in the IR
spectrum. With sufficient quantities of the ketonitrile 124 in hand, the reduction
of the nitrile and ketone functional groups were explored.
C13H27
O
CN
C13H27
O
CNC13H27
O
CN
CN
LiCH2CN B
[Slow] [Fast]
127 124 126
Scheme 2.3: Potential side reaction of ketonitrile generation
Cobalt boride is a mild reducing reagent used to convert nitriles to amines90,91
and was expected to generate the hydroxamine 109 from the ketonitrile 124.
When the ketonitrile 124 was exposed to cobalt boride, generated in situ by
reacting cobalt chloride and sodium borohydride, a new product was isolated
(Table 2.1.1). The crude isolated material had no starting material by TLC and
showed a new highly polar spot expected for the hydroxyamine 109. The 1H
NMR spectrum of this crude material also confirmed consumption of the starting
material and broad new signals at 3.80, 3.13 and 2.85 ppm which suggested the
1,3-hydroxyamine system of 109. Despite the evidence of a successful reduction,
performing this reaction on a large scale (>500 mg) was problematic. Acidic
conditions were required to remove excess cobalt boride. This led to protonation
of the amine, essentially forming a surfactant which led to emulsions. Under basic
conditions, the hydroxamine 109 became an excellent ligand for the cobalt ion,
leading to broad NMR signals. As a consequence, this reaction was impractical
and an alternative reduction procedure was explored.
Lithium aluminium hydride in THF has been used to reduce nitriles to amines92
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Table 2.1.1: Reduction of the ketonitrile 124
C13H27
OH
C13H27
O
CN
Conditions
NH2
124 109
conditions 109
CoCl2, NaBH4, EtOH, RT, 1h, HCl workup. 56% (impure crude)
LiAlH4, THF, 3h, RT. 55% purified.
and was successfully employed in the generation of the hydroxamine 109. A
crystallisation workup was applied by sequential addition of water and sodium
hydroxide solution which precipitated the bulk of the lithium/aluminium salts
which were removed by filtration. Subjecting the crude material to column chro-
matography gave the desired hydroxamine 109 in reasonable yields (Table 2.1.1).
The 13C NMR spectrum of the isolated product possessed considerable signal
overlap around 30 ppm because of the similarity of chemical shifts contained
in the myristoyl chain. Similar signal overlap occurs in a large majority of the
compounds containing the myristoyl chain (e.g. ethyl myristate 11193) and con-
sequently the number of carbon signals reported in the experimental does not
equal the number of carbons that theoretically have independent chemical shifts.
The 1H NMR spectrum of 109 contained a broad signal at 3.80 ppm assigned to
the methine with a hydroxyl substitution. A new stereocenter led to two doublet
of triplets at 3.13 and 2.85 ppm and assigned to the methylene protons with an
amine substitution. Reduction was confirmed by the absence of the nitrile and
carbonyl 13C NMR signals and the presence of a hydroxyl substituted methine
signal at 73.4 ppm.
Conversion of the 3-hydroxyamine 109 to the target 108 was expected via a
substitution reaction as per Scheme 2.1. 2-Bromo-N -methylacetamide 125 was
required to prepare the target 108 from the amine 109, and was made by a sub-
stitution reaction, using 2-bromoacetyl bromide and methylamine hydrochloride
(Scheme 2.4).94,95 The deprotonation of methylamine hydrochloride with sodium
hydroxide generated methyl amine, an excellent nucleophile, which quickly per-
fored a substitution with the acid bromide 128 to give 125 in good yield. At-
tempts to purify 125 by vacuum distillation94 were unsuccessful due to thermal
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decomposition of 125. Nevertheless, the crude material obtained after workup
was used in the subsequent reactions with the hydroxyamine 109.
Br
Br
O MeNH3.HCl, NaOH
-10°C, 30 min, 
75%
Br
N
H
O
128 125
Scheme 2.4: Generation of the glycyl derivative 125
Conversion of the hydroxyamine 109 to the glycine target 108 required the mono-
substitution with 2-bromo-N -methylacetamide 125. The amine functional group
contained on 109 is inherently a better nucleophile than its hydroxyl functional
group. A alkylation reaction with 125 was expected to preferentially derivat-
ise the amine to give 108. However, when a mixture of 3-hydroxyamine 109,
bromide 125 and potassium carbonate was heated under reflux, this gave the
double substitution product 129 (Table 2.1.2). Figure 2.2 shows the expanded
1H NMR spectrum of 129 which provided sufficient information to assign the
unwanted double substitution product. Two key signals visible at 3.19 ppm (4H)
and 2.81 ppm (6H) were assigned to the respective alkyl protons ➁ and ➂ shown
in Figure 2.2. 129 was isolated instead of the target 108 as it contains a free
amine available for a second substitution with the bromide 125. The inherent
preference of the alkylation reaction to form the double substituted product 129
implies that the first substitution is slow with respect to the second (Table 2.1.2).
Table 2.1.2: Relative reaction rate for competing substitution reactions
C13H27
O
OH
OHN HN
O
H
N
N
C13H27
C13H27
O
H
N
H
N
O
Slow Fast
Cond.H H
H
Br
N
H
O
Cond.
Br
N
H
O
109
125125
108 129
Conditions 108:129
1 eqv 125, K2CO3, THF, 66°C, 48h. 0 : 100*
1 eqv 125, K2CO3, DMSO, 66°C, 24h. 0 : 100
1 eqv 125, K2CO3, DMF, 66°C, 24h. 0 : 100
1 eqv 125, CsOH, 4A-MS, DMF, 25°C, 60h. complex mixture
*129 was isolated 45% yield based on 125
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Attempts were made to optimise the reaction to isolate the mono-substitution
product 108. Experiments were conducted using DMSO or DMF as the solvent,
however the exclusive formation of the double addition product was again ob-
served in both cases. These attempts were performed to investigate if a rate
change of the first substitution, with respect to the second substitution, could
be induced by using more polar and protic solvents. No changes were noted
and formation of the undesired double substitution product 129 was observed.
A method for mono-substitution of primary amines using caesium hydroxide and
4Å-MS was reported by Salvatore.96 According to the authors, the caesium cation
under anhydrous conditions leads to chelation with amine thus affecting its re-
activity.97 However, when 109 and 125 were stirred with caesium hydroxide in
DMF for 60 hours 129 was formed as part of a complex mixture and consequently
a protection strategy for the synthesis of the mono substitution product 108 was
envisioned.
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Figure 2.2: Double substitution product obtained from direct alkalation
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2.1.1 Carbamate protective strategies
In light of the inherent reactivity of the hydroxyamine 109 towards double substi-
tution, a protection strategy towards 108 was pursued. Carbamates are standard
protective groups for amines and several installation and deprotective methods
are available.98 The conversion of the amine to a carbamate 130 is possible though
a substitution reaction. Scheme 2.5 pivots on conditions that promote carbamate
substitution reported by Salvatore.99 Application of these conditions should pro-
mote the acylation reaction between 130 and the methyl glycine fragment 125.
Deprotection of 131 would generate the target 108.
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Scheme 2.5: Proposed mono-substitution of 109 via benzyl carbamate
protection
The hydroxyamine 109 was converted to its benzyl carbamate derivative 130
in good yield using benzyl chloroformate and a non-nucleophilic base, DIPEA
(Scheme 2.6).100 The 1H NMR spectrum of the carbamate showed a distinct
benzyl singlet at 5.12 ppm and a multiplet in the aromatic region integrating to
5 hydrogens. The 13C NMR spectrum also showed 4 new aromatic signals and
130 was confirmed by the presence of new carbamate and benzyl signals at 157.3
and 66.9 ppm respectively.
Salvatore reported using caesium carbonate under phase transfer conditions to
improved the inherently low nucleophilicity of the carbamate nitrogen.99 Follow-
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Scheme 2.6: Benzyl carbamate protection of 109
ing the same conditions the benzyl carbamate 130 and 125 were stirred with
TBAI and caesium carbonate in DMF at room temperature (Scheme 2.7). The
expected product 131 was not isolated from the reaction mixture, instead two
new compounds 132 and 133 were isolated in trace quantities and characterised
by NMR spectroscopy.
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Scheme 2.7: By-products isolated from the substitution of 130
The NMR spectra of the two isolated products 132 and 133 were notable in the
absence of a benzyl group. Compound 132 contained a new carbamate carbonyl
signal at 154.9 ppm and a signal at 5.80 ppm indicative of a carbamate proton
(Scheme 2.7). Compound 133 contained an amide carbonyl signal at 169.5 ppm
and a carbamate carbonyl signal at 155.0 ppm. The 1H NMR spectrum of 133
did not contain a carbamate proton signal at 5.80 ppm instead new signals at
3.91 and 2.80 ppm indicated the presence of the methyl glycine fragment.
The proposed mechanism for the formation of 132 and 133 is shown in Scheme 2.8.
The first step is the deprotonation of the hydroxyl group contained on 130 to give
the anion 134. The alkoxide anion 134 is a excellent nucleophile and performs
an intramolecular nucleophilic substitution via the tetrahedral intermediate 135
to give the cyclic carbamate 132. Subsequent deprotonation of 132 generates the
alkoxide 136 capable of a substitution reaction with 125 leading to the genera-
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tion of 133. These by-products inspired the development of alternative methods
to generate 132 directly from the free hydroxyamine 109 and its subsequent
alkylation.
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Scheme 2.8: Cyclic carbamate formation and alkylation
As the cyclic carbamate 132 is also effectively a protecting group, its direct form-
ation was investigated (Scheme 2.9). The formation of cyclic carbamates from
1,3-hydroxyamines are readily performed using a variety of reagents such as phos-
gene, carbon monoxide, carbonate esters and carbonyldiimidazole (CDI).98 Sub-
stitution of the cyclic carbamate 132 with the methyl bromoacetate 125 would
be promoted through the use of a strong base. Hydrolysis of the carbamate on
133 would generate the target 108. The first step required carbamate cyclisation
and as carbonyldiimidazole was available, this reagent was tested for the synthesis
of 132.
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Scheme 2.9: Dual alcohol and amine protection via cyclic carbamate
formation
The conversion of the hydroxyamine 109 to the cyclic carbamate 132 was achieved
using two equivalents of CDI in THF at reflux (Scheme 2.10).101,102 The mater-
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ial isolated was significantly less polar that the starting material. The 1H NMR
spectrum of 132 contained a 2 proton multiplet at 3.35 ppm and shifts in the
hydroxyl substituted methine signals were witnessed. A new carbamate N-H sig-
nal of 132 was visible at 5.35 ppm (Figure 2.3) with the remaining NMR signals
matching that obtained from Scheme 2.7.
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Scheme 2.10: Posibile intermediates during reaction using CDI
Unfortunately repeating the reaction under the same conditions gave inconsist-
ent yields, ranging from 40 to 90%. To gain further insights, the reaction was
periodically monitored using 1H NMR (Figure 2.3). After 3 hours the reaction
mixture ➁ showed complete consumption of the starting material ➀. The reaction
mixture ➁ shows new downfield signals indicating the formation of the interme-
diate 137. After heating ➂ shows a mixture of the intermediate 137 and the
desired carbamate 132. ➃ was obtained after prolonged heating and workup.
The variable yields were attributed to removal of the intermediate 137 during an
acidic workup. After some experimentation, the optimised conditions used single
equivalent of CDI in THF and held at reflux for 6 hours. Repeatable excellent
yields were obtained and shorter reaction times were observed with no further
purification required beyond an acidic workup.
When an alkylation reaction was performed by sequential deprotonation of the
acidic amide of 132 using sodium hydride, followed by addition of 2-bromo-N -
methylacetamide 125 and heating under reflux, two products were obtained in
low yield (Scheme 2.11). The first product was identified as 133 and its 1H
NMR spectrum was identical to the product originally isolated in Scheme 2.7.
The second major product 138 required careful NMR analysis to confirm its
structure.
Figure 2.4 shows an expanded overlay of the 1H NMR spectra for 133 and 138.
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Figure 2.3: Monitoring Scheme 2.10 by 1H NMR spectrometry.
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Scheme 2.11: Alkylation of cyclic carbamate
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Interestingly 138 no longer possesses a downfield amide signal at 6.46 ppm. The
imidazolium ring structure of 138 was primarily assigned as the methyl signal
appeared appeared as a singlet at 3.02 ppm. Two carbonyl signals remained
170.2 and 157.7 ppm in the 13C NMR spectrum of 138, as did the indicative AB
pattern in the 1H NMR spectrum. A shift of the hydroxyl substituted 13C carbon
signals from 78.0 ppm in 133 to 68.8 ppm in 138 confirmed the cleavage of the
carbamate, a change mirrored in the 1H NMR spectra.
2.79
1.09
1.09
1.16
1.06
1.06
ppm 346
N N
O
O
HO
C13H27
O N
O H
N
O
C13H27
1
1
1
2
2
2
3
3
3
1
23
133
138
Figure 2.4: Overlay of the 1H NMR spectra of compounds 133 and 138.
The proposed mechanism for the formation 138 from 133 under basic conditions
is shown in Scheme 2.12. Sodium hydride can deprotonate the glycyl amide
in 133, resulting in the anion 139 capable of intramolecular reaction to give
the alkoxide 140 that generates 138 after workup. The formation of 140 is
favoured over 139 though stability gained by the formation of a urea. Despite
the formation of the by-product 138, sufficient quantities of 133 were obtained
to enable the investigation of the hydrolysis of its carbamate.
Standard conditions for hydrolysis of cyclic and acyclic carbamates employ basic
conditions and can be performed using a number of weaker bases such as po-
tassium tert-butoxide, barium hydroxide, caesium carbonate or lithium hydrox-
ide.98 When 133 was treated with lithium hydroxide in wet methanol (Table 2.1.3),
the urea 138 was isolated as the product. A similar observation was made with
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Scheme 2.12: Formation of unwanted imidiazolium alcohol 138.
caesium carbonate and thus further hydrolysis experiments of 133 under basic
conditions were abandoned.
Table 2.1.3: Carbamate de-protection trials
OH HN
H
N
O
C13H27
O N
O
OH
O
C13H27
OH HN
O
C13H27
OH
Cond.O N
O H
N
O
C13H27
N N
O
O
HO
C13H27
133
138 141
142 108
Conditions 133 138 141 142 108
LiOH, H2O/MeOH, 25°C, 15h. Minor Major - - ND
Cs2CO3, H2O/MeOH, 25°C, 15h. Minor Major - - ND
CH3COOH, HBr Recovered - ND ND ND
TFA, CHCl3, 61°C, 15h. Recovered - ND ND ND
~1M HCl, H2O/MeOH, 25°C, 24h. Recovered - ND ND ND
~6M HCl, H2O/MeOH, 55°C, 15h. Minor - Major ND ND
Examples of carbamate hydrolysis under acid conditions were not prevalent in
the literature for systems such as 133.98 Acidic conditions have been used to
cleave methyl and ethyl carbamates a reagent such as hydrobromic acid in acetic
acid. No change to the TLC was seen on exposure of 133 to hydrobromic acid
in acetic acid. Exposure of 133 to trifluoroacetic acid also showed no change in
TLC (Table 2.1.3). Forcing conditions were applied by reacting 133 with hy-
drochloric acid, at elevated temperatures. Under these conditions a new product
was observed by NMR spectroscopy (Figure 2.5). The 1H NMR spectrum show
a upfield shift from 3.90 ppm in 133 to 4.10 in 141 combined with a significant
change to is AB coupling pattern. With the AB pattern intact it was probable the
trigonal planar carbamate was still present and this was confirmed by two new
carbonyl signals and matching oxygen substituted signal. Carbamate hydrolysis
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was excluded as no hydroxyl substituted 13C signal was present around 72 ppm
expected from a secondary alcohol. Amide hydrolysis was confirmed by the lack
a of matching 1H methyl signal at approximately 2.8 ppm and the lack of a 13C
signal at 27.40 ppm. The liability of amide cleavage over carbamate cleavage was
a major synthetic obstacle while utilising the cyclic carbamate as a protective
group.
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Figure 2.5: 1H and 13C NMR spectra overlays of crude reaction mixture
containing 141 with its precursor 133
The cyclic carbamate 132 allows for mono-substitution to give 133 (Scheme 2.11).
However, the use of a cyclic carbamate protective system gave rise to a new
synthetic obstacle as standard deprotection methods, under basic conditions, led
to the generation of the undesired rearrangement product 138 (Table 2.1.3). The
lability of the glycyl amide bond in preference to the carbamate amide bond
under acidic conditions led to a synthetic dead end. The incompatibility of 133
with basic conditions, and the lability of the glycyl amide bond, were critical
obstacles in the efforts to generate the target 108. Protection methods that would
effectively mask the reactivity of the acidic amide contained on 133 enabling
carbamate hydrolysis under basic conditions were then explored.
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2.1.2 Benzyl acetamide protection strategies
To circumvent the base catalysed rearrangement of 133 to 138 seen in the
previous section the use of a benzyl protected acetamide 143 was investigated
(Scheme 2.13). Substitution of 132 with 143 would generate tertiary amide 144
and hydrolysis of 144 prior to debenzylation would give access to the target
108. Scheme 2.13 pivots on amide debenzylation which are well reported in the
literature.98
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Scheme 2.13: Alternative synthesis of 108 amenable to basic hydrolosis
conditions
The proposed synthesis of the bromide fragment 143 used 2-bromoacetyl bromide
128 akin to Scheme 2.4, except N -methylbenzylamine 145 was to be used instead
of methylamine hydrochloride. N -Methylbenzylamine 145 was made from benzyl
bromide 146. A substitution reaction between methylamine and benzyl bromide
in methanol was performed at room temperature (Scheme 2.14). A 1:1 molar
mixture of 145:147 was obtained despite using 13 equivalents of methyl amine.
The mixture was used in the next step without purification.
The next synthesis step was the alkylation of N -methylbenzylamine 145 with
2-bromoacetyl bromide. The crude mixture containing N -methylbenzylamine
145 was exposed to bromoacetyl bromide in dry DCM at 0°C (Scheme 2.14)
using triethylamine as an acid scavenger. Purification of the reaction mixture
was achieved by an acidic work up and column chromatography to give 143 in
low yield over two steps. The 1H NMR spectrum showed a number of rotamer
signals expected for a tertiary amide and contained a benzyl signal at 4.60 ppm
(Figure 2.6). The 13C NMR spectrum mirrored the rotamer splitting trend and
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contained a key carbonyl signal at 167.0 ppm indicative of amide substitution.
The 1H NMR spectrum matched those reported by Cappelli103 and a sample
was obtained with an acceptable purity for the following reaction. The low yield
was attributed to utilising a crude mixture as the starting material but sufficient
quantities of 143 were obtained by synthesis on the large scale.
Br
N
O
HNBr
MeNH2 (13eq) BrCH2COBr, TEAN
PhPh RT, 20 Min
14% Overall
RT, 15h, 93%, 
~30 wt% pure
replacemen
146 145 147 143
Scheme 2.14: Two step formation of 2-bromo-N -methyl-N -benzyl
acetamide
The cyclic carbamate 132 was reacted with the bromide 143 using sodium hy-
dride in THF (Scheme 2.15). The reaction proceed smoothly without the forma-
tion of the by-product 138 and gave 144 in high yield. The 1H NMR spectrum
contained signals at 4.34, 3.50 and 3.33 ppm from the protons adjacent to the
carbamate system. 144 had overlapping signals centered around 4.19 ppm con-
taining the AB pattern caused by substitution of the trigonal planar carbamate
system and splitting from rotamers induced by the benzyl acetamide sytem. Con-
sequently the 13C NMR spectrum was also complex. The key amide carbonyl
signal was present at 168.1 ppm and complemented by a carbamate carbonyl at
154.6 ppm. Sufficient quantities of 144 were obtained to perform deprotective
carbamate trials.
Hydrolysis of the cyclic carbamate 144 using lithium hydroxide in wet ethanol
proceeded smoothly in good yield to give the secondary amine 148 (Scheme 2.15).
The new product 148 no longer contained a typical carbamate carbonyl signal at
around 155 ppm and the hydroxy substituted 13C signal shifted from 77.8 ppm
in 144 to 73.2 ppm. Hydrolysis was also confirmed as the 1H NMR hydroxyl
substituted methine signal showed a shift to 3.79 ppm in 148. A single carbonyl
signal, present as a rotamer pair at 171.3 and 170.9 ppm, was characteristic
of the tertiary amide present on 148. A successful hydrolysis of 144 under
basic conditions was attributed to the benzyl protection of the acidic amide thus
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Figure 2.6: Rotamer signals in the 1H NMR spectrum of 143 and
comparason with 2-bromo-N -methylacetamide 125
circumventing the unwanted cyclisation product 138 in Scheme 2.15.
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Scheme 2.15: Substution of the cyclic carbamate 132 with
2-bromo-N -methyl-N -benzylacetamide 143 and carbamate deprotection
under basic conditions
With the isolation of 148, a single debenzylation step was required to convert
148 to the desired transition state mimetic 108. Initial debenzylation attempts
using palladium on carbon and acetic acid under a hydrogen atmosphere were un-
successful (Table 2.1.4).98 Birch reductions were often reported for debenzylation
reactions.104 When 148 was exposed to sodium metal in condensed ammonia at
-84°C, a new material was isolated that no longer contained aromatic signals in
the 1H or 13C NMR spectra. Debenzylation was also confirmed by the disappear-
ance of the 1H NMR benzyl rotamer signals at 4.60 and 4.47 ppm. Restoration of
a secondary amide led to a new broad 1H NMR signal at 6.89 ppm and confirmed
by a 13C NMR amide carbonyl signal at 171.7 ppm. Sufficient quantities of the
target 108 were obtained for biological testing, therefore no optimisation studies
were performed to improve the yield of this reaction.
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Table 2.1.4: Deprotective debenzylation of 148 using a Birch reduction.
OH HN
H
N
O
C13H27
OH HN
N
O
C13H27
Conditions
148 108
Conditions Conversion 148:108 Yield 108
CH3COOH, Pd/C, H2, 48h. 100:0 -
Na, NH3, -84°C, 20 min. 33:67 30%
2.1.3 Benzyl amine protective strategies
An alternate strategy to the synthesis of the mimetic 108 was investigated.
Scheme 2.16 is a concise benzyl protective pathway that inherently avoids the
formation of the double substitution byproducts (Table 2.1.2) and complications
arising from the use of cyclic carbamates (Scheme 2.11). The benzyl group could
be installed using a reductive amination of benzaldehyde. A benzyl protective
group is superior to a carbamate system as it leaves the reactivity of the amine
intact. A substitution reaction between 149 and 125 would generate the tertiary
amine 150. Removal of the benzyl protection group would generate 108 in sig-
nificantly less steps compared to Scheme 2.13 which was used previously. Other
alkyl halides could be used instead of 125 to generate further secondary amine
analogues.
A simple method for the preparation of the benzyl protected amine 149 was
adopted from the literature.105 When the amine 109 was stirred with benzalde-
hyde in a mixture of DCM:THF 5:1 using anhydrous magnesium sulphate, the
hydroxyamine 109 was completely converted to the imine which was then re-
duced with sodium borohydride in methanol to give the amine 149 in excellent
yield. New aromatic signals were present in both the 1H and 13C NMR spectra
of the amine 149. The benzyl 1H NMR AB signal overlapped with the hydroxy
substituted signal at 3.77 ppm. Benzylation was confirmed by a new 13C signal
at 54.0 ppm.
Substitution reactions using 149 were tested to take advantage of the reactiv-
ity of the amine. When the amine 149, 2-bromo-N -methylacetamide 125 and
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Scheme 2.16: Synthesis via protective benzylation using reductive
amination
Table 2.1.5: Reductive amination prior to substitution iterations
C13H27
OH
NH C13H27
OH
N
H
N
O
1. PhCHO, 
MgSO4, 
25°C,15h.
2. NaBH4, 
25°C, 4.5h, 
87 %.
Cond.
C13H27
OH
NH2
109 149 150
Conditions 150
125, K2CO3, THF, 25°C, 96 h. 41 % Purified
125, K2CO3, THF, 66°C, 15 h. 64 % Conversion
125, DIPEA, DMF, 70°C, 15 h. 69 % Purified
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potassium carbonate were stirred at room temperature, the reaction proceeded
slowly. Heat was required to increase the reaction rate (Table 2.1.5). When the
substitution reaction was performed using DIPEA in DMF, the tertary amine
150 was isolated in good yield. The 1H NMR spectrum of 150 contained an AB
pattern at 3.1 ppm complemented by an apparent doublet at 2.79 ppm indicative
of the methyl amide rotamer. The 13C spectrum had a amide carbonyl present
at 171.5 ppm and the tertiary amine system had 3 signals present between 50 -
60 ppm.
Debenzylation of the benzylamine 150 was expected to generate the target mi-
metic 108. Standard hydrogenolysis using palladium on carbon proved unsuc-
cessful and resulted in complex mixtures. Birch conditions resulted in recovery of
the starting material (Table 2.1.6). A hydrogen transfer method using palladium
on carbon and formic acid in methanol at room temperature gave excellent res-
ults.106 The reaction showed complete consumption of the starting material 150
to give 108 in excellent yield. Scheme 2.16 proved synthetically beneficial as it
allows access to secondary amines using mild reaction conditions.
Table 2.1.6: Deprotective amine debenzylation
C13H27
OH
N
H
N
O
Conditions C13H27
OH
N
H
H
N
O
150 108
Conditions 108
Pd/C, H2, EtOH, 25°C, 15h. Complex mixture
Na, NH3, t-BuOH, -84°C, 30 min. SM recovered
Pd/C, 5% Formic acid in MeOH, 25°C, N2, 15h. 68 % Purified
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2.2 Structure activity relationship of 109
An investigation into the structure-activity relationship of the hydroxyamine 109
was proposed. Several aspects of the amine 109 are synthetically accessible.
Changing the linker length will provide information about its structure activity
dependency. Substitution of the hydroxyl group will help provide information into
its mode of action, as well as investigate favourable amine substitutions that may
improve its activity. Amine derivatisation, using chemistry explored previously,
was hoped to improve the potency profile of the parent hydroxamine 109.
C13H27
OH
NH2
Linker Lengh Substitution
Substitution
Change oxidation state
Hydroxyamine
109
Figure 2.7: Structure-Activity investagation.
2.2.1 Variation of amine linker length
Investigating the structure-activity dependancy of the carbon linker bridge between
hydroxy and amine functional groups led to two new targets 112 and 114 (Fig-
ure 2.8). Synthesis of the C1 and C3 hydroxyamines 112 and 114 would give
critical information about the importance of the linker length towards potency.
Synthesis of the new targets required separate synthetic strategies before a re-
duction to their successive amines.
C13H27
OH
NH2 C13H27
OH
NH2 C13H27
OH
NH2
112 109 114
Figure 2.8: new respective C1 and C3 linker targets 112 and 114
The synthesis of the C1 hydroxyamine 112 was proposed by reduction of the cy-
anohydrin 113 (Scheme 2.17). A method was reported by Chandia107 for cyano-
hydrin formation which was adapted for myristic aldehyde. Myristic aldehyde 151
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was exposed to sodium sulphite prior to addition of sodium cyanide. The sulph-
ite adduct activates nucleophilic addition of cyanide to form 113. The myristic
sulphite adduct was extremely insoluble in both aqueous and organic solvents.
The biphasic mixture limited the reaction rate and mechanical dispersion to re-
duce the particle size of the precipitated adduct was required, and produced a
visible change as the cyanide addition proceeded. An extractive workup isolated
the desired cyanohydrin from excess inorganic salts and the crude material was
purified by column chromatography. The key 13C NMR signals at 120.1 and 61.6
ppm were attributed to their respective nitrile and alcohol substituted carbons.
The 1H NMR spectrum did not contain a aldehyde signal which was replaced by
a downfield triplet at 4.47 ppm. The introduction of the cyanohydrin system also
resulted in a hydroxyl and nitrile stretch at 3395 and 2253 cm-1 respectively.
The same method previously used to reduce nitriles in Table 2.1.1 was applied
to the cyanohydrin 113. When the cyanohydrin 113 was reacted with lithium
aluminium hydride, the starting material was consumed and a new polar com-
pound was isolated. The 13C NMR spectrum contained no nitrile signal. The 1H
NMR spectrum showed a clear ABX pattern, a pair of doublet of doublets at 2.66
and 2.51 ppm, due to the 2-hydroxyamine system. With the C1 hydroxyamine
112 isolated, attention was focused on a synthetic strategy towards the C3 target
114.
C13H27
O
C13H27 CN
OH
C13H27
OH
NH2
NaHSO3, NaCN
15h, 25°C
49%
LiAlH4
0-25°C, 3h
29%
151 113 112
Scheme 2.17: Synthesis of the C1 linker
Propargylamine could be used to incorporate the 3 carbon unit in the hydroxyam-
ine 114. Protection of propargylamine was required as to mask the inherent re-
activity of the amine functional group (Scheme 2.18). The addition of lithiated
TMS protected propargyl amine 152 to myristoyl aldehyde, after quenching with
TMSCl, would generate the alkyne 153. Hydrogenation of the alkyne in 153 over
palladium was expected to give 154, that upon deprotection would yield the C3
target 114 .
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Scheme 2.18: Synthesis of the C3 linker
TMS protected propargylamine 155 was prepared by a method developed by
Corriu.108,109 The procedure involved the deprotonation of two equivalents of
HMDS with n-butyllithium, followed by the addition of propargyl bromide. This
method successfully generated gram quantities of 155 after a buffered quench
and purification by distillation (Scheme 2.19). 155 was isolated with a 15% mol
impurity of HMDS . Unfortunately, N,N -bis(trimethylsilyl)propargylamine 155
was found to significantly degrade, even when stored at -20°C. To address this
issue a one pot addition reaction that immediately utilises 152 was explored.
HN
Si
Si
Br
N
Si
Si
n-BuLi
-84 - 25°C, 15h
49%
N
Si
Si
unstable
Li
KH2PO4(aq)
Na2HPO4(aq)
156 157 152 155
Scheme 2.19: Synthesis of TMS protected amine
Corriu detailed a single pot substitution, addition and protection procedure in
the same paper.108 The sequential synthesis avoided the isolation of 155, instead
the anionic intermediate 152 was immediately reacted with myristic aldehyde
151. The alkoxide addition product was then protected with TMSCl to give 153
(Scheme 2.20). The crude isolated material showed complete consumption of the
myristic aldehyde 151 in the 1H and 13C NMR spectra. The 1H NMR spectrum
showed a triplet of triplets at 4.46 ppm and doublet at 3.55 ppm indicative of the
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propargyl alcohol/amine system, confirmed by respective 13C signals at 63.3 and
39.5 ppm. The substituted alkyne was confirmed by two downfield alkyne signals
at 86.2 and 84.0 ppm. The presence of two distinct types of trimethylsilyl group
was confirmed by two singlets in the 1H NMR spectrum with a 1:2 integration
ratio at 0.26 and 0.24 ppm. The purity of the crude product was acceptable and
further purification, beyond extended periods under reduced pressure removing
the volatile starting materials and intermediates, was avoided due to the expected
instability of 153 on silica gel.
N
Si
SiOSi
HN
Si
Si
Br
C13H27
1) n-BuLi, -84 - 25°C, 15h.
3) TMSCl, -84 - 25°C, 5h.
74%
2) C13H27CHO, -84 - 25°C, 20h.
156 157 153
Scheme 2.20: Squential addition reaction to generate 153
Methods for the hydrogenation of the alkyne were investigated using standard
hydrogenation techniques. Scheme 2.21 shows the outcome of a hydrogenation
using hydrogen and palladium on carbon on the TMS protected alkyne 153.
Palladium(0) is often poisoned by amines and it was hoped that hydrogenation
would proceed smoothly if the TMS protective groups remained. The starting
material was consumed but the alkene 158 was isolated instead of the desired
alkane 154. The 1H NMR spectrum possessed two clear alkene signals at 5.46
and 5.34 ppm. The Z -isomer was assigned as the two vinylic hydrogens had a
coupling constant of 11.0 Hz. Isolation of a single isomer was confirmed as only
two downfield alkene signals were present at 134.8 and 132.9 ppm in the 13C NMR
spectrum. The TMS protection groups remained intact as the 1H integration ratio
of 9:18 remained for the two signals at 0.21 and 0.20 ppm. The generation of 158
proved to be interesting, repeatable and convenient result as TMS deprotection
would make 159 available for biological assessment.
The alkene 158 was deprotected using TBAF to give the aminoalcohol 159 in
modest yield. The low yield was attributed to the extensive purification required
to remove TBAF from the polar hydroxyamine 159. The 1H NMR spectrum of
159 no longer possessed signals at 0.22 and 0.20 ppm indicating the absence of
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Scheme 2.21: Deprotection and hydrogenation stratergy utilised to isolate
the C3 alkene 159
TMS groups. Cleavage of the TMS groups allowed access to the novel alkene 159
for biological assessment. The deprotection of 153 prior to the hydrogenation
should generate 114 via the alkyne 160. This pathway was pursued as it would
generate 115 for potency testing.
When 153 was treated to TBAF at room temperature (Scheme 2.22), removal of
the TMS groups was observed and 160 was isolated in good yield. 160 was then
exposed to palladium on carbon under a hydrogen atmosphere (Scheme 2.22) and
the alkyne was reduced to the alkane 114 in good yield. The hydrogenation of the
alkyne was confirmed as no downfield signals of either the alkene 159 or alkyne
115 were present in the 1H and 13C NMR spectra. A 1H NMR multiplet at 3.55
ppm was assigned to the hydroxy substituted methine and a pair of multiplets at
2.40 and 2.24 ppm from the propargylamine. The 1H and 13C NMR spectra were
similar to that obtained for 109.
NH2HO
C13H27
H2, Pd/C
NH2
C13H27
OH
15h, 25°C
74%
N
Si
SiOSi
C13H27 25°C, 15h 
62%
TBAF
153 160 114
Scheme 2.22: Deprotection and hydrogenation stratergy utilised to isolate
the C3 linked alkyne 115 and its saturated analogue 114
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With the isolation of the C3 linked hydroxyamine 114 complete, the desired
series shown in Figure 2.8 was finalised. Two new compounds, 115 and 159 were
isolated and used to expand the structure-activity relationship introduced from
the inherent rigidity associated with the alkene and alkyne functional groups.
2.2.2 Aromatic amine derivatives
New amines 161 and 162 were envisioned to expand the structure-activity re-
lationship study of the hydroxyamine 109 (Scheme 2.23). Incorporation of a
3-phenyl ethyl group to the hydroxyamine 109 adds a longer linker compared
to the benzyl amine 149 generated previously (Table 2.1.5). The synthesis of
161 was envisioned by a reductive amination of the hydroxyamine 109 with 3-
phenylpropanal 163. The biphenyl derivative 162 aimed to determine the effect
of a large hydrophobic group on potency. Synthesis of 162 was proposed by
hydrolysis of the carbamate precursor 164.
OH
N
H
C13H27
OH
N
H
C13H27
OH NH2
C13H27
C13H27
O N
O
O
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N
H
C13H27
109
161
162
163
164
149
Scheme 2.23: New aromatic targets
The reductive amination, using 3-phenylpropanal 163, proceeded using condi-
tions described previously in Table 2.1.5 (Scheme 2.24). The hydroxyamine 109
and 3-phenylpropanal 163 were stirred with magnesium sulphate for 15 hours be-
fore exposure to sodium borohydride. 161 was isolated in low yield and contained
4 new aromatic 13C NMR signals between 142.0 and 126.0 ppm. The methylene
carbons adjacent to the amine were assigned to the two 13C NMR signals at 49.26
and 49.18 ppm. The propyl chain appeared as a multiplet of overlapping 1H NMR
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signals between 2.54 and 2.77 ppm. Attention then shifted towards the synthesis
of 164, the precursor of 162 shown in Scheme 2.23.
OH
N
H
C13H27
OH
NH2C13H27
O
1) MgSO4, 
25°C, 15h.
2) NaBH4, 
25°C, 24h.
25%109 161163
Scheme 2.24: Generation of 161 by reducive amination
The carbamate precursor 164 was generated using a alkylation reaction of the
carbamate 132 with 4-(chloromethyl)1,1’-biphenyl 165 (Scheme 2.25). When
the carbamate 132, the chloride 165 and a catalytic amount of sodium iodide
were stirred with NaH in THF for 90 hours at 25°C, a new non-polar compound
was isolated with a 13C NMR spectrum containing the 8 signals assigned to the
biphenyl system and a signal at 154.4 ppm indicative of carbamate carbonyls. The
1H NMR spectrum contained an AB pattern at 4.65 and 4.56 ppm assigned to each
of the benzylic protons. 1H NMR signals at 4.25 and 3.25 ppm were characteristic
of the oxazolidone system. Hydrolysis of the carbamate used conditions described
previously (Table 2.1.3). A solution of the carbamate 164 and lithium hydroxide
in wet ethanol was heated to 150°C for 2 hours using microwave irradiation. A
new polar compound was isolated which no longer contained a carbonyl signal
in the 13C NMR spectrum. The loss of the carbamate was also mirrored by the
shifting of the 1H NMR benzyl protons to 3.94 and 3.87 ppm.
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Scheme 2.25: Synthesis of 162 from the carbamate 132
2.2.3 Selective amine and hydroxyl inactivation
Further targets were designed to probe the structure-activity of the dependency
on the hydroxy and amine functional groups. The first target, the 3-hydroxynitrile
166, is designed to probe the structure activity dependency of the amine con-
tained on its free amine 109. A similar comparison, between the masked hydroxy
target 167 and the free hydroxyamine 109, provided the structure-activity rela-
tionship of the hydroxy functional group. A method to generate the targets 166
and 167 was investigated.
C13H27
OH
CN
C13H27
O
NH2C13H27
OH
NH2
109 166 167
Figure 2.9: New respective deactivated amine and hydroxyl targets 166
and 167
The hydroxynitrile 166 is an intermediate in the synthesis of the methoxyamine
167. Scheme 2.26 shows the synthesis of 167 from the ketonitrile 124. A se-
lective reduction of the ketonitrile 124 would generate the hydroxynitrile 166.
Methylation of the hydroxyl group in 166 would generate the ether 168 which
could then be reduced to the amine 167.
C13H27
O
CN
C13H27
OH
CN
C13H27
O
NH2
[RED] MeI [RED]
C13H27
O
CN
124 166 168 167
Scheme 2.26: Selective reduction of ketone, followed by methylation and
subesquent reduction to generate 167 via 166
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The selective carbonyl reduction was achieved by exposure of 124 to sodium
borohydride at room temperature (Scheme 2.27). No 13C NMR carbonyl signal
at 197.5 ppm was present, being replaced by a signal at 68.0 ppm, characteristic
of hydroxyl substitution. Reduction was confirmed since the 1H NMR methylene
adjacent to the nitrile appeared as singlet in the starting material at 3.44 ppm
and now appeared as multiplet at 2.52 ppm. No carbonyl signal was present in
the IR spectra at 1716 cm-1 which was replaced by a hydroxyl signal at 3372 cm-1.
With the successful isolation of the first target, methylation of the hydroxy group
contained on 166 was investigated.
C13H27
O
CN
C13H27
OH
CN25°C, 15h
71%
NaBH4
124 166
Scheme 2.27: Selective carbonyl reduction of the ketonitrile 124
An initial attempt to methylate the hydroxyl group on 166 was performed by de-
protonation with sodium hydride in methyl iodide at room temperature (Scheme 2.28).
The starting material was consumed and two new products, 169 and 170 were
isolated. 169 and 170 contained alkene signals that were matched with the vinylic
nitriles reported by Bai.110 The 13C spectra each contained a pair of downfield
alkene signals and a mechanistic explanation accounting for the formation of 169
and 170 was proposed in Scheme 2.29.
C13H27
OH
CN
C13H27
CN C13H27
CN
C13H27
O
CN
H
H
1H 6.72ppm (dt, 
J = 16.3, 7.0 Hz)
1H 6.48ppm (dt, 
J = 10.9, 7.7 Hz)
NaH (2.5 eq), MeI
0-25°C, 4h.
34% 24%
166 169 170168
Scheme 2.28: Methylation attempt using sodium hydride.
The use of excess sodium hydride led to deprotonation and formation of the
two nitrile anion conformers 171 and 172 (Scheme 2.29). Each conformer then
undergoes a methoxy elimination to generate the isomers 169 and 170. Milder
conditions were investigated to avoid generation of the undesired alkenes.
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Scheme 2.29: Formation of the alkenes 169 and 170.
A method was reported by Paz that used silver oxide to aid methylation in a 3-
hydroxy nitrile system.111 The 3-hydroxynitrile 166 was exposed to silver oxide
and methyl iodide in DMF at 100°C. The non-polar elimination products 169 and
170 were witnessed by TLC. Consequently the 3-hydroxynitrile 166 was exposed
to silver oxide and neat methyl iodide and stirred in a sealed vessel for 5 days.
The starting material was consumed and no elimination products 169/170 were
present by TLC or NMR. The 1H NMR spectra showed a new methoxy signal at
3.40 ppm and the hydroxy substituted methine signal shifted from 3.94 ppm in
166 to 3.44 ppm. Substitution was confirmed by the new methoxy signal at 57.5
ppm in the 13C NMR spectrum.
C13H27
OH
CN
C13H27
O
CN
MeI (neat), AgO
25°C, 5 day
95% crude
166 168
Scheme 2.30: Methylation of 166
The 3-methoxynitrile 168 was exposed to lithium aluminium hydride at room
temperature (Table 2.2.1). A complex mixture was obtained and an alternative
reduction method using cobalt boride was applied. Sodium borohydride was ad-
ded to a solution of 3-methoxynitrile 168 and cobalt chloride mirroring conditions
used previously (Table 2.1.1). The 13C NMR spectrum of 167 no longer showed a
nitrile signal. A 1H NMR spectrum of 167 showed the amine substituted methine
triplet at 2.78 ppm and methoxy singlet at 3.30 ppm.
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Table 2.2.1: Reduction of the 3-methoxynitrile 168
C13H27
O
CN
C13H27
O
NH2
Cond.
168 167
Conditions Yield
LiAlH4, 25°C, 2h. Complex mixture
CoCl2 (2 eq), NaBH4 (10 Eq), 0 - 25°C, 3h. 32 %
2.3 in vitro Protozoan toxicity
Development of the structure-activity relationship began by toxicological assess-
ment of 6 compounds, either synthesised in this chapter or available off the shelf,
against T.brucei rhodesience and P.falciparum (Figure 2.10). The assays were
conducted by Prof. Sumalee Kamchonwongpaisan at the National Centre for
Genetic Engineering and Biotechnology, Thailand. The initial assessment was
promising with the hydroxyamine 109 showing selective sub-micro molar activ-
ity towards T.brucei rhodesience. A series of control compounds were tested to
check that the potency was due to the hydroxyamine feature. Myristic acid 7
did not show any toxicity towards T.brucei or P.falciparum as it is a natural
substrate. Hexadecylamine 173 is identical to the hydroxyamine 109 except the
hydroxyl group is absent. 173 was 2 orders of magnitude less potent than 109,
showing the critical role of the hydroxyl group in a hydrogen bonding interaction.
Interestingly methylation of the hydroxyl group had little effect upon activity to-
wards T.brucei rhodesience but it significantly improved selectivity. 167 showed
the same activity towards T.brucei rhodesience as its free hydroxyamine coun-
terpart 109. This trend indicated that the oxygen may be acting as a hydrogen
bond acceptor in T.brucei rhodesience, and hence potency was uninfluenced by
methylation. This trend was again observed with the activity of 167 towards
P.falciparum which was the same when compared to its unsubstituted counter-
part 109. Methylation of the hydroxyl group of 109 validated the idea of hy-
droxyl substitution for a starting point for further structure-activity relationship
investigations.
The structure-activity dependency on the amine was demonstrated to be very
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high. When the amine was masked as a nitrile in 166, the activity drops signi-
ficantly when compared with the free amine 109. The potency and selectivity
remained unchanged when the hydrochloride of 109 was assessed indicating buf-
fering in biological media was likely. The importance of the hydroxyl and amine
functional groups was validated, consequently became primary features of all re-
maining compounds.
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83
1.1
1.1
-
T.brucei IC50:
P.Falciparum TM4 IC50:
P.Falciparum K1CB1 IC50:
VERO IC50:
T.brucei IC50:
P.Falciparum TM4 IC50:
P.Falciparum K1CB1 IC50:
VERO IC50:
SI
83
4.5
1.4
-
SI
156
2.3
2.0
-
SI
2.5
-
-
-
SI
4.8
-
-
-
7 109 174
166 167 173
Figure 2.10: Inital activities of selected compounds againsed T. brucei
rhodesience
Having shown the hydroxyamine 109 was a good lead, a series of compounds
was developed to investigate the structure activity dependency of carbon linker
between hydroxyl and amine functional groups. Compounds 112 and 109, with a
one or two carbon linker, showed very similar activities towards T.brucei rhodesi-
ence and P.falciparum. Increasing the linker length beyond two carbons saw a
overall drop in activity. Since molecules containing a three carbon linker, namely
hydroxy amines 114, 159 and 160, did not improve potency inclusion into later
generations of compounds was avoided. The results also validate the use of a 2
carbon linker as opposed to a one carbon linker.
Figure 2.12 shows the selectivity index for the compounds shown in Figure 2.10
and Figure 2.11. The selectivity was promising, as many synthesised compounds
showed toxicity towards T.brucei rhodesience while not impinging the activity of
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Figure 2.11: in vitro activities of hydroxyl-amine linker length derivatives
against T. brucei rhodesience and P.falciparum
a host cell. Two of the more potent hydroxyamines, compounds 109 and 112
showed over 80-fold selectivity towards T.brucei rhodesience compared to a model
host cell line. Selectivity towards P.falciparum was, in general, not observed with
the first two series of compounds shown in Figure 2.10 and Figure 2.11. The high
selectivity towards T.brucei rhodesience is a promising start as to explore further
compounds containing the myristoyl hydroxyamine motif of 109.
A carbamate protection, discussed in section 2.1.1, led to the generation of the
first substituted target 108. The activity of several of the intermediates and
108 were assessed against T.brucei rhodesience and P.falciparum and are shown
in Figure 2.13. The structure activity dependancy on the hydroxyl and amine
functional groups is clearly shown by the cyclic carbamate 132 which shows little
activity against both T.brucei rhodesience and P.falciparum. Compound 144 was
assumed to have activity though a generalised toxicity mechanism and did not
show any selectivity towards T.brucei rhodesience or P.falciparum over a human
cell line. These results can be rationalised since the nitrogen in 132, 133 and
144 are part of a amide bond, and therefore does not form a charged species
at physiological pH. Introduction of the glycine as a substituted amine did not
show any improved activity compared to 109, however, the selectivity over the
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Figure 2.12: Selectivity of hydroxamines of T. brucei rhodesience
compaired to VERO
VERO cell line increased to over 167. This adds to the evidence that this series
of compounds may be working by NMT inhibition.
The synthesis of several substituted amine derivatives of the hydroxyamine 109
were developed in sections 2.1.3 and 2.2.2. The benzyl amine 149 showed a similar
activity and selectivity profile towards T.brucei rhodesience compared with 109
(Figure 2.14). This demonstrated that the benzyl substituent was not hindering
the binding mechanism of the hydroxyamine fragment of 149 at the active site or
altering its transportation and bioavailability. Introduction of the benzyl amine
substituent increased the selectivity of 149 towards P.falciparum. 149 showed
sub micro-molar potency and 60 fold selectivity towards P.falciparum K1CB1,
a multi drug resistant strain of malaria over the VERO cell line. Introduction
of a 3-phenyl propyl amine substituent, shown in 161, did not impact potency
with 161 showing the same activity as 109 towards T.brucei rhodesience. Despite
161 having the same activity as 109, the introduction of a 3-phenyl propyl amine
substituent led to a 7 fold decrease in selectivity. No selectivity was observed to-
wards T.brucei rhodesience or P.falciparum by introduction of a benzyl biphenyl
substitution 162 indicating a generalised toxicity mechanism was present.
The hydroxyamine 109 is a novel myristic acid derivative that has been demon-
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Figure 2.13: in vitro activities of carbamate and glycyl derivatives against
T. brucei rhodesience and P.falciparum
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Figure 2.14: in vitro activities of aromatic amine derivatives against T.
brucei rhodesience and P.falciparum
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strated to show an 80-fold selectivity and micro-molar activity towards T.brucei
rhodesience. Although the specific mode of action of the compounds has not been
implicitly described in this chapter, as in vitro assays with isolated NMT were
not currently available, inhibition of NMT was considered likely. This chapter
provides an excellent baseline to explore the introduction of statin fragments into
109. The following chapter will explore the concept of piggybacking some activ-
ity from the HMG-CoA reductase inhibitors with the potential of applying them
to NMT.
C13H27
O
N
can be substituted
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n
Oxygen 
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n = 0 or 1
H
H
ionisable 
nitrogen essential
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109
Figure 2.15: Results of structure-activity studies on the hydroxyamine 109
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Chapter 3
CoA-myristoyl mimetics
3.1 Introduction of early HMG-reductase inhib-
itor fragments
Having demonstrated activity of the hydroxyamine 109, synthesis of more potent
derivatives of 109 was explored. One aspect of the transition state that was not
investigated in Chapter 2 was a Coenzyme A mimetic, which was successfully
used in the development of the statins. Structures from the early development
of the statins provided inspiration for new targets. In 1980, Sato reported the
cholesterol biosynthesis inhibitor 73 with a micro-molar cholesterol biosynthesis
inhibitory potency.77 The lactone 73 contains a simple lipophilic CoA segment
and the incorporation of this structure into the aminoalcohol 109 was explored.
The hydroxyamine 175 has a similar structure to the early statin 73 and was en-
visioned to improve the efficacy of N -Myristoyltransferase inhibitors. Therefore,
synthesis of the new target 175 was explored.
Scheme 3.1 shows two possible synthetic routes to the target hydroxyamine 175.
A linear route could be conceived by starting with a Grignard reaction between
3-phenylpropanal and tridecylmagnesium bromide to generate 176. Oxidation
of the resulting alcohol followed by addition of lithiated acetonitrile would give
the hydroxynitrile 177. Reduction of the nitrile in 177 would give the desired
amine 175 in 3 steps. An alternative convergent approach was envisaged in
which the acetylide anion 178 could be added to the ketonitrile 124. This route
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Figure 3.1: Introduction of the 2-ethylphenyl moiety to the hydroxyamine
109 as the tertiary alcohol 175.77
would allow for a modular approach to expand the functionality of 109. However,
the addition of the phenylacetylide anion 178 to ketonitriles is uncommon, and
challenges were expected.
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Scheme 3.1: Proposed linear and convergent synthesis of hydroxyamine
175.
The key hurdle for the convergent synthesis of 175was the addition the phenylacetyl-
ide 178 to the ketonitrile 124 as the competing deprotonation reaction was ex-
pected to be favoured. Organocerium reagents have been reported to improve
addition reactions of easily enolisable systems.112–114 Figure 3.2a shows the con-
trasting yields between organolithium and organocerium reagents in the addition
of phenyl acetylide to cyclopent-3-en-1-one 182. The lithium phenylacetylide
77
178 gave 183 in modest 30% yield whereas the cerium phenylacetylide 184 gave
183 in 89% yield. Lithium acetylides are inherently strong bases and are ex-
pected to easily deprotonate the protons alpha to both the carbonyl and nitrile
and form the enolate 185 (Figure 3.2b). Organocerium acetylides are less basic
and have been demonstrated to improve nucleophilicity.112–114 The use of organo-
cerium reagents was expected to favour ketonitrile addition and introduce new
functionality shown in 186.
O
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R = CeCl2 89%
R = Li 30%
-78°C, 3h
HO
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(a) Improvements to the addition reaction outcome using
cerium reagents.112
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(b) Competing reaction outcomes of the addition reaction to the ketonitrile 124
Figure 3.2: Convergent synthesis strategies towards 175 shown in
Scheme 3.1
Addition reactions using simple Grignard reagents and lithiated acetylides were
performed to determine if standard conditions generated the addition product
181. When methylmagnesium bromide or lithium phenyl acetylide were added
to the ketonitrile 124, only starting material was recovered (Table 3.1.1). This
result confirmed the acidic nature of the ketonitrile 124 and its preference to
enolise in the presence of Grignard reagents and lithium acetylides. The cerium
acetylide was made by transmetalation of lithium phenylacetylide using anhyd-
rous cerium chloride and showed promising results. Anhydrous cerium chloride
was obtained by progressively heating the heptahydrate up to 140°C overnight
in vacuo. Phenylacetylene was deprotonated with n-butyllithium at -84°C and
stirred with anhydrous cerium chloride before addition of 124. The use of a large
excess of the organocerium reagent nucleophile did not improve the yield. Per-
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forming the reaction with a small excess of the cerium transmetalated nucleophile
at -84°C for 5 hours gave 181 in modest yield.
Table 3.1.1: Addition optimisation using cerium chloride
C13H27
O
CN C13H27
CN
OH
R
Cond.
=
= CH3187
124
181
Conditions 124:181 Yield 181
MeMgI (1.3 eq), 124, 0°C, 1h. Recovered 124 -
PhC≡CH 188 (1.2 eq), n-BuLi (1.1 eq),
THF, 124, -84°C to RT, 15h. Recovered 124 -
PhC≡CH 188 (1.3 eq), n-BuLi (1.2 eqv),
Anh. CeCl3 (1.4 eqv), 124, -84°C to -45°C, 2h.
71:29 13%
PhC≡CH 188 (2.4 eq), n-BuLi (2.2 eq),
Anh. CeCl3 (2.5 eqv), 124, -84°C, 2h.
- 15%
PhC≡CH188 (1.4 eq), n-BuLi (1.3 eq),
Anh. CeCl3 (1.5 eq), 124, -84°C, 5h.
44:56 34%
The 1H NMR spectrum of the product, the propargyl alcohol 181, possessed sig-
nals at 7.46-7.30 ppm (m, 5H) associated with the phenyl group and a indicative
AB pattern at 2.86 and 2.82 ppm due to non-equivalent protons adjacent to the
nitrile. The 13C NMR spectrum possessed two signals at 88.5 and 86.5 ppm that
were assigned to the disubstituted alkyne. The carbonyl signal of the ketonitrile
124 at 197.7 ppm was replaced by a new signal at 69.0 ppm consistent with a
hydroxyl substituent. The nitrile signal had shifted from 114.0 to 116.7 ppm
confirming the nitrile was still intact and available for the subsequent reduction
steps.
Exposure of the propargyl alcohol 181 to palladium on carbon under a hydrogen
atmosphere reduced the alkyne to the alcohol 189 in 2.5 hours (Scheme 3.2). The
13C NMR spectrum of 189 confirmed reduction as the two key alkyne signals were
no longer present. The nitrile in 189 was then reduced to the primary amine 175
using lithium aluminium hydride in modest yield. Reduction was confirmed as
175 no longer showed a nitrile 13C NMR signal of at 116.7 ppm. Overall the
synthetic route to 175 is short and modular which allows for analogues to be
made quickly.
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Scheme 3.2: Hydrogenation and reduction of addition product 181.
Figure 3.3 shows compound 77 which was reported by Stokker79,80 to be a HMG-
reductase inhibitor. The hydrophobic 2,4-dichlorophenyl moiety was discovered to
emulate the hydrophobic segment of Compactin. The 2,4-dichlorophenyl moiety
was introduced into the new potential NMT inhibitor target 190 and its synthesis
explored.
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Figure 3.3: Introduction of the 2,4-dichlorophenyl fragment.
The new target 190 was made using a similar procedure to the phenylethyl de-
rivative 175 (Table 3.1.1 and Scheme 3.2). 2,4-Dichlorophenylacetylene 191 was
made using an adapted procedure described by Ghaffarzadeh who reacted 2,4-
dichloroacetophenone 192 with phosphorous pentachloride in pyridine under mi-
crowave irradiation on the 1 mmol scale. (Scheme 3.3).115 The reaction was scaled
up to 40 mmol by placing the reagents in a preheated oil bath at 150°C for 12.5
min. The reaction gave the alkyne 191 in modest yield, however this material
contained some minor chlorinated impurities. Despite these minor impurities the
material showed NMR spectral data identical to that reported by Arioli116 and
was used in the following addition reaction.
With gram quantities of the alkyne 191 available, the reaction conditions used
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Scheme 3.3: Generation of aromatic terminal alkyne using PCl5 and
cerium transmetalated addition.
to add phenylacetylene to the ketonitrile 124 were applied. A sequential lith-
iation of the terminal alkyne 191 followed by transmetalation with anhydrous
cerium chloride and addition to 124 at -84°C for 5 hours gave 193 in good yield
(Scheme 3.3). The 1H NMR spectrum of the propargyl alcohol 193 showed aro-
matic signals of the starting alkyne 191 and aliphatic signals from the myristoyl
chain. Isolation of 193 was confirmed as the 13C NMR spectrum no longer had a
carbonyl signal at 197.7 ppm and no carbonyl IR signal at 1716 cm-1. A new hy-
droxyl substituted carbon signal was present in the 13C spectrum at 69.2 ppm with
a new hydroxyl stretch at 3423 cm-1 in the IR spectrum. The carbon spectrum
also showed signals at 94.6 and 82.3 ppm indicative of a disubstituted alkyne.
Unreacted starting materials were easily recovered using column chromatography
and scale up generated desired propargyl alcohol 193 in a modest yield.
Hydrogenation of the alkyne 193 proceeded using palladium on carbon under a
hydrogen atmosphere at room temperature (Scheme 3.4). The material isolated
after filtration though celite did not show 13C alkyne signals at 94.6 and 82.3 ppm
of the starting material. The nitrile on 194 had a 13C signal at 117.4 ppm and a IR
signal at 2254 cm-1. Exposure of 194 to lithium aluminium hydride generated the
target 190 in low yield due to isolation difficulties during chromatography. The
infrared spectrum of the aminoalcohol 190 no longer showed a nitrile absorbance
at 2254 cm-1. The singlet at 2.61 ppm of 194 was transformed into a multiplet
at 2.70 ppm indicative of a amine substituted methine. Sufficient quantities of
hydroxyamine 190 were generated for biological assessment.
New targets were then envisioned by changing the location of the hydrophobic
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Scheme 3.4: Hydrogenation and reduction of 193.
phenylethyl fragment (Figure 3.4). Benzyl amine substitutions may have better
access to a hydrophobic pocket. This approach is analogous to the positioning
these hydrophobic features in the HMG-CoA reductase inhibitors 7779,80 and
195.117 Synthesis of 196 and 197 was proposed by a reductive amination of 109
with their respective benzaldehydes.
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Figure 3.4: New targets that incorporate the 2,4-dichlorophenyl fragment.
The hydroxyamine 109 was stirred with 2,4-dichlorobenzaldehyde before addition
of sodium borohydride (Scheme 3.5). A new polar and UV active spot was isolated
in modest yield. The 13C NMR showed 6 aromatic signals combined with two
amine substituted methine signals at 50.4 and 48.1 ppm. The 1H NMR spectrum
showed the expected alkyl amine substituted methine at 2.99 and 2.79 ppm, with
the benzyl protons seen as an AB pattern at 3.91 and 3.86 ppm. Focus was then
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shifted to the synthesis of 197 using similar conditions.
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Scheme 3.5: Reductive amination of 109 to give 196 and 197
A reductive amination using 2,4-dichlorosalicaldehyde gave 197 in modest yield
(Scheme 3.5). The DEPT spectrum of 197 in DMSO-d6 showed 4 substituted
signals in the aromatic region and the 1H NMR spectrum showed pair of doublets
at 6.82 and 6.62 ppm with long range coupling of 2.1 Hz. The benzyl and al-
kyl amine substituted methylene signals were present as a singlet and multiplet
at 3.99 and 2.64 ppm respectively. The hydroxy substituted methine signal at
3.44 ppm remained. Further targets based from HMG-reductase inhibitors were
planned.
3.2 4’-Fluorobiphenyls
During the drug development of the synthetic statins, the addition of a 4’-
fluorophenyl group greatly improved potency towards the inhibition of HMG-
CoA reductase. The potency improvement can been seen by comparing 77 and
89 in Figure 3.5.80 Introduction of the 4’-fluorophenyl group improved HMG-
CoA reductase binding though polar interactions between the guanidinium group
contained on Arg590 and the fluorophenyl substituent.84 Consequently the 4’-
fluorophenyl moiety is a feature all the synthetic Statins. Inclusion of the 4’-
fluorophenyl moiety thus led to two new NMT inhibitor targets 199 and 200, and
their synthesis was planned by building on chemistry described in this chapter.
The synthesis of the targets 199 and 200 was envisaged using the organocerium
addition reaction described previously. The first target was the unchlorinated
biphenyl 199 which required the synthesis of its alkyne precursor 201. A Suzuki
cross-coupling reaction between the boronic acid 202 and 2-bromoacetophenone
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Figure 3.5: Incorporation of the 6-(4’-fluorophenyl)-2,4-dichlorobiphenyl
system.
203 would generate the acetophenone 204. Subjecting the acetophenone 204 to
the same conditions used to make 191 in Scheme 3.3 would give the first target
alkyne precursor 201 (Scheme 3.6). Conversion of 201 to the cerium acetylide
and addition to the ketonitrile 124 would generate 205 and reduction of the
alcohol would generate the first target 199.
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Scheme 3.6: Proposed synthesis of the key biphenyl precursor 201
A similar biphenyl has been made by reacting 2,4-fluorophenylboronic acid with
2’-bromoacetophenone 203.118 Applying these conditions, an aqueous solution
of the boronic acid 202 and the bromide 203 was stirred with TBAB and pal-
ladium acetate overnight at 70°C which gave the biphenyl 204 in good yield
(Scheme 3.8). The 1H and 13C NMR spectra of 204 matched that described by
Yoshikai.119 Methods to convert the acetophenone system contained on 204 were
then investigated.
An effective method for converting the acetophenone 204 to the alkyne 201 used
phosphorous pentachloride.115 The biphenyl acetophenone 204 was exposed to
phosphorous pentachloride in pyridine and heated at 110°C using a microwave
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Scheme 3.7: Synthesis of new targets 199 and 200 via organocerium
addition
reactor. The 1H NMR methyl signal at 2.06 ppm of the starting acetophenone
204 was converted to the a terminal alkyne signal at 3.05 ppm. The presence the
alkyne in 201 was confirmed by the disappearance of the respective 13C NMR
ketone and methyl signals at 204.6 and 30.6 ppm and conversion to new signals at
83.1 and 80.5 ppm. A sufficient amount of the terminal alkyne 201 was generated
for the subsequent addition reaction.
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Scheme 3.8: Suzuki coupling of 203 prior to elimination to give 201.
Using the chemistry described previously, the terminal alkyne 201 was converted
to the propargyl alcohol 205 in modest yield (Scheme 3.9). The 1H NMR signals
showed both aromatic and aliphatic signals which included a distinctive AB pat-
tern at 2.71 and 2.67 ppm attributed to the methylene alpha to the nitrile. The
13C NMR spectrum of the isolated material was difficult to analyse due to 13C-19F
coupling however a key signal at 69.0 ppm indicated the successful formation of
the alcohol and this was confirmed by a IR stretch at 3432 cm-1. The 13C NMR
spectrum showed alkyne signals of 201 shifted downfield to 91.4 and 86.0 ppm in
205 with the nitrile signal of 124 also showing a subtle shift from 114.0 to 116.6
ppm in 205. The desired addition product was easily separable using column
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chromatography recovering 62 % of the starting alkyne.
Hydrogenation of the alkyne of 205 using palladium on carbon under a hydrogen
atmosphere proceeded smoothly (Scheme 3.9). The 1H NMR showed new benzyl
doublet of doublets at 2.62 ppm with the AB pattern of 205 collapsing into a
singlet at 2.36 ppm. The isolated material had a distinct absence of alkyne and
alkene signals in both the 1H and 13C NMR spectra. Sodium borohydride was
added to a solution of the hydrogenation product 208 and cobalt chloride to give
the hydroxyamine 199 in low yield (Scheme 3.9). The1H NMR spectrum showed
two distinct broad multiplets at 2.90 and 2.54 ppm which correlate with aryl and
amine substituted methylenes.
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Scheme 3.9: Transmetative addition and subsquient reduction.
With the first 4-fluorobiphenyl target 199 generated, attention was focused onto
the synthesis of the 6-(4’-fluorophenyl)-2,4-dichlorophenyl target 200, which re-
quired the synthesis of the alkyne precursor 206 summarised in Scheme 3.10.
The organopalladium species required for the Suzuki cross-coupling reaction is
formed by a C-H activation at the ortho position of 2,4-dichlorobenzaldehyde 80.
Scheme 3.10 illustrates how C-H activation is directed at the ortho position by
converting the aldehyde to the oxime 209 in a strategy described by Dubost.120
Applying a Cory-Fuchs synthesis to 210 would generate the alkyne precursor 206
as input for the addition reaction with the ketonitrile 124.
Scheme 3.11 shows two C-H activation pathways to functionalise the ortho po-
sition of the starting benzaldehyde 80 by conversion to its methyl oxime 209.
A shorter efficient cross coupling of 209 with 4-fluorophenylboronic acid 211
was based on conditions reported by Sun.121 This pathway would generate the
biaryl 212 directly from the methyl oxime 209 and hydrolysis would generate
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Scheme 3.10: Generation of the alkyne 206 through a bromination,
Suzuki cross-coupling and Cory-Fuchs alkyne synthesis.
the biarylbenzaldehyde 210 in 3 steps from 2,4-dichorobenzaldehyde 80. An al-
ternative method by bromination of the methyl oxime 209 would generate 213
which, after hydrolysis, would be converted to 6-bromo-2,4-dichlorobenzaldehyde
214 using a procedure reported by Dubost.120 A Suzuki cross-coupling reaction
of 214 with 4-fluorophenylboronic acid 211 would give the biarylbenzaldehyde
210 in 4 steps from 2,4-dichlorobenzaldehyde 80.
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Scheme 3.11: ortho C-H activation by oxime functionalisation of 80
towards the synthesis of 210
The first stage in the synthesis of the biaryl 210 was to generate the oxime
209. The benzaldehyde 80 was stirred with methylhydroxyamine hydrochloride
and pyridine at room temp for 2 hours (Scheme 3.12).120 The method used a
non-aqueous workup by filtering the reaction mixture though a plug of silica to
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isolate 209 with a E:Z ratio of 95:5 in near quantitative yields and spectral data
identical to the literature.120 The mixture of isomers was used in the following
steps without purification.
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Scheme 3.12: Direct C-H activated suzuki
Introduction of the oxime functional group set the system up for ortho-substitution
though C-H activation. Stokker et al used a benzyl imine to stabilise a palladium
complex, which was isolated before a Grignard reaction generated the biaryl sys-
tem (Reaction 1 Scheme 3.1380). Repetition of this pathway was avoided as it
required an equivalent of expensive palladium acetate. A direct cross-coupling
method using copper triflate and a catalytic amount of palladium acetate was
reported by Sun et al. to couple O-methyl-(E )-2-methyl-benzaldoxime 215 with
4-fluoroboronic acid 211 in a 82% yield (Reaction 2 Scheme 3.13121). How-
ever, applying these to conditions to 209 returned starting materials (Reaction
3 Scheme 3.13). The result may be attributed to electron withdrawing effects
present on the aromatic system on 209. Consequently, synthesis of 2-bromo-4,6-
dichlorobenzaldehyde 214 was explored (Scheme 3.11).
Bromination of the oxime 209 was reported by Dubost120 using palladium acetate
and N -bromosuccinimide (Scheme 3.14). The reaction proceeded via the oxime
stabilised palladium intermediate 217, and a mixture of geometric isomers was
isolated with a ratio of E:Z 60:40 in good yield. These isomers were separated
by column chromatography on a small scale but resolving the mixture on a large
scale was not required.
With the brominated oxime 213 in hand, an assessment of whether to install the
4-fluorophenyl moiety before or after oxime deprotection was required. Scheme 3.15
shows both pathways. A Suzuki cross-coupling reaction on 213 would give the
precursor 218 to the intermediate biaryl 210. An alternative pathway would be
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Scheme 3.13: 1) Addition of Grignard reagent to 92 reported by Stokker
et al80 2) C-H activated Suzuki cross-coupling reported by Sun et al.121 3)
Unsucsessful C-H activated Suzuki cross-coupling reaction on 209
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Scheme 3.14: Ortho C-H bromination via a oxime stabilised paladium
intermediate reported by Dubost et al.120
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to hydrolyses the oxime prior to coupling generating 210 with the same number
of steps.
Cl
Cl
N
O
Br Cl
Cl
O
Br Cl
Cl
OF
Cl
Cl
N
O
F H
F
B
OH
OH
213 214 210
212
211
211
Scheme 3.15: Suzuki cross-coupling reaction of oxime 213.
Scheme 3.16 illustrates the Suzuki cross-coupling reaction between 211 and 213
which was based on conditions used previously in Scheme 3.8. 4-Fluorophenylboronic
acid and the oxime 213 were stirred with palladium acetate and TBAB at 70°C
overnight to give 212 in low yield. The brominated oxime 213 was consumed
in the reaction and gave a complex mixture. The major fraction of the mixture
was isolated and assigned as the E -isomer 218. 218 contained a benzyl-imine 1H
NMR signal at 8.02 ppm which correlated with the benzyl-imine signal of the E -
isomer of 213 at 8.15 ppm. Two new aromatic 1H NMR signals at 7.25 and 7.11
ppm indicated the formation of the biaryl system in 218. The remaining fractions
were isolated as complex mixtures. It was probable that the mixture to contained
the mono and disubstituted products 219 and 220 respectively (Scheme 3.16). As
a result, hydrolysis of the brominated oxime 213 prior to coupling was performed
as per Scheme 3.15.
The oxime 213 was converted to its benzaldehyde 214 using a aqueous form-
aldehyde solution and a catalytic amount of p-toluenesulfonic acid at 100°C
(Scheme 3.17).120 The reaction gave excellent reproducible yields and gave multi-
gram quantities of 2-bromo-4,6-dichlorobenzaldehyde 214.120 With the genera-
tion of the benzaldehyde 214, Suzuki cross-coupling reaction with 4-fluorophenylboronic
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Scheme 3.16: Suzuki cross-coupling reaction using the oxime 213.
acid 211 was explored.
The Suzuki cross-coupling reaction between the bromide 214 and 4-fluorophenylboronic
acid 211 was performed using palladium acetate, tetrabutylammonium bromide
and potassium carbonate in DMF at room temperature (Scheme 3.17). The con-
ditions were based on a literature method, without supporting the palladium
(II) on molecular sieves.122 The reaction gave 210 in good yield. The 1H NMR
spectrum of 210 gave a benzaldehyde signal at 10.05 ppm within variance of the
literature values of 10.280 and 10.13 ppm123. Two new fluorine coupled 1H NMR
multiplets at 7.25 and 7.13 ppm integrating for 2H indicated a successful biaryl
coupling. A new 13C NMR benzaldehyde signal at 189.8 ppm was present as was
a large fluorine splitting (J = 249 Hz) present in the C-F substituted 13C signal
at 164.4 ppm. The conversion of the benzaldehyde 210 into the key terminal
alkyne intermediate 206 continued.
Conversion of aldehydes to alkynes can be performed in a single step by Seyferth-
Gilbert Homologation using the Ohira-Bestmann reagent, however a two step
Cory-Fuchs synthesis was favoured. Preference for undertaking two step syn-
thesis was primarily based on a patent published by Li124 that utilised signific-
antly cheaper and more readily available starting materials. The biaryl 210 was
stirred with 2 equivalents of carbon tetrabromide and 4 equivalents of triethyl
phosphite at -45°C for 90 min (Scheme 3.18).124 The aldehyde signal in 210 at
10.05 ppm was replaced with a new singlet at 7.22 ppm in 221 in the 1H NMR
spectrum. A debromative elimination would generate the required alkyne 206.
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Scheme 3.17: Hydrolysis of the oxime 213 and subsequent Suzuki
cross-couping reaction with 4-fluoroboronic acid 211.
When the dibromide 221 was stirred in a solution of potassium tert-amylate
(KTA) in toluene, the bromoalkyne 222 was isolated in good yield. The 1H
NMR of 222 showed a absence of the vinylic signal of the starting material 221
at 7.22 ppm and two new substituted alkyne 13C NMR signals at 75.8 and 59.7
ppm. The reaction was repeated and the intermediate 222 was treated in situ
with methanol, dimethylphosphite and KTA which gave 206 in excellent yield.
The addition of methanol prior to addition of dimethyl phosphite and KTA was
reported by Li to avoid byproducts.124 The new terminal alkyne 206 had a singlet
at 3.37 ppm in the 1H NMR spectrum and two signals at 87.1 and 78.7 ppm in
the13C NMR spectrum. The addition reaction could now be investigated between
the alkyne 206 and the ketonitrile 124.
The addition reaction between the alkyne 206 and the ketonitrile 124 using the
cerium chemistry described previously in Table 3.1.1 gave the desired propargyl
alcohol 207 in good yield. (Scheme 3.19) The 13C NMR spectrum showed char-
acteristic substituted alkyne signals at 81.7 and 69.2 ppm which are typical for
this type of propargyl alcohol. The 1H NMR signal at 2.69 ppm was typical of
the methylene alpha to the nitrile. Heterogeneous hydrogenation of the alkyne
in 207 was explored.
Hydrogenation of the alkyne contained on 207 was attempted using palladium on
carbon under a hydrogen atmosphere at room temperature (Table 3.2.1). Con-
sumption of the starting material occurred, however the alkene 223 was isolated.
The reaction stopped after the first alkyne hydrogenation indicating hydrogen-
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Scheme 3.18: Modified Cory-Fuch alkyne synthesis utilising triethyl
phosphite and dimethyl phosphite.
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Scheme 3.19: Addition of alkyne 206 to the ketonitrile 124.
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ation of the cis-alkene 223 did not progress using these conditions. The NMR
spectra were initially confusing but provided information as to why the second
hydrogenation step did not proceed. New vinylic signals of 223 in the 1H NMR
spectrum were present at 6.47 and 5.53 ppm and are shown in Figure 3.7. The
apparent pair of doublet of doublets can be assigned to a 1:1 mixture of diastereoi-
somers. Rotation is restricted between the single bond between the benzene ring
and the alkene causing an axis of chirality. With two centres of asymmetry in the
molecule, 4 diastereoisomers can be produced and are illustrated in Figure 3.6.
Table 3.2.1: Incomplete hydrogenation of 207.
F
C13H27
OH
CN
Cl
Cl
F C13H27
OH
CN
Cl
Cl
F
C13H27
OH
CN
Cl
H
H
Cl
Cond.
207 223 224
Conditions 207:223:224
Pd/C (25 %wt), H2, EtOAc, 25°C, 15h. 0:100:0
Pd/C (25 %wt), H2, EtOAc, 25°C, 96h. 0:100:0
Pd/C (25 %wt), H2, EtOAc, 78°C, 15h. complex mixture
Ar Cl
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CN
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C13H27
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C13H27
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Cl
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CN
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Figure 3.6: Possible diastereoisomers contained in 223.
Each of the two pairs of diastereoisomers, 225/228 and 227/226 show two alkene
signals. The vinylic benzyl proton (Ha) was identical for both pairs of diastereoi-
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somers and appears as a doublet at 6.49 ppm. The neighbouring vinylic proton
(Hb) showed different chemical shifts for each pair of diastereoisomers and con-
sequently these vinylic signals at 5.53 ppm appear as two separate doublets at
5.57 and 5.50 ppm (Figure 3.7). The highly hindered and rotationally restricted
system consequently showed a complicated 13C NMR spectrum. Signals were
further split independently from that caused by a 19F substitution. Previous hy-
drogenations were performed successfully in Scheme 3.4 and Scheme 3.9. The
hinderance induced from a 2-chloro-6-phenyl substitution of the vinylbenzyl sys-
tem in 223 led to the incomplete hydrogenation and an alternative synthesis of
the target 229 was investigated.
10.95
ppm 5.56.06.5
H H
Figure 3.7: 1H NMR of the mixture of isomers contained in 223.
The first alternative to be trailled was the use of a chemical hydrogen donor,
diimide. Diimide was prepared in situ from p-toluenesulfonyl hydrazide and
sodium acetate in ethanol under reflux.125 The 1H NMR spectrum of the crude
product showed the reaction did not occur.
F
C13H27HO
CN
Cl
H
H
Cl
F
C13H27
OH
CN
Cl
Cl
TsNHNH2 
NaOAc
EtOH, 79°C
15h
223 224
Scheme 3.20: Hydrogenation attempt using tosyl diimmide.
Isomerisation of the double bond to the E configuration may make the alkene
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less hindered that the Z, making it more susceptible to hydrogenation. When the
alkene 223 was exposed to iodine at room temperature no reaction occurred.
F
C13H27HO
CN
Cl
H
H
Cl
F
C13H27
OH
CN
Cl
Cl
I2(cat)
25°C, 15h
223 230
Scheme 3.21: Isomerisation attempt using Iodide.
With little evidence that isomerisation was proceeding an alternative reduction
using lithium aluminium hydride was proposed. Literature provided evidence
that allyl alcohols, specifically 3-phenyl propenol, are susceptible to 1,4-hydride
addition.126–128 Variable yields of 12 - 55% were obtained previously using lithium
aluminium hydride for nitrile reduction of this type of hydroxynitrile and for the
total reduction of the ketonitrile 124. The alkene 223 was exposed to lithium
aluminium hydride at room temperature in THF (Scheme 3.22). The starting
material was consumed, indicating nitrile reduction, however 1H NMR analysis
of the crude showed a complex mixture. The mixture contained several new Z -
alkene signals and resolving the mixture was not attempted as chromatographic
separation was deemed unlikely. An attempt was made to reduce the nitrile to
the free amine 231 prior to hydrogenation. Sodium borohydride was added to
a solution of 223 and cobalt chloride (Scheme 3.22). The starting material was
consumed and the 1H signal at 2.44 ppm of the starting material was no longer
present. A significantly cleaner crude was isolated using cobalt chloride and so-
dium borohydride compared to previous attempts lithium aluminium hydride.
The crude amine 231 was exposed to palladium on carbon under a hydrogen at-
mosphere. No changes were seen to the alkene signals. With the alkene remaining
intact methods to completely remove the alkene were abandoned.
A complex mixture was obtained in Table 3.2.1 when 223 was exposed to pal-
ladium on carbon under a hydrogen atmosphere at 78°C which was reexamined
more closely. Two new singlets were present around 2.4 ppm in the 1H NMR
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Scheme 3.22: Unsucsessful attempts to generate 229.
spectrum indicating a full but incomplete hydrogenation occurred. When the
alkyne 223 was exposed to a weight equivalent of palladium on carbon under
a hydrogen atmosphere in refluxing ethyl acetate for 5 hours (Figure 3.8a), two
difficult to separate products 208 and 224 were isolated in low yield. The struc-
ture of the reductive dechlorination biphenyl 208 was confirmed as it had a 13C
NMR spectra identical to that of an authentic sample obtained from a previ-
ous synthesis (Scheme 3.9). The elevated temperatures utilised in Scheme 3.8a
are similar to a reported reductive dechlorination reaction.129 Figure 3.8b shows
the reductive dechlorination reaction on a similar system that uses palladium on
carbon and tritium gas to convert 232 to 3H-radiolabeled amphetamine 233.130
Careful spectral analysis was required to confirm that 224 was successfully separ-
ated from the other possible mono-chlorinated products. The DEPT spectrum of
224 offered critical information on the chlorine substitution pattern. Figure 3.9
shows the aromatic region overlays of the DEPT NMR spectra of the reductive
dechlorination product 208, the intact 3,5-dichloro-4’-fluorobiphenyl 206 and the
desired 2,4-dichlorobiphenyl product 224. These comparisons were required as
fluorine coupling along the biphenyl system yields the absolute number of 13C
signals invalid. Introduction of new C-H bonds by reductive dechlorination leads
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to extra positive DEPT signals in 208 when compared with the 3,5-dichloro-4’-
fluorobiphenyl system precursor 206 and 224. The 3,5-dichloro-4’-fluorobiphenyl
system remained intact in 224 as it contained 6 positive DEPT signals expected.
The 1H NMR spectrum of 224 no longer showed signals at 6.47 and 5.53 ppm
indicating the successful hydrogenation of cis-alkene in 223. The aromatic region
contained 4 distinct signals expected for the 3,5-dichloro-4’-fluorobiphenyl system
(Figure 3.10). The pair of doublets at 7.10 and 7.40 with meta-coupling of 2.2 Hz
provide concluding evidence that reductive dechlorination had not occurred and
a mono dechlorination product was not isolated. The 13C signal at 117.3 ppm
in 224 confirmed the presence of a nitrile. Synthesis of 224 was not considered
ideal, using large quantities of palladium on carbon and starting materials so as
to generate 224 in low yield, but with milligram quantities of 224 isolated its
reduction in the following step was explored.
F
C13H27HO
CN
Cl
H
H
Cl
F
C13H27
OH
CN
Cl
Cl
Pd/C
(1 wt eqv) 
H2
78°C
5 h
F
C13H27
OH
CN
9.5% 5.3%
50%
recovered223 208 224
(a) Forcing conditions used to isolate 224.
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3H
3H
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3H2
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(b) Reductive dechlorination reported by Lamb
et al.130
Figure 3.8: Reductive dechlorination using hydrogen and palladium on
carbon.
The nitrile was reduced by adding sodium borohydride to a solution of 224 and
cobalt chloride at 0°C (Figure 3.10). Purification gave the target in modest
yield with the distinct absence of the nitrile signal of the starting material. The
3,5-dichloro-4’-fluorobiphenyl system remained intact with 1H NMR signals and
splitting equivalent to those in Figure 3.10. The amine substituted methylene
1H signals were characteristic appearing with significant overlap as a pair of mul-
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Figure 3.9: Expansion of the 13C-DEPT aromatic region of 208, 206 and
224.
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Figure 3.10: Expansion of the 1H NMR aromatic region of 224 and
subsquent reduction of the nitrile 224.
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tiplets at 2.6 ppm. With the synthesis of 229 complete, alternative targets were
proposed.
The introduction of the 6-(4’fluoro)-2,4-dichloro functionality, derived from the
potent HMG-reductase inhibitor 77, was proposed as a amine substituent (Fig-
ure 3.11). Further structure-activity information about the 6-(4’fluoro)-2,4-dichloro
moiety would be obtained by comparison of the target 234 to its precursor 109.
Generation of 234 by reductive amination would make use of 2-(4’-fluorophenyl)-
4,6-dichlorobenzaldehyde 210 synthesised previously in Scheme 3.17.
C13H27
OH
NH2
C13H27
OH
N
H
ClCl
O
HO
O
Cl
HMG-CoA reductase
activity unknown
Cl
IC50 = 0.005 µM
F
F
T.brucei IC50: 
P.falciparum TM4 IC50:
P.falciparum K1CB1 IC50 :
VERO IC50:
0.27 ± 0.01 µM
20.2 ± 0.95 µM
20.8 ± 2.38 µM
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-
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Figure 3.11: Introduction of the 6-(4’fluoro)-2,4-dichloro fragment as a
amine substitution.
The benzaldehyde 210 was stirred with the amine 109 and anhydrous mag-
nesium sulphate at 50°C for 48 hours before addition of sodium borohydride
(Scheme 3.23). The 1H NMR spectrum of the product showed a new benzylic AB
pattern which overlapped with the hydroxy substituted methine and appeared as
a multiplet at 3.71 ppm. Two 13C NMR substituted amine signals at 48.4 and
47.9 ppm were present. The mixture of alkyl and aromatic signals in both the
1H and 13C spectra correlated with those obtained from previously synthesised
compounds of this type.
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26%
109 210 235
Scheme 3.23: Reductive amination to generate 235.
3.3 Fluvastatin
With the introduction of the 2-(4’-fluorophenyl)-4,6-dichlorophenyl system com-
plete, other means to introduce the established statin structural features to NMT
inhibitors were explored. Scheme 3.24 shows fluvastatin 236, a clinically avail-
able HMG-reductase inhibitor, which contains a indole core substituted with
4’-fluorophenyl and a isopropyl group. The isopropyl group, along with the 4’-
fluorophenyl, are standard features of many of the synthetic statins and its inclu-
sion was explored by incorporation into the new target 116. Comparison with the
previous targets will explore the structure-activity dependency of the isopropyl
group towards NMT inhibition.
N
F
OH
HO OH
O
C13H27
N
F
OH
NH2
HMG-CoA reductase
IC50 = 28nM
NMT 
IC50 = ?
236 116
Scheme 3.24: Incorporation of fluvastatin features into NMT inhibitors.
Incorporation of the hydrophobic fluvastatin fragment into a potential NMT in-
hibitor required the synthesis of the key alkyne intermediate 237 (Scheme 3.25).
The same addition reaction using the alkyne 237, akin to Scheme 3.19, would
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introduce this fluvastatin fragment as a tertiary alcohol. The first phase of the
synthesis of the key alkyne intermediate 237 was to prepare the indole 96 via a
Bischler-Möhlau indole synthesis.131 The second phase was to formylate the indole
to give 238 before performing a two step Corey-Fuchs132 synthesis to generate
237.
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N
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239 98 240 96
238241237
Scheme 3.25: Overview for the synthesis of propenal
One of the starting materials for the Bischler-Möhlau indole synthesis was the
acetophenone 239, which was obtained by bromination of 4’-fluoroacetophenone
242 (Table 3.3.1). When bromine was added to a solution of 4’-fluoroacetophenone
242 at room temperature 239 was isolated from a mixture containing the dibrom-
inated 243 and the starting material. The 1H NMR showed a downfield singlet
at 4.41 ppm (2H) and a 13C NMR signal at 30.5 ppm, both indicative of a
monobromo substituted methylene. The 1H and 13C NMR spectra both showed
splitting in the aromatic region due to fluoride substitution. The melting point
and FT-IR of the 2-bromo-4´-fluoroacetophenone matched that reported in the
literature.133 Purification of multigram quantities of 239 by column chromato-
graphy was problematic and methods were explored that avoided the dispropor-
tionation reaction described by Kröhnke134 in Scheme 3.26.
Table 3.3.1 shows the improved result by addition of the Lewis acid, aluminium
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Table 3.3.1: Bromination of 4-fluoroacetophenone
F
O
F
O
Br
F
O
Br
Br
Br2
-HBr
242 239 243
Conditions 242:239:243 Yield
0.9 eq Br2, CHCl3, 25°C, 1.5h 7:84:9 77%
1 eq Br2, AlCl3, Ether, 25°C, 15min 2:97:<1 79%
trichloride, which was used in the bromination of acetophenone.135 The reac-
tion rate was accelerated thus avoiding significant formation of the dibrominated
product 243 from the competing disproportionation reaction. The method was
implemented on 10 – 20 g scale without the need for purification by column
chromatography.
O
Br
2
HBr
O O
Br
Br
Scheme 3.26: Disproponation reaction of acetophenone proposed by
Kröhnke et al.134
Although N -isopropylaniline is commercially available it was prepared in one step.
The reductive amination of aniline and acetone exposed to zinc dust and acetic
acid gave N -isopropylaniline in excellent yield (Scheme 3.27).136 The 1H NMR,13
C NMR and IR spectra all possessed signals which matched those reported in the
literature. A small impurity of N,N -diisopropylaniline 244 was present but it
was deemed to be insignificant for the following step. The method was successful
at the 20 - 40 g scale without the need for further purification.
NH2 HN NZn, CH3COOH, 
(CH3)2CO
70°C, 3.5h, 
95%
245 98 244
Scheme 3.27: Formaion of N -isopropylanaline by reducive amination
With 2-bromo-4’-fluoroacetophenone 239 and isopropyl aniline 98 in hand, a
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Bischler-Möhlau synthesis of the indole 96 was attempted.83,131,137 The reac-
tion proceeds by a substitution reaction between the acetophenone 239 and N -
isopropylaniline 98 to give 240 which can undergo an intramolecular electrophilic
aromatic substitution to generate the indole 96.
F
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Br NH
F
O
N
N
F
replacemen
239 98 240 96
Scheme 3.28: Bischler-Möhlau indole synthesis of Fluvastatin segement
Initially 240 was isolated before proceeding with annulation. A mixture of the
acetophenone 239 and 2 equivalents of N -isopropylaniline 98 was heated at re-
flux in ethanol for 20 hours. The1H NMR spectrum of 240 showed a new singlet
at 4.60 ppm, this combined with signals comparable to each starting material,
provided evidence that substitution had occurred. The substitution reaction re-
leases an equivalent of hydrobromic acid and the literature procedure used a
second equivalent of N -isopropylaniline as a acid scavenger. Although purific-
ation of 240 was achieved by chromatography, recovery of N -isopropylaniline
proved difficult.
The substitution reaction was optimised by testing a range of bases. Alternative
bases were tested to avoid using a second equivalent of N -isopropyl aniline 98 and
to provide a simple purification procedure. Table 3.3.2 summarises trials in which
substitution product 240 was isolated before the annulation step. The use of a
biphasic sodium carbonate system showed consumption of the bromide but gave
a complex mixture without significant generation of the desired ketoamine 240.
The use of triethylamine showed full consumption of the bromide 239, however
a major proportion of N -isopropylaniline 98 was present after workup. Triethyl-
amine, a competitive nucleophile, underwent alkylation and formed a quaternary
ammonium salt that was removed during workup. N,N -Diisopropylethylamine
(DIPEA, Hunigs base)138, a non-nucleophilic base, gave promising results. The
excess DIPEA was removed via acid workup and the crude material was of suffi-
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cient purity for the next step. Attempts were then made to combine the substi-
tution and annulation steps into a one pot procedure.
Table 3.3.2: Optimisation of the substitution reaction.
F
O
Br NH
F
O
N
239 98 240
Conditions 239:240 Yield
1:2 eq 239:98, EtOH, 78°C 20h. 0:100 73%
1:1:1.5 eq 239:98:Na2CO3, EtOH, 78°C 2h. complex mixture N/A
1:1:1.1 eq 239:98: TEA, EtOH, 78°C 24h 0:100 N/A
1:1:1.5 eq 239:98:DIPEA, EtOH, 78°C 6.5h. 0:100 >95% (crude)
A two stage, one pot alkylation followed by annulation was not formally repor-
ted in the literature (Scheme 3.29). Tang et al.131 discussed yields greater than
90% using a non-radiolabeled system, but on hot runs only achieved 60% thus
requiring purification of 240 before annulation. The final manufacturing process
discussed a one pot substitution and annulation method however a detailed ex-
perimental was not presented.83 Attempts using DIPEA or a second equivalent
of N -isopropylaniline 98 followed by addition of zinc chloride (Scheme 3.29) gave
only the acetophenone 240 without significant annulation to the indole 96. The
activity of the zinc chloride Lewis acid catalyst was neutralised by exposure to a
Lewis base. Efforts were then focused towards isolating the ketoamine 240 before
conversion to the indole 96.
F
O
Br NH
N
F
ZnCl2
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or
DIEPA
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98 96
Scheme 3.29: One pot indole synthesis of 96.
The annulation of ketoamine 240 using zinc chloride to give the indole 96 is
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reported.131,137 In practice the reaction required a vast excess of the Lewis acid
to promote internal electrophilic aromatic substitution despite vigorous drying.
(Table 3.3.3). Reactions frequently would not initiate or conversion would be slow.
Longer reaction times were coupled with low yields because the ketoamine 240
was thermally unstable. The reaction generates 1 mol equivalent of water which
may deactivate zinc chloride as the reaction progresses, so the use of molecular
sieves as a water scavenger was trailed. The use of molecular sieves did improve
yields but mechanical problems (stirring and filtering) were encountered on scale
up and thus their use avoided. The final conditions involved the use of a large
excess of zinc chloride, more than that described in the literature. However
a method was successfully applied at a 10 – 20 g scale requiring only simple
purification. The formation of the desired indole 96 was confirmed by 1H and 13C
NMR spectra and melting point which matched the literature. The subsequent
formylation was explored.
Table 3.3.3: Optimisation of indole formation using zinc chloride as a catalyst.
F
O
N N
F
240 96
Conditions 240:96 Yield
2 eq ZnCl2, EtOH, 78°C, 17h. 100:0 N/A
20 eq ZnCl2, EtOH, 78°C, 72h. 0:100 42%
purified 240, 30 eq ZnCl2, 3 wt eq 4A mol sieve, 15h. 0:100 >98%
crude 240, 30 eq ZnCl2, 10 eq 4A mol sieve, 78°C, 24h. <2:98 57%
crude 240, 25 eq ZnCl2, 78°C, 15h. <2:98 70%
Conditions for formylation of the indole 96, via a Vilsmeier-Haack reaction, were
available.137,139 When the indole 96 was exposed to two equivalents of (chloro-
methylene)dimethyliminium chloride generated in situ from phosphorous oxy-
chloride and DMF (Scheme 3.30), 238 was isolated in good yield. Aldehyde
signals could be seen in the 1H and 13C NMR spectra at 9.81 ppm and 183.7
ppm respectively.137 Methods to perform a Corey-Fuchs alkyne synthesis on 238,
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towards 237, were explored.
N
F
POCl3, DMF
0 - 80°C, 2h
57%
N
F
O
96 238
Scheme 3.30: Vilsmeier-Hack formylation of 96.137,139
Scheme 3.31 illustrates the conversion of the formylindole 238 to the alkyne 237
using a procedure detailed by Thottathil.132 The aldehyde 238 was reacted with
two equivalents of triethyl phosphite and carbon tetrabromide at -45°C for 3.5
hours. The vinylic dibromide 241 no longer showed an aldehyde signal, replaced
by a new vinylbenzyl 1H signal at 7.57 ppm. The DEPT spectrum showed the
correct number of CH signals taking into account fluorine splitting. Remaining
carbon tetrabromide was removed during column chromatography and the vinylic
dibromide 241 was isolated in excellent yield. The second step of the Corey-Fuchs
synthesis was followed from the same literature procedure.
Conversion of the dibromide 241 to the alkyne 237 was distinct from a stand-
ard Corey-Fuchs procedure and did not undergo a Fritsch-Buttonberg-Wiechell
rearrangement. Thottathil132 detailed a procedure that used potassium tert-
amylate, a mild base, instead of butyllithium to eliminate the vinylic benzyl
proton on 241 to give the intermediate 246. Potassium tert-amylate was added
to a solution of the dibromide 241 in toluene at 0°C. The first elimination re-
action showed consumption of 241 after 20 min and 246 was visible as a new
spot. The second phase converted the bromide 246 to the alkyne 237 using mild
conditions in a single pot. Methanol, dimethyl phosphite and a second equivalent
of potassium tert-amylate was added to the solution of the bromoalkyne 246 at
0°C. The alkyne 237 was isolated in excellent yield with new singlet at 3.55 ppm
in the 1H NMR spectrum, indicative of a terminal alkyne. The presence of the
alkyne system was visible in the 13C NMR spectra with key signals at 85.9 and
76.4 ppm. With gram quantities of the alkyne 237 available, the synthesis of the
target amine 116 continued via an addition reaction outlined in Scheme 3.32.
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Br
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F
P(OEt)3, CBr4
-45°C 3.5h
89%
KTA
0°C, 20 min
Br
81%
N
F
H
1) MeOH             
2) (CH3O)2P(O)H 
3) KTA
238 241
246
237
Scheme 3.31: Coversion to the alkyne using a modified Corey-Fuchs
approach.
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N
F
C13H27
OH
CN
N
F
C13H27
OH
NH2
[RED]
237 247 116
Scheme 3.32: Proposed synthesis of 116.
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The use of organocerium reagents to add alkynes to the ketonitrile 124, used
throughout this chapter, proceeded under the usual conditions to give 247 in
excellent yield. The terminal alkyne 1H NMR signal was no longer present and
replaced with a new overlaid signal at 2.83 ppm indicative of the hydroxy ni-
trile system contained on 247. The two terminal alkyne 13C NMR signals were
replaced by two new signals at 96.6 and 79.1 ppm. The fluvastatin fragment
was stable under the addition conditions as aromatic region and isopropyl sig-
nals remained unchanged. Reduction of the alkyne contained in 247 was then
explored.
N
F
N
F
OH
C13H27
CN
-84°C, 4h
87%
n-BuLi, CeCl3O
C13H27
CN
237 247124
Scheme 3.33: Cerium acetylide addition of 237 to 124.
Hydrogenation of the indole 247 mirrored problems encountered previously with
the hydrogenation of 207 (Table 3.2.1). When the alkyne 247 was exposed to
palladium on carbon under a hydrogen atmosphere overnight at room temper-
ature the alkene 248 was isolated (Scheme 3.34). Figure 3.12 shows the vinylic
region of the 1H NMR spectrum of 248. The alkene signals of 248 appeared at
a pair of doublets 6.68 and 5.95 ppm and the cis-isomer was assigned from the
coupling constant of 12.2 Hz. The isopropyl indole substitution on 248 was less
hindering compared to the previous 2-chloro substitution on the biphenyl 223 as
no further splitting of the signal at 5.95 ppm originated from restricted rotation.
The decrease in hindrance was attributed to the substitution bond angles of the 5
membered ring of the indole system compared to the 6 membered ring in the bi-
phenyl 223. Despite the indole 248 being less hindered than the 2-chlorobiphenyl
223 the second hydrogenation step did not proceed and consequently the reaction
was repeated at higher temperature.
The alkene intermediate 248 was exposed to palladium on carbon in ethyl acetate
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OH
C13H27
CN
C13H27
N
F
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CN
Pd/C, H2
78°C, 15h
74%
N
F
CN
HO C13H27
i-prPd/C, H2
25°C, 15h
74%
247 248 249
Scheme 3.34: Hydrogenation of 247.
under reflux in a hydrogen atmosphere. The hydrogenation of the cis-alkene
proceeded and the product 249 was isolated without the over-reduction problems
encountered previously in Figure 3.8a when chlorine substituents were present.
Neither the alkyne or alkene signals of the starting material and the intermediate
were present. A new benzylic triplet was present at 2.89 ppm in the 1H NMR
spectrum and the hydroxynitrile methylene signal appeared at 2.47 ppm. A signal
at 117.4 ppm in the 13C spectrum confirmed the availability of the nitrile for the
final reduction step.
0.9781
ppm 678
F HO 13H27
i
H
H
248
Figure 3.12: Expanded aromatic region of 248.
When sodium borohydride was added to a solution of the nitrile 249 and cobalt
chloride (Scheme 3.35), the nitrile was consumed and the amine formed in good
yield. No signal was present at 117.4 ppm in the 13C spectrum and nitrile reduc-
tion was confirmed with a absence of the nitrile absorbance at 2255 cm-1 in the
IR spectrum. The 1H signals of the amine 249 at 2.89 and 2.47 ppm collapsed
into a multiplet at 2.90 ppm that fitted with other hydroxyamines of this type.
Alternative approaches as to incorporate the fluvastatin moiety were explored.
110
C13H27
N
F
OH
CN
C13H27
N
F
OH
NH2
CoCl2, NaBH4
0-25°C, 2h
66%
249 116
Scheme 3.35: Reduction of the nitrile on 249.
Two new targets, 117 and 250, were envisioned and incorporated the fluvastatin
fragment though a reductive amination of the hydroxyamine 109. These targets
were designed to test if the incorporation of the fluvastatin moiety, though a
amine linker, increased the potency of 109. The first target 117 made use of the
available formylated fluvaststin intermediate 238 isolated in Scheme 3.30.
C13H27
OH HN
N
F
C13H27
OH HN
N
F
C13H27
OH
NH2
0.27 ± 0.01 µM
20.2 ± 0.95 µM
20.8 ± 2.38 µM
22.3 ± 1.09 µM
SI
83
1.1
1.1
-
T.brucei IC50:
P.Falciparum TM4 IC50:
P.Falciparum K1CB1 IC50:
VERO IC50:
Activity unknown Activity unknown
109
117 250
Figure 3.13: New targets for synthesis 117 and 250.
The reductive amination of the hydroxyamine 109 with the benzaldehyde 238
was performed as a two step procedure (Scheme 3.36). Sodium borohydride was
added to the imine intermediate, formed by stirring 109 and benzaldehyde 238
at 50°C in a sealed vessel for 48 hours. The amine 117 was UV active and
contained complex 1H and 13C NMR aromatic signals which were comparable to
the starting aldehyde 238. The myristoyl chain signal at 1.30 ppm was present
in the 1H NMR spectrum along with a key hydroxy substituted methine at 3.62
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ppm. The amino benzyl methylene signal at 3.59 ppm was complimented by the
adjacent amine substitution multiplets between 2.4 and 2.6 ppm confirming the
presence of a secondary amine. With the first fluvastatin reductive amination
target 117 isolated, different strategies were explored towards the synthesis of
the longer linker length target 250 in Figure 3.12.
C13H27
OH HN
N
F
C13H27
OH
NH2
N
F
O 1) MgSO4, 
50°C, 48h
2) NaBH4, 
0-25°C, 2h
26%
109 238 117
Scheme 3.36: The reductive amination of 109 with 238.
The synthesis of the target 250 is outlined in Scheme 3.37. Installing the propenal
chain, to the indole 96 was proposed from methods developed for the manufacture
of fluvastatin. Removal by reduction of the alkene in 100 was to ensure the
mobility of the longer linker. The reductive amination of the aldehyde 251 with
the hydroxyamine 109 was expected to give 250 in 3 steps from the indole 96.
Acylation of the indole 96 in Scheme 3.37 required the synthesis of 3-(N -Methyl-
N -phenylamino)acrolein (MPAA) 99 using methods reported by Lee et al.140
N -methylformanilide 252 and butylvinyl ether 253 were added to a solution of
oxalyl chloride at -10°C to give MPAA 99 in good yield (Scheme 3.38). The
reaction proceeds via the imine intermediate 254 which is hydrolysed to 99 upon
workup. The 1H NMR spectrum showed a aldehyde signal 9.27 ppm (d, J =
8.1 Hz, 1H) coupled to a vinylic proton at 5.47 ppm (dd, J = 13.0, 8.1 Hz, 1H).
13C NMR signals matched the literature.140 The material was purified by vacuum
distillation, to give multigram quantities of MPAA 99.
The modified Vilsmier-Hack acylation using MPAA 99 was well reported in the
literature.83,131,140 The reaction, shown in Scheme 3.39, was designed specifically
for the generation of the propenal 100; a key intermediate in a process to gener-
ate fluvastatin 3. The reaction proceeds as a 3 stage, single pot operation. The
first stage is the generation electrophilic iminium salt 255 by reacting 99 with
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Scheme 3.37: Proposed synthesis of 250.
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BuN
H
O
O
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H2O
-BuOH
(COCl)2, CH3CN
-10 - 25°C, 
120 min, 50%
252 253 254 99
Scheme 3.38: Preparation of MPAA 99.140
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phosphorous oxychloride. The second step saw the introduction of the nucleo-
philic indole 96 which generated the resonance stabilised iminium salt 256 via a
electrophilic aromatic substitution. Quenching converted the iminium salt 256
to the propenal 100 which was isolated in excellent yield. The new aldehyde
signal at 9.59 ppm (d, J = 7.6 Hz, 1H) showed coupling to a new alkene signal at
6.34 ppm (dd, J = 16.2, 7.6 Hz, 1H). The 13C NMR spectrum showed a new al-
dehyde signal at 193.4 ppm that confirmed the installation of the propenal chain.
Hydrogenation of the alkene on 100 was explored.
N O N Cl
N
F
N
F
N
N
O
F
H2O
POCl3
-5°C, 2h.
82°C, 3h
55°C, 3h
79%
99 255 96
256100
Scheme 3.39: The modified Vilsmeer-Hack on 96 using MPAA 99
The penultimate step in Scheme 3.37 was the removal of the alkene in 100, its
position and purpose was specific to HMG-CoA reductase inhibition and not con-
sidered a structurally significant feature for the proposed NMT inhibitors. If the
potency of the target 250 shows potential, the structure activity relationship for
inclusion of the alkene could easily be explored. 100 was recovered when exposed
to triethylsilane and palladium chloride in a selective hydrogenation procedure.141
(Table 3.3.4). A total reduction to the saturated alcohol 257 followed by oxida-
tion to the aldehyde 251 was pursued. The use of lithium aluminium hydride gave
the allylic alcohol 258 as the major product. Exposure to sodium borohydride
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also gave 258 as the sole product. Favourable results were obtained using so-
dium borohydride in pyridine142,143 obtaining a 19:81 mix of 258:257, however
the mixture could not be separated by column chromatography. Standard alkene
hydrogenation procedures, using palladium on carbon under a hydrogen atmo-
sphere, led to a complex mix of products.
Table 3.3.4: Hydrogenation of propenal system.
N O
F
R
R =
O
R
OH
R
CH3
R
CH3
R
OH
RCond.
100 258 257 259 260 251
Conditions 100 258 257 259 260 251 Yield
EtOH, Et3SiH, PdCl2, rt, 48h. 100% - - - - <1%
THF, LiAlH4, rt, 15h. <1% 69% 31% - - -
EtOH, NaBH4, rt, 15h. <1% 100% - - - -
Py, NaBH4, -20°C, 72h. <1% 19% 81% - - -
EtOAc, Pd/C, H2 , rt, 68h. 2% 10% 34% 19% 5% 30%
EtOAc, Pd/C, KOAc, H2O, <1% - 15% - - 85% 72%
H2, rt, 36h.
Special hydrogenation conditions, based on the hydrogenation of cinnamalde-
hyde, were then applied to 100.144 Addition of potassium acetate and water
increased the selectivity towards 3-phenylpropanal, avoiding the generation of
significant quantities of either 3-phenylpropanol or cinnamic alcohol. These con-
ditions were mirrored, using hydrogen at atmospheric pressure, and a 15:85 mix-
ture of 257:251 was obtained. Critically, the separation of mixture was achieved
by column chromatography and 251 was isolated in good yield. The product
contained characteristic signals in the 1H NMR spectrum at 9.73 (1H, t), 3.17
(2H, t) and 2.71 (2H, m); assigned to the saturated aldehyde chain of 251. The
13C NMR spectrum mirrored the change with new signals at 200.4, 44.4 and 17.7
ppm.
Reductive amination using the aldehyde 251 was explored to make the amine 250.
The hydroxyamine 109 was heated in the presence of the 251 before addition
of sodium borohydride (Scheme 3.40). The 1H NMR spectrum of the amine 250
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showed 4 distinct amine substituted methine multiplets between 2 and 2.5 ppm.
The hydroxy multiplet and benzyl triplet signals were present at 3.77 and 2.64
ppm respectively. No aldehyde signal of the starting material was present in
the 1H NMR spectrum and 250 showed expected signals from both the fluvastatin
and myristic fragments.
C13H27
OH HN
N
F
N
F
O
C13H27
OH NH2
23%
1) MgSO4, 
50°C, 20h.
2) NaBH4,  
0-25°C, 15h.
4109 250
Scheme 3.40: reductive amination using 251
A suite of new compounds have been synthesised that combine fragments in-
spired by HMG-CoA reductase inhibitors with the hydroxyamine 109. Many of
the compounds were synthesised using organocerium reagents or though a reduct-
ive aminations from aldehydes. The toxicity of these new derivatives of parent
hydroxyamine 109 was assessed against T. brucei rhodesience and P. falciparum.
3.4 in vitro Protozoan toxicity
The synthesis of compounds throughout this chapter were designed to incor-
porate the fragments of HMG-reductase inhibitors that are associated with the
binding site of the Coenzyme A substrate, and apply their binding potential to-
wards NMT. It is assumed that increased potential towards NMT will result in
a greater toxicity towards T. brucei rhodesience and P. falciparum. Compound
261 showed nano-molar potency as a cholesterol biosynthesis inhibitor77 and the
phenyl moiety was incorporated, at two sites, into the hydroxyamine 109 de-
veloped in Chapter 2 as to explore its application towards NMT. Introduction of
a non-polar benzylamine substitution, discussed in chapter 2, improved selectiv-
ity towards P.falciparum. Figure 3.14 shows the tertiary alcohol 175 which has
been demonstrated to offer no improvements to potency and selectivity towards
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either T.brucei rhodesience or P.falciparum by incorporating a 3-phenyl fragment
linked as a tertiary alcohol.
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Figure 3.14: Structure-activity results against T. brucei rhodesience and
P. falciparum though introduction of the phenyl fragment inspired from 261
To further explore the potential for incorporation of statin fragments into po-
tential NMT inhibitors, several tertiary alcohols were synthesised throughout
this chapter and their activities against T.brucei and P.falciparum are shown in
Figure 3.15. The inclusion of a 2,4-dichlorophenyl substitution in 190 slightly
improved the selectivity towards T.brucei compared to unhalogenated 175. This
trend was not followed by introduction of the biphenyl system in 199, for which
the potency was about 10 times less than the unsubstituted 109, with 199 show-
ing a typical activity type associated with tertiary alcohol series. No notable
changes in activity were observed though the combination of the 2,4-dichlorophenyl
substitution in 190 with the biphenyl substitution contained on 199. A slight
drop in potency towards P.falciparum was observed by introduction of the fluvast-
atin fragment in compound 116, which again did not improve the potency or
selectivity compared to 109. No changes were observed in the toxicity to VERO
cells in any of the tertiary alcohols compared to the parent compound 109.
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Figure 3.15: Structure-activity results of statin inspired tertiary alcohols.
118
Throughout this chapter several of the statin-like fragments were incorporated
into the hydroxyamine 109 as amine substituents. Some selectivity improvements
were observed in the benzylamine 149, generated in Chapter 2 and consequently
other aromatic statin-like amine substitutions were synthesised and their toxicity
assessed against T.brucei rhodesience and P.falciparum (Figure 3.16). No im-
provements to potency or selectivity were observed by introducing a 2,4-dichlorobenzyl
amine substitution in 196, a trend continued by adding a 2-(4’-fluorophenyl)
substitution in 262. 197 showed improved results compared to 196, however its
potency and selectivity profile did not improve on the profile of the unsubstituted
benzylamine 149. No improvements to potency or selectivity were demonstrated
by incorporation of a fluvastatin fragment in compounds 117 and 250.
The specific mode of action for the activity of the parent hydroxyamine 109
has not been implicitly demonstrated, but inhibition of NMT is likely. Genetic
comparisons or specific homology studies have not been performed, so as to com-
pare the active sites of NMT and HMG-reductase. If the active sites of NMT
and HMG-reductase were structurally similar, antagonists, or fragments thereof,
for HMG-reductase could potently be applied to NMT. Throughout this chapter
a ’piggy-backing’ concept was explored that incorporated statin fragments into
the proposed NMT inhibitor 109. An order of magnitude drop in potency was
demonstrated by compounds shown in Figure 3.15 and Figure 3.16 compared to
the parent hydroxyamine 109. Since incorporation of statin fragments offered
limited improvements to the potency of 109 towards T.brucei rhodesience or
P.falciparum it can therefore be concluded that the structural features of the
statins have a specific mechanism of action towards HMG-reductase which can
not be easily exploited and applied to NMT. Further inclusion of the statins
were abandoned and variations of the myristoyl chain contained in the parent
hydroxyamine 109 were instead explored in Chapter 4 in a attempt to improve
potency.
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Figure 3.16: Structure-activity results of statin inspired benzylamines.
120
Chapter 4
Myristic chain derivatives
In Chapter 2 the hydroxyamine 109 was demonstrated to have a selective toxicity
towards T.brucei and the installation of a benzylamine substitution improved the
selectivity towards P.falciparum. The importance of the oxygen and ionisable
nitrogen was demonstrated, as was the importance of the linker length in the
hydroxyamine system. In Chapter 3, HMG reductase inhibitors fragments were
incorporated as alcohol and amine substitutions, which did not improve the po-
tency or selectivity profiles of 109. Variation of the myristoyl chain contained
109 is to be explored throughout this chapter as to introduce features that could
improve the potency or selectivity of 109.
Can be substituted
n
Oxygen 
essential
Linker length
n = 0 or 1
Ionisable 
nitrogen essential
O
N
H
H
H
No improvement by 
incorperation of HMG-reductase 
inhibitor fragments
Myristoyl chain variations 
unexplored
Benzyl substitution 
improves P.falciparum 
selectivity
109
Figure 4.1: Structure activity relationship of 109.
121
4.1 C5 Cis-alkene
The first myristoyl chain derivative introduces a cis-alkene to the myristoyl chain
of the hydroxyamine 109. The position of the alkene on C5 was based on a
increased myristoylation rate when the Z5 myristic isomer of myristic acid was
used to myristoylate peptides in a model system (Figure 4.2).145 A series of alkyne
myristic acid derivatives (Y2-Y13) were also tested in the same system. Inter-
estingly, when the alkyne was installed on Y5 no myristoylated peptides were
formed in the same assay. It was postulated that Z5 myristic acid could have a
positive binding efficiency towards NMT due to the kink in the myristoyl pocket
and the inactivity of the Y5 analog was caused from the rigidity introduced at
position 5.
O
OH
O
OH
C8H17
1
1
Figure 4.2: Myristoylation rates using alkyne (Y2-Y13) and z -alkene
(Z3-Z12) derivatives of myristic acid. Figure reproduced from Kishore et
al.145
The new target 263 embeds the alkene at the C5 position as to explore the antag-
onist properties of the alkene and merge it with hydroxyamine system in 109 de-
veloped in chapter 2 (Figure 4.3). The C5 cis-alkene could be introduced into the
hydroxyamine 263 using alkyne chemistry. A substitution reaction between ethyl
4-bromobutrate 264 and 1-decyne 265 would give the alkyne 265 (Scheme 4.1).
A stereospecific partial hydrogenation of the alkyne in 265 would give the cis-
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alkene 266. The hydroxyamine 263 would then be made following the procedure
developed in Chapter 2 using lithiated acetonitrile followed by reduction.
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Figure 4.3: The new hydroxyamine target 263 based on Z5.
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Scheme 4.1: Proposed synthesis of the alkene 263
Although, 1-decyne 267 is commercially available, it was made in two steps from
1-decene 269. The procedure used was adapted from a method for the generation
of 1-pentadecyne reported by Mun.146 Addition of bromine to 1-decene at room
temperature proceeded in excellent yield (Scheme 4.2). The reaction gave rise
to sufficiently pure 270 for the subsequent elimination reaction. The 1H NMR
spectrum of 270 showed 3 distinctive multiplet signals between 4.20 and 3.60
ppm indicative of 1,2-dibromo substitution. The 13C NMR spectrum showed 10
signals and were identical to the literature.147 As the boiling point of 267 is
significantly lower than 1-pentadecyne146 the elimination reaction was conducted
in a distillation setup.148 When the dibromide 270 and potassium hydroxide were
reacted under phase transfer conditions as part of a reactive vacuum distillation,
multigram quantities of 1-decyne 267 were isolated. A fractionation column was
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used to avoid distillation of the intermediate bromoalkenes. The distillate had
1H and 13C NMR spectra that were identical to those found in the literature.149
C8H17 Br
Br
C8H17C8H17
Br2, DCM
25°C, 97%
KOH, Aliquat 336
100°C, 94%
269 270 267
Scheme 4.2: alkylation of cyclic carbamate
The next phase was to perform a substitution reaction between the alkyne 267
and the halo-ester 264. The halo-ester 264 has two potential electrophiles in the
molecule, the halide and the ester, so several reaction outcomes were possible.
Surprisingly, this transformation did not proceed when either butyllithium150 or
sodium hydride151 was used to deprotonate 1-decyne to form its acetylide. On
reaction of the acetylide with the bromide 264 at room temperature, only starting
materials were recovered. The same conditions were repeated under reflux and
starting material was again recovered.
Table 4.1.1: Substitution of terminal alkyne
C8H17
C8H17
Br
O
O
O
O
Cond.
267 264 265
Conditions 264 : 265
267, n-BuLi (0.9 eqv), THF, -84°C to RT, 5min, 264
(1.1 eqv), -84°C to RT, 15h. 100 : 0
267, 264 , NaH (1.5 eqv), THF, RT, 15h. 100 : 0
267, 264 , NaH (1.5 eqv), THF, 66°C, 15h. 100 : 0
An improved leaving group, iodide, was installed to give 271. The use of 271
with butyllithium at room temperature returned starting materials (Table 4.1.2).
When the reaction under the same conditions were heated under reflux a new
product 272 was isolated. The same product was observed when HMPA was
used as an additive. The new product was identified as the ether 272 from its
NMR spectra and the mechanism grounds.
The loss of the ester group was visible by the disappearance of carbonyl signal in
the 13C NMR spectrum and lack of the ethyl ester signals in the 1H NMR spec-
trum. The ether 272 contained 14 13C NMR signals including key substituted
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Table 4.1.2: substitution of terminal alkyne
C8H17
C8H17
R
O
O
O
O
R=Br
R=I
O
C8H17
C8H17
Cond.
KI
92%267
264
271 265272
Conditions 264 or 271 : 272 : 265
267, n-BuLi (0.9 eqv), THF, -84°C to RT, 5min, 271
(1 eqv), -84°C to RT, 24h. 100 : 0 : 0
267, n-BuLi (0.9 eqv), THF, -84°C to RT, 20 min, 271
(0.8 eqv), 66°C, 15h. 0 : 100 : 0
267, n-BuLi (0.9 eqv), THF, -84°C to RT, 5 min,
HMPA (1.1 eqv), 264 (1.1 eqv), -84°C to RT, 15h. 0 : 100 : 0 (TLC)
alkyne signals at 80.0 and 70.4 ppm. Symmetry was inferred as the terminal
methyl 1H NMR signal at 0.90 ppm integrated to 6H with respect to the down-
field ether substituted methylene triplet at 4.00 ppm. The mechanism for the
formation of the ether 272 is proposed in Scheme 4.3. The ester undergoes a
two-fold addition reaction with alkyne anion 273 to generate the alkoxide 274.
The alkoxide 274 can cyclise via a intramolecular substitution reaction to give
272. Formation of 272 provided evidence for the preferential nucleophilic affinity
of the acetylide 273 towards the carbonyl over the halogen group. Consequently
an alternative synthesis was envisaged without the use of a halo-ester starting
material.
A new pathway was developed based on a reported substitution reaction between
terminal alkynes and haloacids using sodium hydride in refluxing THF.151 Ap-
plying these substitution conditions between 1-decyne 267 and 4-bromobutyric
acid 276 would give 5-hexadecynoic acid 277. The method uses two equival-
ents of sodium hydride to deprotonate the carboxylic acid the alkyne anion. The
carboxylate would deter addition at the carbonyl favouring substitution. A Fisher
esterification of 277 would then give 265 which intersects with Scheme 4.1 for
conversion to the target 263.
Preparation of 4-bromobutyric acid 276 was required. A method using a ring
opening reaction on γ-butyllactone was available and applied on the large scale.152
A mixture of γ-butyllactone, hydrobromic and sulphuric acid was held under
reflux for 6 hours resulting in isolation of 276 in good yield and purity. 1H NMR
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C8H17
I
O
O
O
C8H17
C8H17
I
O
C8H17
C8H17
O
C8H17
C8H17
I
273 271
275
274272
Scheme 4.3: Proposed mechanism for the generation of the undesired
ether 272.
Br
O
OH
C8H17
C8H17 O
OH
4 Steps
OH
NH2
C8H17
267
276 277 263
Scheme 4.4: Generation of 263 via the carboxilic acid 277.
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spectrum showed the distinctive triplet at 3.48 ppm from a bromine substituted
methylene and all signals were identical to those found in the literature.152 A
Finkelstein reaction with potassium iodide gave 278 in excellent yield.153,154
Br
OH
O
O
O
HBr, H2SO4
100°C, 6h
72%
I
OH
ONaI, Acetone
25°C, 15h
92%
279 276 278
Scheme 4.5: Preparation of 4-bromobutyric acid and 4-iodobutyric acid.
A substitution reaction was tested between 1-decyne and the respective bromo
and iodo acids 276 and 278. No conversion was witnessed when exposing the
halo-acids 276 and 278 to 1-decyne and sodium hydride in THF and DMF re-
spectively at room temperature (Table 4.1.3). When butyllithium was used to
deprotonate the alkyne and HMPA155–157 was used as an additive at room tem-
perature, a complex mixture was observed and the desired 5-hexadecynoic acid
277 was isolated in a 10% yield. The other major products were not character-
ised. The low yield, while employing carcinogenic HMPA, in the early phases of
Scheme 4.4 was deemed a critical obstacle and a alternative procedure to generate
5-hexadecynoic acid 277 was explored.
Table 4.1.3: Substitution reaction of acids 276 and 278
C8H17
R
OH
O O
OH
R=Br
R=I
C8H17
267 276
278
277
Conditions Yield
276, 267 (1.3 eqv), NaH (5 eqv), THF, RT, 24 h. 0%
278, 267 (1.3 eqv), NaH (5 eqv), DMF, RT, 72 h. 0% conversion
267 (3.3 eqv), n-BuLi (3.2 eqv), THF, -84°C to RT, 5
min, HMPA (2.1 eqv), 276 (1 eqv), -84°C to RT, 15h. 10%
Attempts to generate the carboxylic acid 277 in a single step were abandoned.
Alternative methods that masked the reactivity of the carboxylic acid func-
tional group were investigated. A substitution reaction using a TBS protected
4-bromobutanol 280 was reported by Tasdemir (Scheme 4.6), however a altern-
ative protection was investigated due to low yields reported by Tasdemir.158 A
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THP protected 4-bromobutanol, made using 3,4-dihydro-2H -pyran (DHP), and
the subsequent acetylide substitution was reported in the literature155,159,160 and
is the basis of the protective pathway towards the target 263.
Br
OTHP
OTHP
n-BuLi, 6:1 THF:HMPA
-78 to -10°C, 2h
65%
n
Br
OTBS
n-BuLi, THF, HMPA
-78°C, 24h
23-32%
m
OTBSm
n
I
(CH2)7CH3
(CH2)4 OTHP
n-BuLi, HMPA, THF, -78°C
Heat
65%
(CH2)7CH3 (CH2)4 OTHP
Scheme 4.6: The low yielding TBS protected acetylide substitution
reported by Tasdemir (Top).158 THP protected acetylide substitutions
reported respectivly by Falck155(middle) and (bottom).Albu159
Scheme 4.7 outlines the applied THP protection strategy that circumvents the
problems observed earlier by masking the reactivity of the carboxylic acid func-
tional group. A substitution reaction between 1-decyne and the protected alcohol
281 would generate the alkyne 282 for partial hydrogenation to the critical alkene
intermediate 283. A deprotective oxidation using Jones reagent would convert
the cis-alkene 283 to the desired carboxylic acid 284. The acid 284 would
be available for conversion, over 3 steps, to the target hydroxyamine 263 using
strategies previously discussed in Scheme 4.1.
The starting material for Scheme 4.7, 4-bromobutanol, is synthesised by a ring
opening of THF with hydrobromic acid.161 THF was heated under reflux with hy-
drobromic and sulphuric acid for 5 hours (Scheme 4.8). The excess acids were re-
moved though a basic workup to give a product which had NMR spectra identical
with the literature.162 4-Bromobutanol was isolated on multi-gram scale with suf-
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OH Br
O O
O O
C8H17
O O
C8H17
OH
C8H17
OOH
NH2
C8H17
3 steps
280 281 282
283284263
Scheme 4.7: THP protection strategy to generate the z alkene
ficient purity to be used in the following step without further purification.
The reaction of 4-bromobutanol with 3,4-dihydro-2H -pyran, using a catalytic
amount of p-toluenesulfonic acid, was stirred overnight at room temperature and
gave the protected alcohol 281. The product from the reaction was purified by
column chromatography to give 281 that had 9 13C NMR signals and matched
those reported by Snider.160 With the reactivity of the carboxylic functional group
successfully masked the substitution reaction between 281 and 1-decyne was
explored.
Br
OH Br
O OO
HBr, H2SO4
66°C, 5h
33%
DHP,  p-TsOH
15h, 25°C
25%
THF 280 281
Scheme 4.8: Preparation of the bromide 281.
The substitution of alkyl halides with acetylide anions was reported by Faulk155
(Scheme 4.6). 1-Decyne was deprotonated using butyllithium and stirred with
281 overnight in THF with HMPA. No conversion was witnessed. A literature
acetylide substitution (Reaction 3 Scheme 4.6) used butyllithium and HMPA at
elevated temperatures.159 No detailed conditions were reported by Albu159 but
promising results were obtained when using two equivalents of each HMPA and
the alkyne anion at elevated temperatures overnight. The material isolated after
column chromatography showed the theoretical 19 signals in the 13C NMR spec-
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trum with two key substituted alkyne signals at 80.6 and 79.9 ppm. A successful
substitution reaction was confirmed in the 1H NMR spectrum with signals at
2.17 and 2.11 ppm assigned to the proparglylic protons. When the reaction was
scaled, a shorter reaction time gave excellent results with yields at 80 - 83 % on
a multigram scale. With the substitution difficulties encountered now overcome
by protection, methods for partial reduction of the alkyne were explored.
Table 4.1.4: Substitution of THP protected 4-bromobutanol with 1-decyne.
Br
O O
O O
C8H17
C8H17
Cond.
281 282267
Conditions 281 : 282
267, HMPA (1.1 eqv), n-BuLi (0.9 eqv), -84°C to RT,
5min, 281 (1.1 eqv), -84°C to RT, 15h.
100 : 0
267 (2.2 eqv), HMPA (2 eqv), n-BuLi (2 eqv), -84°C,
30min, 281 (1 eqv), -84°C to 66°C, 15h.
57%
267 (2.1 eqv), HMPA (2 eqv), n-BuLi (2 eqv), -84°C,
30min, 281 (1 eqv), -84°C to 66°C, 3h.
83%
Partial reduction of the alkyne on the substitution product 282 was envisioned
as per Scheme 4.7. Lindlars catalyst is routinely used to hydrogenate alkynes to
their cis-alkene counterparts.163 The catalyst was not immediately available and
its preparation164 from palladium chloride was expensive and laborious. A trial
using a Zn(Cu/Ag) amalgam165 did not proceed with starting material recovered
(Table 4.1.5). A hydrogenation trial using a catalytic amount of nickel boride,
prepared in situ from nickel acetate and sodium borohydride and poisoned with
ethylene diamine before addition of 282 showed promising results in line with the
literature166,167 with new 1H NMR alkene signals at 5.37 ppm witnessed.
Further examination of the literature reported the partial alkyne reduction of
a similar system using a equivalent of nickel boride under hydrogenation condi-
tions.155 A complete alkyne hydrogenation was witnessed when these conditions
were applied to the alkyne 282 and the alkene 283 was isolated without the
need for purification. The two alkyne signals in the 13C NMR spectrum of the
starting material were replaced with two new signals at 130.4 (CH) and 129.6
(CH) ppm. Unfortunately the individual 1H NMR alkene signals overlapped and
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Table 4.1.5: Partial hydrogenation of the alkyne 282
O O
C8H17
O O
C8H17
Cond.
282 283
Conditions Conversion
Zn(Cu/Ag), MeOH/H2O, 25C, 15h. 0%
Ni(OAc)2 (10 mol%), NaBH4 (10 mol%), EDA (20
mol%), EtOH, H2, 96h.
20%
Ni(OAc)2 (1 eqv), NaBH4 (1.3 eqv), EDA (4.4 eqv),
EtOH, H2, 90 min.
80% yield
the stereochemistry of the product was inferred from the results obtained in the
literature.
Although the reduction of the alkyne to the alkene was successful, this step was
postponed in the synthesis to avoid any risk of isomerism. Scheme 4.9 shows the
generation of alkyne ester 285 prior to exposure of the alkyne to the hydrogen-
ation conditions utilised in Table 4.1.5. Nitriles have been shown to be sensitive
to reduction in the presence of cobalt boride90,168 and thus it was considered ad-
vantageous to install the alkene, via hydrogenation, prior to the introduction of
the ketonitrile system. The first step of Scheme 4.9 is the deprotective oxidation
of 282.
O O
C8H17
O
O
C8H17
OH
NH2
C8H17
O
CN
C8H17
OH
C8H17
O
O
C8H17
O
282286285
287 288 121
Scheme 4.9: Ester formation prior to partial hydrogenation
The conversion of the THP ether 282 to its acid 286 was performed in one step
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by exploiting the THP groups sensitivity to acidic oxidative conditions. Jones
reagent, which is inherently acidic, was reported169 to act as both a deprotective
and oxidative reagent towards a THP protected alcohol. When the THP ether
282 was stirred with Jones reagent overnight, the starting material was no longer
visible to TLC and no alphatic1HNMR THP signals were present which confirmed
deprotection. A new 13C NMR signal at 180.1 ppm indicated the successful
oxidation of the alcohol intermediate. A crude material was isolated in quantitive
yield with sufficient purity to avoid column chromatography and proceed to the
next esterification step.
O O
C8H17
OH
C8H17
O
O
C8H17
O
CrO3, H2SO4
15h, 25°C
Quant.
C3H7Br, K2CO3
TBAI
56°C, 3h.
90% 
(2 steps)
282 286 285
Scheme 4.10: Conversion to the alkyne ester
Conversion of the acid 286 to its propyl ester 285 used standard conditions.170
The crude acid was stirred with excess 1-bromopropane and potassium carbonate
in refluxing acetone for 3 hours using a catalytic amount of TBAI. The propyl
ester was isolated in excellent yield and purity after column chromatography.
3 new signals were present in the 13C NMR spectrum with the critical signals
observed at 66.0 (CH2) and 10.5 (CH3) ppm. The 1H NMR spectrum also showed
3 new signals at 4.01 (t, 2H), 1.62 (m, 2H) and 0.92 (t, 2H) ppm confirming the
presence of the propyl ester 285.
With multigram quantities of 285 isolated, the ketonitrile 288 was prepared via
the alkene 287 (Scheme 4.11). The ester was converted to the alkene 287 using
conditions developed in Table 4.1.5 in good yield with two new signals at 131.3
and 128.5 ppm in the 13C NMR spectrum attributed to the alkene. The 1H NMR
spectrum also showed new alkene signals at 5.36 ppm confirming partial reduction
had occurred. The penultimate step in the generation of the target hydroxyamine
121 was the introduction of the ketonitrile system to 287.
The same conditions were used to convert the ester 287 to the ketonitrile 288
as in Chapter 2. The conditions were replicated in Scheme 4.11 by exposing the
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OO
C8H17
O
CN
C8H17
O
C8H17
O
Ni(OAc)2, NaBH4
EDA, H2
90 min, 25°C
49%
CH3CN
n-BuLi
-84°C, 45 min
59%285 287 288
Scheme 4.11: introduction of the cis-alkene prior to conversion to the
ketonitrile 288
ester 287 to lithiated acetonitrile at -84°C for 45 min. The ketonitrile 288 was
isolated in good yield after column chromatography. The new compound had
representative signals for the ketonitrile, 197.5 and 113.9 ppm in the 13C NMR
spectrum and 3.43 ppm in the 1H NMR spectrum. As a result of the introduction
of the ketonitrile system enough polarity was introduced to resolve the individual
alkene signals at 5.43 and 5.28 ppm. Analysis of the splitting pattern confirmed
the isolation of the cis-isomer assigned from the coupling constant of 10.80 Hz
(Figure 4.4). The reduction of the ketonitrile system contained on 288 would
generate the target C5 cis-hydroxyamine 263.
ppm 5.255.305.355.405.45
5.282
J =10.80
J =7.27
J =1.64
ppm
Hz
Hz
Hz
A B
O
B
A
H
H
H H
C7H15
d, J =
10.80 Hz
t, J =
1 .64 Hz
t, J =
7 .27 Hz
CN
288
Figure 4.4: 1H NMR spectrum of the ketonitrile 288 confirming the Z
geometry.
The conditions were also replicated from Chapter 2 to reduce the ketonitrile 288
system. The hydroxyamine 263 was generated by exposing the ketonitrile 288 to
lithium aluminium hydride at 0°C (Scheme 4.12). The carbonyl and nitrile 13C
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NMR signals were respectively replaced with new signals at 72.9 and 40.7 ppm
indicative of hydroxy and amine substitutions. The 1H NMR spectrum mirrored
the introduction of the hydroxyamine system with 3 new multiplets at 3.80, 3.14
and 2.86 ppm. The alkene remained intact with 13C NMR signals at 130.3 and
129.7 however its stereochemistry is inferred from its precursor as the alkenes
individual 1H NMR signals now appeared as a combined multiplet at 5.25 ppm.
The C5 hydroxy amine 263 was the first compound to introduce functionality
to the myristoyl chain of the parent amine 109. Unfortunately the biological
activity of 263 did not improve on the potency demonstrated by the 109. The
selectivity of 263 towards T.brucei rhodesience was diminished compared to 109
but its toxicity towards the VERO cell was lowered. It could be inferred that the
activity of Z5 myristic acid has a alternative mechanism for peptide enrichment in
the biological system other than improved binding efficiency into the hydrophobic
pocket of NMT. Since the introduction of an alkene at position 5 did not improve
the potency or selectivity profile of 109 alternative strategies to functionalise the
myristoyl chain were explored.
OH
NH2
C8H17
O
CN
C8H17
OH
NH2C13H27
LiAlH4
0°C to 25°C, 3h
28%
0.27 ± 0.01 µM
20.2 ± 0.95 µM
20.8 ± 2.38 µM
22.3 ± 1.09 µM
T.brucei IC50:
P.Falciparum TM4 IC50:
P.Falciparum K1CB1 IC50:
VERO IC50:
SI
83
1.1
1.1
-
3.12 ± 0.05 µM
21.0 ± 2.79 µM
17.5 ± 2.25 µM
>50 µM
SI
>16
>2.4
>2.9
-
288 263 109
Scheme 4.12: Reduction to give the hydroxyamine 263 and its biological
comparison with 109
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4.2 C6 Phenoxy Ether
A screen of 244 commercial available myristic acid analogues against HAT re-
vealed 20 with high toxicity (Figure 1.1240,41). The incorporation, through syn-
thesis, of these features into the myristic chain of new NMT inhibitors is not
practicable. Computational static docking experiments were performed using
AutoDock Vina and designed to investigate the possibility that enzyme-ligand
interactions were responsible for the activity of the report myristic analogues by
competitive inhibition.
5-(4-Butoxyphenyl)pentanoic acid 289 was listed as having a high activity against
HAT. A clear trend became visible when simulated docking a series of phenoxy
ethers inspired from the structure of 289. A single simulated docking experiment
was performed on a series of myristic acid analogues using established proto-
cols.171,172 The series moved the phenoxy moiety from the C3 position in 290
though the myristic chain ending with C10 in 291 (Figure 4.5).
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Figure 4.5: The binding efficiency of a series of myristic acid analogues
computational static docked using AutoDock Vina.
The series of individual simulations showed a trend where binding affinity is max-
imised when the phenoxy moiety is situated in the central portion of the myristoyl
chain. A similar trend was observed when docking the same series to enzyme crys-
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tallography data from different species. The trend provided some evidence that
the mechanism behind high HAT toxicity of 289, reported by Doering as having
a HAT activity, may be via competitive inhibition of NMT.41
Figure 4.6: C6 phenoxy substituted 289 docked into the hydrophobic
pocked of 2P6E (Saccharomyces Cerevisiae) using AutoDock Vina.
5-(4-Butoxyphenyl)pentanoicacid 289 featured a phenoxy moiety at the C6 po-
sition was reported to be active against HAT at 10 µM. The new target 120
incorporates the C6 phenoxy feature with the hydroxyamine features of 109 de-
veloped in Chapter 2 (Figure 4.7). The combination of the C6 phenoxy and
hydroxyamine features in 120 may offer improvement to the potency compared
with 109. A synthetic pathway as to generate 120 was explored.
Scheme 4.13 outlines the synthesis of the target 120 utilising a Sonogashira cross-
coupling reaction as the key carbon-carbon bond forming reaction. A hydrogen-
ation of the alkyne in 292 followed by oxidation would give the aldehyde 293.
Using chemistry developed from Chapter 2, the addition of lithiated acetonitrile
was expected to generate the hydroxynitrile 294 which could be reduced to give
the target 120.
1-Bromo-4-butoxybenzene 295 was made following a literature procedure.173 4-
bromophenol was heated with excess 1-bromobutane and potassium carbonate
isolating 295 by vacuum distillation in excellent yield (Scheme 4.14). 1H and 13C
NMR spectra correlated with reported values.173 With gram quantities of 295 in
hand the Sonogashira cross-coupling reaction was explored.
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Figure 4.7: The new sythetic target 120.
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Scheme 4.13: The synthetic pathway towards the target 120.
C4H9O
Br
HO
Br C4H9Br, 
K2CO3
40h, 56°C
76% 295298
Scheme 4.14: Alkylation of 298.
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Gschneidtner174 reported the Sonogashira cross-coupling of THP protected 4-
bromophenol 299 and 2-methylbut-3-yn-2-ol 300 in near quantitative yield (re-
action 1 Scheme 4.15). The conditions, using bis(triphenylphosphine)palladium
dichloride and copper iodide, were replicated for the coupling of the alkyne 296
to the bromide 295 (reaction 2 Scheme 4.15) to give the alkyne in modest yield.
The 1H NMR spectrum of the purified material possessed 10 signals each with
correct integration values and the 13C NMR spectrum contained the expected 13
signals indicating coupling had occurred. The spectrum showed two 13C-NMR
signals 87.7 and 81.1 ppm indicative of a substituted alkyne system. It also had
signals at 67.9 and 62.1 ppm that were assigned to the phenoxy and the alcohol
substituted methylene.
C4H9O
OH
C4H9O
Br
CuI, PPH3     
PCl2(PPH3)2, NEt3
THF, 66°C, 15h, N2
56%
THPO
Br
OH
3 eqv THPO
OHCuI, PPh3
PdCl2(PPh3)2
80°C, 12h
95%
3 eqv
OH
299 300 301
295 296 292
Scheme 4.15: Sonogashira reaction reported by Gschneidtner174 (Top)
modified conditions reported to produce the Sonogashira product 292.
The alkyne was successfully hydrogenated to give 297 by exposure of the al-
kyne 292 to palladium on carbon under a hydrogen atmosphere for 15 hours
(Scheme 4.16). The 13C NMR spectrum no longer showed alkyne signals at 87.7
and 81.1 ppm which were replaced by two new alkyl signals at 35.1 ppm and 32.8
ppm. A new signal in the 1H NMR spectrum at 3.66 ppm (t, 2H) confirmed the
introduction of benzylic protons.
Oxidation of 297 was required to generate the aldehyde 293 as outlined in
Scheme 4.13. Exposing 297 to IBX in DMSO at room temperature resulted
in a complex mixture. A Swern oxidation was conducted, as it is a mild oxida-
tion, utilising the dimethylchlorosulphonium ion generated in situ from DMSO
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C4H9O
OHH2, Pd/C
EtOAC, 15h
88%
C4H9O
OH
292 297
Scheme 4.16: Hydrogenation of 292.
and oxalyl chloride at low temperatures (Scheme 4.17). Applying these conditions
to the alcohol 297 gave the aldehyde 293 in good yield . The 1H NMR spec-
trum showed a triplet at 9.75 ppm indicating the formation of the aldehyde. The
13C NMR spectrum showed a signal at 202.6 ppm and a single oxo-substituted
methylene signal at 67.8 ppm.
C4H9O
OH (COCl)2,
DMSO, TEA
DCM, -84°C - RT, 
1.5h, 67% C4H9O
O
297 293
Scheme 4.17: Swern oxidation of 297.
Using conditions from Chapter 2, addition of lithiated acetonitrile at -84°C re-
turned a significant quantity of the staring material together with at least one
other unknown (Scheme 4.18). The recovery of starting material confirmed that
lithiated acetonitrile was undergoing a acid-base reaction with the aldehyde 293
and the enolate, when quenched with water, returned the starting material on
workup. As a consequence the synthesis of 294 from its aldehyde 293 were
abandoned and a alternative synthesis of 294 explored.
C4H9O
OH
CN
C4H9O
O
CH3CN, BuLi
-84ºC, 2h
293 294
Scheme 4.18: Attempted lithiated acetonitrile addition to the aldehyde
293.
An alternative synthesis of the target hydroxyamine 120, via the ester 302, was
examined (Scheme 4.19). Oxidation of the aldehyde 293 to the carboxylic acid
303 followed by substitution would generate the ester 302. An addition reaction
with lithiated acetonitrile was expected to proceed as ester 302 is significantly
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less acidic than its equivalent aldehyde 293. The reduction of the ketonitrile 304
would give the target 120 for biological evaluation and circumvents problems
encountered in the synthesis of 294 via Scheme 4.18.
O
O O
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LiCH2CN
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NH2
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302304120
Scheme 4.19: Revised synthetic stratergy towards 120 via the ester 302.
Pinnick oxidation conditions were used from a literature method which also con-
tained a unreactive phenoxy ether system.170 The aldehyde 293 was exposed to
sodium chlorite in a buffered biphasic system (Scheme 4.20). 3 equivalents of 2-
methyl-2-butene (2M2B) was used to scavenge the hypochlorous acid byproduct.
The reaction proceeded with consumption of the starting material as observed
by TLC. Both the 1H and 13C NMR spectra showed the disappearance of their
respective aldehyde signals at 9.75 and 202.6 ppm and a new carboxylic acid
carbonyl signal was present at 179.6 ppm in the 13C NMR spectrum. The crude
material was obtained with sufficient purity to be used for the following esterific-
ation reaction without purification.
C4H9O
O
O
OH
O
OC3H7
2M2B, 
NaH2PO4, 
NaClO2
0°C to 
RT, 15h
C3H7Br, 
TBAI, K2CO3
Acetone, 66°C, 
3h, 83% over 2-
Steps
293 303 302
Scheme 4.20: Conversion of the aldehyde 293 to the ester 302.
The crude acid was exposed to conditions also reported by Wright.170 The acid
303 was stirred with excess bromopropane and sodium carbonate in acetone and
heated under reflux for 3 hours using TBAI as a catalyst. After purification by
column chromatography, the 1H NMR spectrum showed new alkyl signals with
the new key triplet at 4.03 ppm indicating ester substitution. The 13C NMR
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spectrum showed 3 new alkyl signals at 66.0, 22.1, 10.5 ppm indicative of the
propyl ester chain. Ester formation was also confirmed by the 13C NMR carbonyl
signal shift from 179.9 to 173.9 ppm. The two step conversion of the aldehyde
293 to its propyl ester gave an excellent yield and gram scale quantities of 302
were available for the subsequent addition reaction.
The ester 302 was exposed to excess lithiated acetonitrile at -84°C and the ketoni-
trile 304 was isolated in good yield (Scheme 4.21). The 1HNMR spectrum showed
t a singlet at 3.40 ppm indicative the methine adjacent to the carbonyl and nitrile.
The 13C NMR spectrum also showed the disappearance of the propyl alkyl sig-
nals and generation of new signals at 113.9 and 197.5 from the ketonitrile system.
The phenoxy moiety remained intact confirmed by the pair of aromatic signals
and the oxygen substituted methylene at 3.94 ppm in the 1H NMR spectrum.
The reduction of the ketonitrile system was explored using lithium aluminium
hydride.
C4H9O
O
OC3H7
n-BuLi, CH3CN
-84°C, 10 min
57 % C4H9O
O
CN
302 304
Scheme 4.21: Lithioacetonitrile addition to the ester 302.
The C6 phenoxy ketonitrile 304 was exposed to a suspension of lithium alu-
minium hydride for 3 hours. The crude was purified by column chromatography
and the 13C NMR spectrum contained new hydroxy substituted signal at 73.5
ppm. Three new broad multiplets 1H NMR spectrum were present at 3.80,
3.13 and 2.83 ppm respectively attributed to the hydroxy and amine substituted
methine signals.
LiAlH4
0°C, 3h
12%
C4H9O
O
CN
C4H9O
OH
NH2
304
120
Scheme 4.22: Reduction of 304
The hydroxyamine 120 is a myristoyl chain derivative inspired from the work of
Doering et al.41 Unfortunately 120 did not improve on the selectivity or potency
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profile compared to 109. The absolute mode of action of 5-(4-butoxyphenyl)pentanoic
acid 289 was not demonstrated by Doering.41 If competitive inhibition of NMT
was the mechanism of toxicity of 5-(4-butoxyphenyl)pentanoic acid 289 it could
be assumed that incorporation of the 4-butoxyphenyl fragment into the myris-
toyl chain of a NMT inhibitor would lead to greater toxicity towards T.brucei
rhodesience or P.falciparum. As no improvements to the potency profile of 120
was observed it was considered unlikely that the mechanism of action of 5-(4-
butoxyphenyl)pentanoicacid 289 was via competitive inhibition of NMT. Altern-
ative strategies are to be proposed in the following chapter as to improve the
potency and selectivity profile of 109.
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0.27 ± 0.01 µM
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20.8 ± 2.38 µM
22.3 ± 1.09 µM
T.brucei IC50:
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VERO IC50:
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21.1 ± 3.42 µM
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>18
>2.4
>2.2
-
C4H9O
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109 120
Scheme 4.23: Comparison of biological activies of 120 and ??.
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Chapter 5
Conclusions
The aim of the study was to develop new leads for the treatment against the pro-
tozoa causing African sleeping sickness (T. Brucei) and Malaria (P. Falciparum).
The compounds investigated were inspired by the transition state of N -myristoyl
transferase. The synthesis of simplified transition state mimetics 305 provided
structures that were active towards T.brucei rhodesience and P.falciparum (Fig-
ure 5.1).
S
O
N
H2
H
N
O
peptideC13H27
CoA
CoA-Myristoyl-peptide NMT intermediate
R1
OH
N
H
R2
C13H27
1-amino-3-hexadecanols
1 305
Figure 5.1: Using the NMT transition state as a source for
1-amino-3-hexadecanol based mimetics
The synthesis of transition state mimetics used ethyl myristate as a starting ma-
terial. The addition of lithiated acetonitrile to ethyl myristate generated the ke-
tonitrile 124 which was used as a key intermediate in Chapter 3. The ketonitrile
124 was reduced with lithium aluminum hydride to give the hydroxyamine 109.
The amine of the hydroxyamine 109 was substituted using a reductive amination.
The reductive amination of hydroxyamine 109 with benzaldehyde generated 149.
The benzyl protecting group left the reactivity of the amine intact and an alky-
lation with 2-bromo-N -methyl acetamide followed by debenzylation using formic
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acid over palladium gave the glycyl substituted product 108.
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Scheme 5.1: Secondary hydroxyamines developed in Chapter 2 active
against T. brucei and P.falciparum (SI)
The parent hydroxyamine 109 showed micro molar anti-protozoan activity. Structure-
activity relationship studies of this compound demonstrated that the oxygen atom
and an ionizable amine were essential. A linker length between the alcohol and
the amine beyond 2 carbons was demonstrated to negatively impact protozoan
activity and was consequently maintained at 2 carbons for subsequent derivatives.
Substitution of the both the amine and hydroxy functional groups was tolerated
and some species selectivity was also observed. A N -benzyl substitution of the
parent hydroxyamine 109 improved the selectivity towards P.falciparum. Intro-
duction of a glycyl amine substitution in 108 improved the selectivity towards
T.brucei. Using the structure of the transition state of NMT as a guide gave
compounds that successfully inhibited the growth of T.brucei rhodesience and
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P.falciparum.
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Figure 5.2: Structure activity relationships of the hydroxyamine 109.
Further compounds were synthesised to investigate the application of statin frag-
ments into the parent hydroxyamine 109. The synthetic strategies developed in
Chapter 2 were used as the basis to add complexity to the hydroxyamine 109
in Chapter 3. Reductive amination using the hydroxyamine 109 incorporated
statin fragments as amine derivatives. Furthermore a cerium acetylide addition
followed by hydrogenation provided access a range of tertiary alcohol derivatives
by overcoming the inherent acidity of the ketonitrile 124. This proof of concept
study revealed that the hydrophobic fragments of the HMG-reductase inhibitors
reduced the inhibition towards T.brucei and P.falciparum, but they did not hin-
der the activity entirely.
Two further inhibitors were synthesised in Chapter 4 which introduced function-
ality into the myristoyl chains. The first used a alkyne alkylation which required
a HMPA additive and generated the alkyne 282 which was subsequently reduced
to a C5 alkene on the myristoyl chain prior to deprotection (Figure 5.3). The
chemistry developed in Chapter 2 was then applied to install the 3-hydroxyamine
system to generate the hydroxyamine 263. The second chain derivative used a
Sonogashira cross-coupling reaction to install a C6 phenoxy fragment into the
myristoyl chain. The key intermediate 292 was then hydrogenated, converted to
its propyl ester before the same chemistry developed in Chapter 2 was applied
and generated the hydroxyamine 120. The added functionality of both inhibitors
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Scheme 5.2: Secondary hydroxyamines developed in Chapter 3 active
against T. brucei and P.falciparum.
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did not improve on the potency profile compared to the hydroxyamine 109 but
a functionalised chain did not remove activity towards T.brucei rhodesience and
P.falciparum completely.
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O O
O O
C8H17
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 -84°C to 66°C, 
3h. 83%
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C4H9O
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CuI, PPH3     
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n-BuLi
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Figure 5.3: Chain derivatives developed in Chapter 4 active against T.
brucei and P.falciparum.
The lead compound is the hydroxyamine 109 shown in Scheme 5.3. Several as-
pects of its structure-activity relationship were determined in Chapter 2, 3 and
4. The results warrant further investigation and could be the starting point for
future research campaigns. Future work must conclusively determine if the ac-
tivity of the hydroxyamine 109 towards T.brucei rhodesience and P.falciparum
is a result of inhibition of NMT. An isolated protozoan NMT assay would pro-
vide critical information about the mode of action of the hydroxyamine 109. A
comparison of its potency towards protozoan NMT and a whole organism assay
could also demonstrate if the transport of hydroxyamine 109 is hindered across
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the cell membrane or it is readily degraded by the protozoa.
Whether or not these compounds are inhibitors of NMT, they could be used as
leads for the inhibition of T.brucei rhodesience and P.falciparum and could be
developed further using chemistry explored in this thesis and more traditional
medicinal chemistry permutations which may yet improve potency profile of 109
(Scheme 5.3). Further structure-activity investigations could begin by isolation
of each enantiomer of the hydroxyamine 109 and conclude if one is significantly
more active than the other. Another strategy could use the acidity of the ketoni-
trile 124 to substitute between the ketone to the nitrile. A hydride reduction
would generate derivatives of the hydroxyamine 109 yet to be explored. Further
investigation is required to determine if and/or which polar substituents are tol-
erated when incorporated into the myristoyl chain. Decreasing the lipophilicity of
the myristoyl chain may improve the physiochemical properties of 109, however
the impacts of such substituents on potency remain largely unexplored.
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Scheme 5.3: Future work
If the activity of the hydroxyamine 109 is not demonstrated through NMT in-
hibition further attempts to optimise 109 based on the NMT transition state is
unwarrented. NMT inhibition is a validated target and a strong contender to-
wards clinical applications with novel modes of action towards protozoan diseases.
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Several leads have been published and show a good prospect for development.
For example, Bell et al reported several interesting novel scaffolds exemplified
in Figure 1.21 which are yet to be derivatised and optimised as NMT inhibitors
with anti-protozoan activity.61 These structures were discovered from a HTS and
are excellent starting points for research campaigns specifically targeting NMT
as anti-trypanosoma compounds. The structures have been demonstrated to be
inhibitors of T. brucei and L. donovani NMT however their structure-activity
relationship in whole cell assays are yet to be investigated through derivatisation.
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Chapter 6
Experimental
6.1 General procedures
Reactions were conducted under a nitrogen atmosphere at room temperature un-
less otherwise stated. Materials were obtained from commercial sources and used
without further purification unless otherwise stated. Melting points were de-
termined on a Crown Scientific Barnstead Electrothermal 9100 apparatus. NMR
spectra were obtained on an Ultrashield Bruker 400 spectrometer and were con-
ducted at 298 K. All 1H NMR spectra were recorded at a frequency of 400 MHz
while all 13C NMR spectra were recorded at a frequency of 100MHz. CDCl3 (1H,
7.26 ppm; 13C, 77.16 ppm). Multiplicity was assigned as follows: s = singlet, d
= doublet, t = triplet, q = quarter, m = multiplet and br = broad. Infrared
spectra were recorded on a Perkin Elmer Fourier Transform-IR spectrometer 100
equipped with a ZnSe-diamond crystal ATR accessory; spectra were acquired
between 4000-650 cm-1. High resolution ESI mass measurements were recorded
in positive and negative ionisation mode on a LTQ Orbitrap XL instrument car-
ried out at Curtin University. Solvents (tetrahydrofuran, dichloromethane and
acetonitrile) were dried using methods described in Armarego and Chai.175 Thin
layer chromatography (TLC) was run on Merck aluminium backed silica gel 60
F254 sheets and visualised under ultraviolet light or permanganate stain. Com-
pounds were purified by flash chromatography on Davisil silica gel 40−63 μm.
Petroleum spirits (PS) refers to the fraction of alkanes that boils between 40-
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60°C.
6.2 Chapter 2 experimental
6.2.1 Linear synthesis towards 108
Ethyl tetradecanoate 111
A solution of myristic acid (19.9 g, 87.3 mmol) and concentrated sulphuric acid
(2.5 mL, 4.7 g, 47 mmol) in EtOH (120 mL) was heated under reflux for 24 h. The
reaction mixture was allowed to cool and concentrated under reduced pressure.
The pale yellow oil was dissolved in petroleum spirit (250 mL) and washed with
water (100 mL), NaHCO3 solution (5%, 100 mL) and brine (100 mL). The organic
phase was dried over anhydrous MgSO4 and concentrated under reduced pressure
to give a crude light yellow oil (21.0 g) that was purified by fractional distillation
under a reduced pressure (200°C / approx 4mm Hg) to give the ester 111 as a
colourless oil (17.7 g, 79 %). The NMR spectra were identical to those reported.176
C13H27 O
O
111
1H NMR (CDCl3): δ 4.12 (q, J = 7.1 Hz, 2H), 2.28 (t, J =
7.6 Hz, 2H), 1.61 (m, 2H), 1.30-1.23 (m, 23H), 0.88 (t, J =
6.9 Hz, 3H). 13C NMR (CDCl3): δ 174.1 (C), 60.3 (CH2), 34.6
(CH2), 32.1 (CH2), 29.82 (CH2), 29.79 (CH2), 29.75 (CH2),
29.61 (CH2), 29.50 (CH2), 29.42 (CH2), 29.31 (CH2), 25.2 (CH2), 22.8 (CH2),
14.40 (CH3), 14.26 (CH3).
3-Oxohexadecanenitrile 124
A solution of anhydrous acetonitrile (2.5 mL, 47.9 mmol, freshly distilled from
P2O5) in anhydrous THF (20 mL) was added dropwise to a solution of n-BuLi
(26.5 mL, 1.6 M in hexanes, 42.4 mmol) in anhydrous THF (40 mL) at -84°C.
After 45 min a solution of ethyl tetradecanoate 111 (5.02 g, 19.6 mmol) in THF
(20 mL) was added dropwise and the reaction mixture warmed to -45°C for 2 hours
before addition of HCl (1M, 50 mL). The reaction mixture was allowed to warm
to room temperature and concentrated under reduced pressure. The residue was
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diluted with CHCl3 (150 mL) and washed with NaHCO3 solution (5%, 50 mL)
and brine (50 mL). The organic phase was dried over anhydrous MgSO4 and the
filtrate concentrated under reduced pressure to give a light yellow solid (5.15 g).
The crude material was triturated with cold (0°C) petroleum spirit (2 x 20 mL)
and dried under reduced pressure to give 124 as a colourless fluffy solid (3.63 g,
74%) that did not require further purification.
C13H27
O
CN
124
Melting range: 89 - 90°C. 1H NMR(CDCl3): δ 3.43 (s, 2H), 2.61
(t, J = 7.4 Hz, 2H), 1.62 (m, 2H), 1.32-1.26 (m, 20H), 0.88 (t,
J = 6.9 Hz, 3H). 13C NMR (CDCl3): δ 197.7 (C), 114.0 (C),
77.2 (CH2), 42.3 (CH2), 32.0 (CH2), 29.77 (CH2), 29.75 (CH2),
29.74 (CH2), 29.67 (CH2), 29.51 (CH2), 29.46 (CH2), 29.38 (CH2), 29.0 (CH2),
23.5 (CH2), 22.8 (CH2), 14.2 (CH3). IR (ATR, cm-1) 2918, 2850, 2259, 1716,
1471, 1310, 1069, 931, 720. HRMS (ESI): Molecular ion not found.
1-Aminohexadecan-3-ol 109
A solution of the ketonitrile 124 (3.52 g, 14 mmol) in anhydrous THF (40 mL)
was added dropwise to a suspension of LiAlH4 (1.74 g, 46 mmol) in anhydrous
THF (15 mL) at -10°C. The reaction mixture was allowed to warm to room
temperature over 3.5 h and cooled to 0°C before sequential addition of water (1.7
mL) and sodium hydroxide (15 %w/v, 1.7 mL), anhydrous THF (50 mL) and
water (5 mL). The reaction mixture was stirred for 30 min and filtered. The
filtrate was concentrated to give a pale yellow material (3.14 g, 87%) that was
purified by column chromatography (5-25% MeOH, 1% TEA in CHCl3) to give
109 as a colourless solid (1.98 g, 55 %).
C13H27
OH
NH2
109
Melting range: 84 - 87°C. 1H NMR (CDCl3): δ 3.82-3.77
(m, 1H), 3.16-3.11 (m, 1H), 2.88-2.81 (m, 1H), 1.63-1.58
(m, 1H), 1.50-1.35 (m, 4H), 1.35-1.20 (m, 23H), 0.88 (t,
J = 6.5 Hz, 3H). 13C NMR (CDCl3): δ 73.5 (CH), 41.1
(CH2), 38.1 (CH2), 37.6 (CH2), 32.1 (CH2), 29.93 (CH2), 29.83 (CH2), 29.81
(CH2), 29.79 (CH2), 29.5 (CH2), 25.7 (CH2), 22.8 (CH2), 14.3 (CH3). IR (ATR,
cm-1) 3358, 3294, 3124, 2918, 2849, 1597, 1463, 1352, 1076, 931, 723. HRMS
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(ESI) m/z C16H35NO [M+H]+ = 258.2791, found = 258.2782.
2-Bromo-N -methylacetamide 125
Methylamine hydrochloride (4.45 g, 65.9 mmol) was added to a solution of NaOH
(6.61 g, 165 mmol, 2.5 eqv) in a 1:1 H2O:DCM mixture (40 mL) in a ice/salt bath.
The mixture was stirred for 5 min before dropwise addition of a solution of 2-
bromoacetyl bromide (6.0 mL, 68.9 mmol, 1.05 eq) in DCM (10 mL). After 30
min the aqueous phase was extracted with DCM (2 x 50 mL) and the organic
combined extracts were dried with anhydrous MgSO4, and concentrated under
reduced pressure to give 125 as an off white solid (7.46 g, 75%) that did not
require further purification. The NMR spectra were identical to those reported.95
Br
N
H
O
125
1H NMR (CDCl3): δ 6.54 (s, 1H), 3.88 (s, 2H),
2.86 (d, J = 4.9 Hz, 3H). 13C NMR (CDCl3):
δ 166.0, 29.3, 27.1. xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
6.2.2 Protection via benzyl carbamate formation
Benzyl (3-hydroxyhexadecyl)carbamate 130
A solution of CBzCl (160 µl, 1.12 mmol in anhydrous DCM (1 mL) was added
dropwise over 10 min to a solution of 3-hydroxylhexadec-1-amine 109 (247 mg,
0.96 mmol) and DIPEA (160 µl, 1.86 mmol) in anhydrous DCM (10 mL) at -
10°C. The reaction mixture was left to warm to room temperature over 15 hours
and diluted with DCM (100 mL). The solution was washed with hydrochloric
acid (1 M, 2 x 100 mL), NaHCO3 solution (5 %, 100 mL) and brine (100 mL).
The organic phase was dried over anhydrous MgSO4 and the filtrate concentrated
under reduced pressure to give a pale yellow solid (329 mg) that was purified by
column chromatography (20% EtOAc in PS) to give the carbamate 130 as a
colourless powder (237 mg, 63%).
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C13H27
130
Melting range: 79 - 80°C. 1H NMR (CDCl3): δ 7.36-
7.30 (m, 5H), 5.14-5.10 (m, 2H), 3.66-3.62 (m, 1H),
3.52-3.50 (m, 1H), 3.23-3.19 (m, 1H), 1.98-1.91 (bs,
2H), 1.70-1.61 (m, 1H), 1.55-1.37 (m, 3H), 1.35-1.20
(m, 22H), 0.90-0.86 (m, 3H). 13C NMR (CDCl3): δ
157.3 (C), 136.7 (C), 128.7 (CH), 128.27 (CH), 128.25 (CH), 69.6 (CH), 66.9
(CH2), 38.3 (CH2), 37.68 (CH2), 37.48 (CH2), 32.1 (CH2), 29.84 (CH2), 29.83
(CH2), 29.81 (CH2), 29.80 (CH2), 29.76 (CH2), 29.5 (CH2), 25.9 (CH2), 22.8
(CH2), 14.3 (CH3). HRMS (ESI): Molecular ion not found. IR (ATR, cm-1):
3426, 3332, 2916, 2850, 1683, 1541, 1257, 1039, 698.
6.2.3 Protection via cyclic carbamate formation
Tetrahydro-6-tridecyl-2H -1,3-oxazine-2-one 132
A solution of CDI (207 mg, 1.25 mmol, 1.07 eqv) in anhydrous THF (3 mL) was
added dropwise to a rapidly stirred solution of hydroxyamine 109 (302 mg, 1.17
mmol) in anhydrous THF (7 mL) under N2 at room temperature. The mixture
was heated under reflux for 6 hours. The reaction mixture was allowed to cool
and concentrated under reduced pressure. The residue was dissolved in CHCl3
(50 mL) and washed with HCl (1M, 3 x 10 mL). The combined aqueous washings
were back extracted with CHCl3 (10 mL). The combined organic extracts were
washed with brine (15 mL), dried over anhydrous MgSO4 and concentrated under
reduced pressure to give 132 as a light yellow solid (297 mg, 90 %) that did not
require further purification.
C13H27
O NH
O
132
Melting range: 116 - 120 °C. 1H NMR (CDCl3): δ 5.80 (s,
1H), 4.24 (m, 1H), 3.35 (m, 2H), 1.93-1.92 (m, 1H), 1.77-1.71
(m, 2H), 1.58 (s, 1H), 1.25 (s, 22H), 0.88 (t, 3H). 13C NMR
(CDCl3): δ 154.9 (C), 77.7 (CH), 39.3 (CH2), 35.1 (CH2), 32.1
(CH2), 29.82 (CH2), 29.79 (CH2), 29.77 (CH2), 29.69 (CH2),
29.63 (CH2), 29.53 (CH2), 29.49 (CH2), 26.4 (CH2), 25.0 (CH2), 22.8 (CH2), 14.3
(CH3). HRMS (ESI) m/z C17H33NO2[M+H]+ = 284.2584, found = 284.2575. IR
(ATR, cm-1): 3289, 2955, 2916, 2848, 1687, 1668, 1482, 1668, 1482, 1307, 1152,
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1054, 767, 694.
N -Methyl-2-(2-oxo-6-tridecyl-1,3-oxazinan-3-yl)acetamide 133
A solution of carbamate 132 (97 mg, 0.34 mmol, 1 eqv) in anhydrous THF (1 mL)
was added dropwise to a suspension of sodium hydride (22 mg, 57%, 0.52 mmol,
1.5 eqv) in anhydrous THF (1 mL) at 0°C. After 45 min, the solution changed
colour from pale yellow to dark brown. The reaction mixture was cooled to 0°C
before a solution of 2-bromo-N -methyl acetamide 125 (133 mg, 0.87 mmol, 2.6
eqv) in anhydrous THF (1 mL) was added rapidly. The reaction mixture was
heated under reflux for 1 hour then allowed to cool to room temperature. The
solution was concentrated under reduced pressure to give a oily semi-solid. The
crude material was dissolved in EtOAc (25 mL), washed with sodiummetabisulfite
(1 %, 25 mL), HCl (1 M, 25 mL), brine (25 mL) and dried over anhydrous MgSO4
before concentration under reduced pressure to give a yellow solid (114 mg). This
material was purified by column chromatography (0-10%MeOH in EtOAc) to give
the substituted carbamate 133 as a off white solid (39 mg, 32 %) and 138 as a
off white solid (37 mg, 31%).
O N
O H
N
O
C13H27
133
Melting range: 107 - 108°C. 1H NMR (CDCl3): δ 6.47-
6.45 (m, 1H), 4.28-4.25 (m, 1H), 4.03 (d, J = 15.3 Hz,
1H), 3.80 (d, J = 15.3 Hz, 1H), 3.50-3.39 (m, 2H), 2.80
(d, J = 4.8 Hz, 3H), 2.04-1.99 (m, 1H), 1.91-1.69 (m,
3H), 1.61-1.54 (m, 1H), 1.49-1.21 (m, 21H), 0.89-0.86
(t, 3H). 13C NMR (CDCl3): δ 169.5 (C), 155.0 (C), 78.0 (CH), 53.5 (CH2), 46.3
(CH2), 34.9 (CH2), 32.1 (CH2), 29.83 (CH2), 29.79 (CH2), 29.77 (CH2), 29.69
(CH2), 29.61 (CH2), 29.51 (CH2), 29.50 (CH2), 27.4 (CH2), 26.3 (CH3), 24.9
(CH2), 22.8 (CH2), 14.3 (CH3). IR (ATR, cm-1): 3326, 2918, 2851, 1659, 1495,
1287, 1135, 763. HRMS (ESI) m/z C20H38N2O3[M+H]+ = 355.2955, found =
355.2957.
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C13H27
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Melting range: 67 - 70 °C. 1H NMR (CDCl3): δ 3.91 (d,
J = 17.5 Hz, 1H), 3.87 (d, J = 17.5 Hz, 1H), 3.77 (m,
1H), 3.59-3.54 (m, 1H), 3.34 (m, J = 4.7 Hz, 1H), 3.02
(s, 3H), 1.74-1.68 (m, 1H), 1.58-1.52 (m, 1H), 1.47-1.42
(m, 3H), 1.31-1.22 (m, 22H), 0.87 (t, J = 6.9 Hz, 3H).13C NMR (CDCl3): δ 170.2
(C), 157.7 (C), 68.8 (CH), 50.3 (CH2), 40.0 (CH2), 37.6 (CH2), 35.3 (CH2), 32.1
(CH2), 29.83 (CH2), 29.82 (CH2), 29.80 (CH2), 29.74 (CH2), 29.5 (CH2), 25.9
(CH2), 25.1 (CH3), 22.8 (CH2), 14.3 (CH3). IR (ATR, cm-1): 3385, 2916, 2849,
1767, 1692, 1491, 1106, 762. HRMS (ESI) m/z C20H38N2O3 [M+H]+ = 355.2955,
found = 355.2962.
6.2.4 Synthesis via duel protected 2-bromo-N -methyl-N -
benzyl acetamide
N -Benzylmethylamine 145
A mixture of benzyl bromide (5.13 g, 30.0 mmol) and methyl amine (8M in
MeOH, 50 mL, 400 mmol, 13.3 eqv) in methanol (60 mL) was stirred rapidly
overnight and concentrated under reduced pressure. The resulting mixture was
diluted with NaHCO3 (50 mL, 5%) and extracted with EtOAc (8 x 50 mL). The
combined organic extracts were dried over anhydrous MgSO4 and the filtrate
concentrated under reduced pressure. The oil (3.38 g) was analysed by 1H NMR
and characterised as a 1:1 molar mixture of 145:147 and used in the following
step without purification.
HN
N
PhPh
145 147
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
1H NMR (CDCl3, 145): 3.76 (s, 2H), 2.46 (s, 3H). (The
NMR spectra were identical to those reported.177) 1H
NMR (CDCl3, 147): 3.52 (s, 4H), 2.19 (s, 3H). (The
NMR spectra were identical to those reported.178)
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2-Bromo-N -methyl-N -benzylacetamide 143
A solution of bromoacetyl bromide (2.6 mL, 29.85 mmol, 1.07 eq) in dry DCM
(20 mL) was added dropwise over 15 min to a stirred solution of crude methyl
benzylamine 145 (3.38 g, 27.87mmol, 1.00 eq) and TEA (3.8 mL, 2.76 g, 27.31
mmol, 0.98 eq) in dry DCM (50 mL) at 0°C. The reaction mixture was left to
warm to room temperature and stirred for 20 min. The mixture was cooled
to 0°C and HCl (1M, 50 mL) was added dropwise. The reaction mixture was
extracted with DCM (2 x 40 mL) and the combined organic extracts were dried
over anhydrous MgSO4. The filtrate was concentrated under reduced pressure to
give a viscous brown oil (6.80 g) that was purified by column chromatography
(10 - 20% EtOAc in PS) to give 143 as a yellow semi solid (1.02 g, 14% over 2
steps).
Br
N
O
143
1H NMR (CDCl3): δ 7.34-7.25 (m, 5H), 4.60 (m, 2H),
4.14-3.93 (m, 2H), 2.99 (m, 3H). 13C NMR (CDCl3):
δ 167.0 (C), 136.6 (C), 135.9 (C), 129.2 (CH), 128.8
(CH), 128.18 (CH), 128.11 (CH), 127.7 (CH), 126.5
(CH), 54.3 (CH2), 51.4 (CH2), 41.5 (CH3), 35.7 (CH3),
34.6 (CH3), 26.5 (CH2), 26.2 (CH2). IR (ATR, cm-1): 3030, 1644, 1452, 1402,
1078, 730, 697. HRMS (ESI) m/z C10H12BrNO [M+H]+ = 242.0175, found =
242.0175
N -Benzyl-N -methyl-2-(2-oxo-6-tridecyl-1,3-oxazinan-3-yl)
acetamide 144
A suspension of NaH (53 mg, 57%, 1.25 mmol, 1.4 eqv) and the above crude car-
bamate 132 (253 mg, 0.893 mmol, 1 eqv) in anhydrous THF (3 mL) was stirred
for 30 min at room temperature. A solution of 2-bromo-N -methyl-N -benzyl acet-
amide 143 (326 mg, 1.346 mmol, 1.5 eqv) in anhydrous THF (3 mL) was added
and the reaction mixture heated under reflux for 1.5h. The reaction mixture was
cooled to 0°C before addition of saturated NH4Cl (2 mL). The mixture was con-
centrated under reduced pressure. The resulting residue was dissolved in CHCl3
(50 mL) and washed with water (50 mL), HCl (1M, 50 mL) and brine (50 mL).
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The organic phase was dried over anhydrous MgSO4 and the filtrate concentrated
under reduced pressure. The resulting crude material (568 mg) was purified by
column chromatography (50-100% EtOAc in PS) to give 144 as a colourless solid
(332 mg, 84%).
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O N
O
N
O
C13H27
144
Melting range: 63 - 65°C. 1H NMR (CDCl3): δ 7.39-
7.27 (m, 3H), 7.25-7.19 (m, 2H), 4.56 (d, J = 22.4 Hz,
2H), 4.35-4.08 (m, 3H), 3.57-3.44 (m, 1H), 3.37-3.27
(m, 1H), 2.93 (d, J = 27.1 Hz, 3H), 2.03-1.88 (m, 2H),
1.78-1.72 (m, 1H), 1.64 (s, 1H), 1.65-1.36 (m, 4H), 1.35-1.20 (m, 20H), 0.88 (t, J
= 6.9 Hz, 3H). 13C NMR (CDCl3): δ 168.4 (C), 167.9 (C), 154.6 (C), 136.8 (C),
136.2 (C), 129.2 (CH), 128.8 (CH), 128.2 (CH), 127.9 (CH), 127.6 (CH), 126.5
(CH), 77.8 (CH), 52.8 (CH2), 51.4 (CH2), 50.37 (CH2), 50.33 (CH2), 46.08 (CH2),
46.04 (CH2), 35.06 (CH2), 35.00 (CH2), 34.4 (CH3), 33.9 (CH3), 32.1 (CH2), 29.82
(CH2), 29.79 (CH2), 29.70 (CH2), 29.64 (CH2), 29.56 (CH2), 29.54 (CH2), 29.49
(CH2), 27.4 (CH2), 24.9 (CH2), 22.8 (CH2), 14.3 (CH3). IR (ATR, cm-1): 3547,
3479, 2919, 2851, 1688, 1672, 1643, 1491, 1284, 1129, 698. HRMS (ESI) m/z
C27H44N2O3 [M+H]+ = 445.3425, found = 445.3429.
N -Benzyl-2-((3-hydroxyhexadecyl)amino)-N -methylacetamide 148
A solution of cyclic carbamate 144 (180 mg, 0.4 mmol) and LiOH (90 mg, 2.15
mmol, 5 eq) in EtOH (4 mL) and water (1 mL) was heated under reflux overnight.
The reaction mixture was allowed to cool to room temperature and concentrated
to dryness in vacuo. The reaction mixture was triturated with small aliquots of
CHCl3, filtered and concentrated to give 148 as a colourless solid (126 mg, 74%)
that did not require further purification.
OH HN
N
O
C13H27
148
Melting range: 75 - 77°C. 1H NMR (CDCl3): δ 7.39-
7.27 (m, 3H), 7.26-7.13 (m, 2H), 5.30 (d, J = 40.3 Hz,
1H), 4.53 (d, J = 53.1 Hz, 2H), 3.81-3.76 (m, 1H), 3.46
(d, J = 6.4 Hz, 2H), 3.03-2.68 (m, 5H), 2.25-2.23 (m,
1H), 1.62-1.35 (m, 5H), 1.35-1.15 (m, 25H), 0.88 (t, J
= 6.9 Hz, 3H). 13C NMR (CDCl3): δ 171.3 (C), 170.9 (C), 137.0 (C), 136.2
(C), 129.2 (CH), 128.8 (CH), 128.2 (CH), 128.0 (CH), 127.7 (CH), 126.4 (CH),
73.2 (CH), 52.4 (CH2), 51.3 (CH2), 50.0 (CH2), 49.7 (CH2), 49.02 (CH2), 48.89
(CH2), 37.9 (CH2), 35.1 (CH2), 34.3 (CH3), 33.7 (CH3), 32.1 (CH2), 29.92 (CH2),
29.82 (CH2), 29.80 (CH2), 29.79 (CH2), 29.5 (CH2), 25.8 (CH2), 22.8 (CH2), 14.3
(CH3). HRMS (ESI) m/z C26H46N2O2 [M+H]+ = 419.3632, found = 419.3619.
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IR (ATR, cm-1): 3281, 3131, 2919, 2849, 1651, 1633, 1431, 1281, 1103, 725.
2-((3-Hydroxyhexadecyl)amino)-N -methylacetamide 108
Sodium metal (72 mg, 3.13 mmol, 22 eqv) was dissolved in condensed ammonia
(approx 5 mL) at -84°C. The blue solution was stirred for 5 min before dropwise
addition of a solution of 148 (60 mg, 0.143 mmol) and tert-butyl alcohol (100
μL) in anhydrous THF (1.5 mL). The solution was stirred for 20 min condensing
ammonia gas into the reaction as required to ensure fluidity. Sat. NH4Cl solution
(2 mL) was added and the reaction mixture allowed to warm to room temper-
ature over 30 min. The reaction mixture was absorbed onto silica and purified
using column chromatography (2-4% MeOH(sat. in NH3) in CHCl3) to give 108 as
a colourless solid (14 mg, 30%).
OH HN
NH
O
C13H27
108
Melting point: 105°C. 1H NMR (CDCl3): δ 6.89 (s,
1H), 3.77 (s, 1H), 3.34-3.27 (m, 2H), 2.92-2.73 (m,
5H), 1.72-1.64 (m, 1H), 1.61-1.50 (m, 1H), 1.50-1.37
(m, 3H), 1.37-1.17 (m, 23H), 0.94-0.80 (m, 4H). 13C
NMR (CDCl3): δ 171.7 (C), 72.2 (CH), 52.7 (CH2),
48.3 (CH2), 38.1 (CH2), 36.2 (CH2), 32.1 (CH2), 29.82 (CH2), 29.77 (CH2), 29.5
(CH2), 26.0 (CH3), 25.7 (CH2), 22.8 (CH2), 14.3 (CH3). HRMS (ESI) m/z
C19H40N2O2 [M+H]+ = 329.3163, found = 329.3151. IR (ATR, cm-1): 3302,
3266, 3103, 2918, 2850, 1667, 1571, 1466, 1270, 1129, 914, 722.
6.2.5 Benzyl amine protection
1-(Benzylamino)hexadecan-3-ol 149
A mixture of the hydroxyamine 109 (463 mg, 1.80 mmol), benzaldehyde (209
mg, 1.97 mmol, 1.1 eqv) and anhydrous MgSO4 (252 mg) in dry DCM:THF (5:1,
15 mL) was stirred overnight. The resulting mixture was filtered and the residue
washed with a small amount of DCM. The combined filtrates were concentrated
under reduced pressure to give a yellow crystalline solid (729 mg). The crystals
were dissolved in MeOH (17 mL) and cooled in a ice bath before slow addition
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of NaBH4 (76 mg, 2.00 mmol, 1.12 eq). The mixture was stirred for 4.5 hours at
25°C and cooled to 0°C before addition of hydrochloric acid solution (1M, 5 mL).
The reaction mixture was allowed to warm to room temperature before the pH
was adjusted to > 7 using NaHCO3 solution (5%) and concentrated to dryness
under reduced pressure. The residue was triturated with CHCl3 (2 x 30 mL)
and the filtrate concentrated under reduced pressure to give 149 as a colourless
crystalline solid (537 mg, 87 %) that did not require further purification.
C13H27
OH
NH
149
Melting range: 45 - 47°C. 1H NMR (CDCl3): δ 7.33-
7.23 (m, 5H), 3.83-3.72 (m, 3H), 3.02 (m, J = 3.6 Hz,
1H), 2.78 (m, J = 3.3 Hz, 1H), 1.66-1.60 (m, 1H), 1.55-
1.37 (m, 4H), 1.36-1.32 (m, 23H), 0.88 (t, J = 6.9 Hz,
3H). 13C NMR (CDCl3): δ 139.6 (C), 128.6 (CH), 128.3
(CH), 127.3 (CH), 73.9 (CH), 54.0 (CH2), 48.6 (CH2),
38.0 (CH2), 35.2 (CH2), 29.94 (CH2), 29.84 (CH2), 29.82 (CH2), 29.80 (CH2),
29.5 (CH2), 25.8 (CH2), 22.8 (CH2), 14.3 (CH3). IR (ATR, cm-1) 3290, 3166,
2919, 2846, 1463, 1452, 1357, 1111, 1072, 880, 796, 745, 695. HRMS (ESI) m/z
C23H41NO [M+H]+ = 348.3261, found = 348.3264.
2-(Benzyl(3-hydroxyhexadecyl)amino)-N -methylacetamide 150
A solution of the benzyl amine 149 (47 mg, 0.135 mmol), 2-bromo-N -methylacetamide
(27 mg, 0.177 mmol, 1.31 eq) and DIPEA (25 mg, 0.248 mmol) in DMF (1 mL)
was stirred overnight at 70°C under N2. The reaction mixture was concentrated
under reduced pressure and the residue dissolved in toluene (5 mL). The solution
was washed with K2CO3 solution (5%, 3 x 1 mL) and the aqueous washings were
back extracted with toluene (2 mL). The combined organic phases were dried
over anhydrous MgSO4 and concentrated under reduced pressure. The residue
(54 mg) was purified by column chromatography (5% MeOH in CHCl3) to yield
150 as a brown oil (39 mg, 69%).
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C13H27
OH
N
H
N
O
150
1H NMR (CDCl3): δ 7.36-7.26 (m, 5H), 7.12-7.11
(m, 1H), 3.73-3.60 (m, 3H), 3.17-3.08 (m, 2H), 2.79
(d, J = 4.9 Hz, 3H), 2.71 (td, J = 6.6, 2.4 Hz,
2H), 1.71-1.60 (m, 2H), 1.45-1.40 (m, 2H), 1.32 (m,
23H), 0.89 (t, J = 6.8 Hz, 3H). 13C NMR (CDCl3):
δ 171.5 (C), 137.5 (C), 129.1 (CH), 128.7 (CH), 127.7 CH), 71.2 (CH), 59.2 (CH2),
58.1 (CH2), 52.7 (CH2), 37.9 (CH2), 33.8 (CH2), 32.0 (CH2), 29.79 (CH2), 29.77
(CH2), 29.72 (CH2), 29.5 (CH2), 25.9 (CH3), 25.7 (CH2), 22.8 (CH2), 14.2 (CH3).
IR (ATR, cm-1): 3383, 3306, 2922, 2851, 1652, 1537, 1144, 908, 731. HRMS (ESI)
m/z C26H46N2O2 [M+H]+ = 419.3632 , found = 419.3628.
2-((3-Hydroxyhexadecyl)amino)-N-methylacetamide 108
A solution of the benzyl amine 150 (32 mg, 0.076 mmol) in formic acid solution
(3 mL, 5% in MeOH) was degassed with nitrogen (x 3). Pd/C (10 mg, 5 wt%)
was added and the reaction mixture stirred for 15h. The reaction mixture was
filtered and concentrated under reduced pressure. The residue was redissolved
in a small quantity of MeOH and the pH adjusted to > 7 with Na2CO3 solution
(5%). The mixture was concentrated to dryness under reduced pressure and
triturated with CHCl3. The filtrate was concentrated under reduced pressure
to give a colourless solid (22 mg) that was purified by column chromatography
(3:1:96 MeOH:TEA:CHCl3) to give 108 as a colourless solid (17 mg, 68%). The
spectra data obtained matched that obtained in experiment 6.2.4
6.2.6 Amine linker length variation
2-Hydroxypentadecanenitrile 113107
Tetradecanal (1.0 g, 4.71 mmol) was added to a vigorously stirred solution of
sodium bisulfite (1.0 mL, 40%, 9.42 mmol, 2 eq) in water (5 mL). A white chunky
precipitate formed instantaneously. NaCN (940 mg, 18.85 mmol, 4 eq) was added
and stirred overnight in a sealed tube. The chunks remained unchanged and were
broken up with a glass rod before methanol (2 mL) was added and sonicated and
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regularly shaken vigorously for 1 hour. A yellow colour progressively developed
and a subtle change of appearance to the precipitate was observed. The reaction
mixture was extracted with CHCl3 (3 x 50 mL) and concentrated under a stream
of nitrogen. The aqueous portions of the work up were added to household bleach
to destroy the remaining cyanide. The crude reaction mixture was purified by
column chromatography (DCM, Short column) to give 113 as a colourless power
(557 mg, 49%).
C13H27 CN
OH
113
Melting range: 52 - 54°C. 1H NMR (CDCl3): δ 4.47 (t, J
= 6.7 Hz, 1H), 2.66-2.50 (m, 1H), 1.84 (dt, J = 9.5, 6.7
Hz, 2H), 1.56-1.43 (m, 2H), 1.42-1.18 (m, 20H), 0.96-0.82
(m, 3H). 13C NMR (CDCl3): δ 120.1 (C), 61.6 (CH), 35.4
(CH2), 32.1 (CH2), 29.81 (CH2), 29.78 (CH2), 29.77 (CH2), 29.72 (CH2), 29.60
(CH2), 29.49 (CH2), 29.48 (CH2), 29.1 (CH2), 24.7 (CH2), 22.8 (CH2), 14.3 (CH3).
IR (ATR, cm-1) 3395, 2913, 2849, 2253, 147, 1323, 1074, 939, 716, 563. HRMS
(ESI): Molecular ion not found.
1-Aminopentadecan-2-ol 112
LiAlH4 (40 mg, 1.05 mmol) was added to a stirred solution of the cyanohydrin 113
(202 mg, 0.844 mmol) in anhydrous THF (5 mL) at 0°C. The reaction mixture
was allowed to warm to room temperature for 3 hours and cooled in a ice bath.
HCl solution (1M) was added and the reaction mixture allowed to warm to room
temperature. The pH of the solution was adjusted > 7 with a solution of K2CO3
(5 %) and the mixture concentrated to dryness under reduced pressure. The solid
was triturated with portions of CHCl3, filtered and the filtrate concentrated under
reduced pressure. The resulting solid was purified by column chromatography
(10:1:89 MeOH:NH3(aq):CHCl3) to give 112 as a colourless solid (60 mg, 29%).
C13H27
OH
NH2
112
Melting range: 66-71°C. 1H NMR (MeOD): δ 3.54-3.48 (m,
1H), 2.66 (dd, J = 13.0, 3.6 Hz, 1H), 2.51 (dd, J = 13.0,
8.0 Hz, 1H), 1.50-1.23 (m, 26H), 0.90 (t, J = 6.9 Hz, 3H).
13C NMR (MeOD): δ 73.4 (CH), 36.0 (CH2), 33.1 (CH2),
30.82 (CH2), 30.80 (CH2), 30.78 (CH2), 30.76 (CH2), 30.5 (CH2), 26.8 (CH2), 23.7
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(CH2), 14.4 (CH3). IR (ATR, cm-1) 3320, 2955, 2915, 2849, 1593, 1490, 1471,
1071, 718. HRMS (ESI) m/z C15H33NO [M+H]+ = 244.2635, found = 244.2625.
N,N -Bis(trimethylsilyl)propargylamine 155109
Hexamethyldisilazane157 (17.0 mL, 13.1 g, 2.2 eq) was added to a solution of
n-BuLi (48.0 mL, 1.6M, 76.8 mmol, 2.1 eq) in Et2O (40 mL) at -84°C and allowed
to warm to room temperature for 1 hour. The solution was cooled in a ice bath
and propargyl bromide 156 (4.1 mL, 80 %wt in toluene, 37.1 mmol) in Et2O (10
mL) was added and stirred overnight. A sample (9.0 mL, utilised in following
experiment) of the reaction mixture was removed and the remaining reaction
mixture quenched on a ice cold buffer solution (3.8g KH2PO4: 4.5 g Na2HPO4
in 50 mL H2O) and filtered. The organic phase was washed with cold brine and
dried over sodium carbonate and concentrated. The crude material was distilled
and the first fraction was discarded before collecting 155 as a clear liquid (3.38
g, 49 %, 86 % pure) that decomposed during storage at -20°C within 3 days. The
NMR spectra were identical to those reported.109
N
Si
Si
155
1H NMR (CDCl3): δ 3.53 (d, J = 2.4 Hz, 2H), 2.13 (t,
J = 2.4 Hz, 1H), 0.15 (s, 18H). 13C NMR (CDCl3): δ
86.3, 69.8, 34.0, 1.8.
Tris(trimethylsilyl)-1-aminoheptadec-2-yn-4-ol 153
A solution of lithiated 155 (9.0 mL, preparation detailed above) was added to
a solution of tetradecanal (495 mg, 2.33 mmol) in ether (1 mL) at -84°C and
warmed to room temperature over 20 hours. Et2O (5 mL) and TMSCl (0.45 mL,
3.54 mmol) was added to the reaction mixture at -84°C and allowed to warm to
room temperature for 5 hours. The reaction mixture added to a ice cold buffer
solution (0.38 g KH2PO4: 0.45 g Na2HPO4 in 5 mL H2O) with Et2O (10 mL)
and quickly filtered. The organic phase quickly washed with ice cold brine, dried
over Na2CO3 and concentrated under reduced pressure for 3 hours to give 153 as
a unstable yellow oil (838 mg, 75%) that was used in the following steps without
further purification.
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N
Si
SiOSi
C13H27 153
1H NMR (C6H6): δ 4.46 (tt, J = 6.4, 1.7 Hz, 1H),
3.55 (d, J = 1.7 Hz, 2H), 1.88-1.82 (m, 3H), 1.62-1.55
(m, 2H), 1.40-1.20 (m, 19H), 0.96-0.86 (m, 3H), 0.26
(s, 9H), 0.24 (s, 18H). 13C NMR (C6H6): δ 86.2 (C),
84.0 (C), 63.3 (CH), 39.5 (CH2), 34.5 (CH2), 32.4 (CH2), 30.19 (CH2), 30.16
(CH2), 30.12 (CH2), 29.9 (CH2), 25.8 (CH2), 23.1 (CH2), 14.4 (CH3), 2.0 (CH3),
0.5(CH3).
Z -Tris(trimethylsilyl)-1-aminoheptadec-2-en-4-ol 158
The forgoing crude TMS ether 153 (745 mg, 1.54 mmol) was dissolved in EtOAc
(3 mL, K2CO3 pretreated). The atmosphere was evacuated and replaced with
nitrogen (x 3) before addition of Pd/C (10%, 125 mg, 17 wt%). A hydrogen
atmosphere was introduced (x 3) and left stirring overnight at room temperature.
The reaction mixture was filtered though celite and concentrated under reduced
pressure to give 158 as a yellow oil (593 mg, 79%) that was used in the following
step without purification.
C13H27
OSi
N
Si
Si
158
1H NMR (C6H6): δ 5.46 (dt, J = 11.6, 4.8 Hz, 1H),
5.37-5.31 (m, 1H), 4.49-4.44 (m, 1H), 3.74 (ddd, J =
17.7, 5.5, 2.2 Hz, 1H), 3.62 (ddd, J = 17.7, 4.6, 2.3 Hz,
1H), 1.73-1.65 (m, 2H), 1.61-1.24 (m, 20H), 0.94-0.90
(m, 5H), 0.21 (d, J = 0.3 Hz, 9H), 0.20 (d, J = 0.3
Hz, 18H). 13C NMR (C6H6): δ 134.8 (CH), 132.9 (CH), 69.4 (CH), 43.0 (CH2),
38.9 (CH2), 32.4 (CH2), 30.20 (CH2), 30.15 (CH2), 30.14 (CH2), 29.9 (CH2), 25.9
(CH2), 23.2 (CH2), 14.4 (CH3), 2.3 (CH3), 0.7 (CH3). IR (ATR, cm-1) 2955, 2923,
2854, 1458, 1249, 1065, 1027, 875, 836, 753, 680.
Z -1-Aminoheptadec-2-en-4-ol 159
The forgoing crude TMS ether 158 (593 mg, 1.22 mmol) was stirred in a solution
of TBAF (4.4 mL, 1M in THF) overnight at room temperature. The reaction
mixture was concentrated under reduced pressure, dissolved in CHCl3 (200 mL)
and washed with water (3 x 100 mL). The combined aqueous phases were back
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extracted with CHCl3 (3 x 75 mL) and the combined organic extracts dried over
anhydrous MgSO4. The filtrate was concentrated under reduced pressure and the
residue (231 mg) was purified by column chromatography (6% in MeOH(Sat. NH3)
in CHCl3) to give 159 as a colourless power (131 mg, 40 %).
C13H27
OH
NH2
159
Melting range: 84 - 90°C. 1H NMR (C6H6): δ 5.57 (dd,
J = 11.3, 6.9 Hz, 1H), 5.42 (dt, J = 11.3, 6.0 Hz, 1H),
4.39 (q, J = 5.9 Hz, 1H), 3.08 (dd, J = 13.4, 7.0 Hz,
1H), 2.91 (dd, J = 13.4, 5.6 Hz, 1H), 1.79-1.67 (m,
4H), 1.56-1.22 (m, 23H), 0.92 (t, J = 6.7 Hz, 3H).13C NMR (C6H6): δ 136.9
(CH), 130.5 (CH), 67.6 (CH), 39.0 (CH2), 38.2 (CH2), 32.4 (CH2), 30.30 (CH2),
30.27 (CH2), 30.23 (CH2), 30.17 (CH2), 29.9 (CH2), 26.1 (CH2), 23.2 (CH2), 14.4
(CH3). IR (ATR, cm-1): 3416, 3340, 2917, 2850, 1594, 1466, 1378, 1067, 720.
HRMS (ESI) m/z C17H35NO [M+H]+ = 270.2791, found = 270.2782.
1-Aminoheptadec-2-yn-4-ol 160
The crude alkyne 153 (972 mg) was stirred in a solution of TBAF (6.5 mL, 1M
in THF) overnight at room temperature. The reaction mixture was concentrated
under reduced pressure, diluted with CHCl3 (200 mL) and washed with water
(3 x 100 mL). The combined aqueous phases were back extracted with CHCl3
(3 x 75 mL). The combined organic phases were dried over MgSO4, filtered and
concentrated to give a yellow semi solid (548 mg). The crude material was purified
by column chromatography [6% in MeOH(Sat. NH3) in CHCl3] to yield 160 as an
off white solid (334 mg, 62%).
NH2HO
C13H27
160
Melting range: 53 - 56°C. 1H NMR (C6H6): δ 4.41 (t, J
= 6.4 Hz, 1H), 3.18 (s, 2H), 1.83-1.76 (m, 5H), 1.58-1.55
(m, 2H), 1.31 (m, 20H), 0.93-0.90 (m, 3H). 13C NMR
(C6H6): δ 85.05 (C), 84.99 (C), 62.3 (CH), 38.7 (CH2),
32.4 (CH2), 31.7 (CH2), 30.22 (CH2), 30.17 (CH2), 29.95 (CH2), 29.87 (CH2),
25.9 (CH2), 23.2 (CH2), 14.4 (CH3). HRMS (ESI) m/z C17H34NO [M+H]+ =
268.2635, found = 268.2625. IR (ATR, cm-1): 3359, 3285, 3088, 2920, 2848, 1466,
1319, 1067, 1005, 723.
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1-Aminoheptadecan-4-ol 114
The propargyl alcohol 160 was dissolved in EtOAc (4 mL) and degassed with
nitrogen (x 3). Pd/C (10%, 22 mg) was added and a hydrogen atmosphere
introduced (x 3). The reaction mixture was stirred overnight and filtered though
celite. The clear solution was concentrated under reduced pressure to give 114
as colourless solid (95 mg, 74%) that did not require further purification.
NH2C13H27
OH
114
Melting range: 90 - 95°C. 1H NMR (C6H6): δ 3.58-3.52
(m, 1H), 2.42-2.37 (m, 1H), 2.27-2.21 (m, 1H), 1.73-
1.12 (m, 28H), 0.96-0.87 (m, 3H). 13C NMR (C6H6): δ
71.3 (CH), 42.2 (CH2), 38.6 (CH2), 37.4 (CH2), 32.4
(CH2), 30.47 (CH2), 30.34 (CH2), 30.25 (CH2), 30.23 (CH2), 30.17 (CH2), 29.9
(CH2), 26.7 (CH2), 23.2 (CH2), 14.4 (CH3). HRMS (ESI) m/z C17H37NO
[M+H]+ = 272.2948, found = 272.2937. IR (ATR, cm-1): 3354, 3281, 3175,
2916, 2850, 1560, 1471, 1074, 719.
6.2.7 Amine substitutions from cyclic carbamate 132
3-([1,1’-Biphenyl]-4-ylmethyl)-6-tridecyl-1,3-oxazinan-2-one 164
A suspension of the cyclic carbamate 132 (98 mg, 0.346 mmol), 4-(chloromethyl)-
1,1’-biphenyl 165 (78 mg, 0.384 mmol, 1.1 eq), sodium hydride (20 mg, 60%,
0.500 mmol, 1.44 eqv) and a single crystal of NaI was stirred in THF (2 mL)
for 90 hours at 25°C under N2. Saturated ammonium chloride solution (approx
0.25 mL) was added and the reaction mixture was concentrated under reduced
pressure. The resulting solid was triturated with CHCl3 (50 mL) and the filtrate
concentrated under reduced pressure to give a yellow solid (157 mg) that was
purified by column chromatography to give 164 as a colourless solid (53 mg,
33%).
C13H27
O N
O
164
Melting range: 127 - 130°C. 1H NMR (CDCl3):
δ 7.61-7.55 (m, 4H), 7.46-7.32 (m, 5H), 4.65 (d,
J = 14.9 Hz, 1H), 4.56 (d, J = 14.9 Hz, 1H),
4.26-4.20 (m, 1H), 3.31-3.23 (m, 1H), 3.23-3.17
167
(m, 1H), 1.99-1.93 (m, 1H), 1.84-1.70 (m, 2H),
1.61-1.44 (m, 2H), 1.43-1.19 (m, 21H), 0.88 (t, J = 6.9 Hz, 3H). 13C NMR
(CDCl3): 154.4 (C), 140.82 (C), 140.73 (C), 136.0 (C), 128.9 (CH), 128.7 (CH),
127.53 (CH), 127.47 (CH), 127.2 (CH), 77.4 (CH), 52.3 (CH2), 44.0 (CH2), 35.1
(CH2), 32.1 (CH2), 29.82 (CH2), 29.79 (CH2), 29.78 (CH2), 29.69 (CH2), 29.62
(CH2), 29.56 (CH2), 29.49 (CH2), 27.4 (CH2), 24.9 (CH2), 22.8 (CH2), 14.3 (CH3).
IR (ATR, cm-1) 2918, 2850, 1685, 1664, 1488, 1272, 1159, 1128, 1006, 757, 699.
HRMS (ESI) m/z C30H43NO2 [M+H]+ = 450.3367, found = 450.3344.
1-(([1,1’-Biphenyl]-4-ylmethyl)amino)hexadecan-3-ol 162
A mixture of the carbamate 164 (25 mg, 0.055 mmol) and LiOH.H2O (106 mg,
2.53 mmol, 45 eqv) in a H2O:EtOH mixture (1:10, 2 mL) was heated in a sealed
vessel at 150°C by microwave irradiation (0 - 400W) for 2 hours. The resulting
reaction mixture was concentrated to dryness under reduced pressure. The white
solid was stirred overnight in CHCl3 (50 mL) and filtered. The filtrate was con-
centrated under reduced pressure to give a white solid (24 mg) that was purified
by column chromatography [5% MeOH (saturated with NH3) in CHCl3] to give
162 as a colourless solid (20 mg, 85 %).
C13H27
OH HN
162
Melting range: 55 - 60°C. 1H NMR (CDCl3): δ
7.64-7.56 (m, 4H), 7.51-7.42 (m, 4H), 7.42-7.34
(m, 1H), 3.94 (d, J = 13.1 Hz, 1H), 3.87 (d, J =
13.1 Hz, 1H), 3.84-3.79 (m, 1H), 3.14-3.06 (m,
1H), 2.96-2.87 (m, 1H), 1.78-1.59 (m, 2H), 1.57-1.38 (m, 3H), 1.38-1.18 (m, 22H),
0.95-0.83 (m, 3H). 13C NMR (CDCl3): δ 141.0 (C), 140.7 (C), 135.4 (C), 129.4
(CH), 128.9 (CH), 127.56 (CH), 127.55 (CH), 127.2 (CH), 72.8 (CH), 52.7 (CH2),
47.4 (CH2), 37.9 (CH2), 34.15 (CH2), 34.14 (CH2), 32.1 (CH2), 29.83 (CH2), 29.80
(CH2), 29.78 (CH2), 29.5 (CH2), 25.8 (CH2), 22.8 (CH2), 14.3 (CH3). IR (ATR,
cm-1) 3290, 2919, 2847, 1489, 1464, 1356, 1110, 1094, 1073, 888, 834, 762, 726,
689. HRMS (ESI) m/z C29H45NO [M+H]+ = 424.3574, found = 424.3554.
168
6.2.8 Amine derivatives via reductive amination
1-((3-Phenylpropyl)amino)hexadecan-3-ol 161
Amixture of 1-aminohexadecan-3-ol 109 (103 mg, 0.400 mmol), 3-phenylpropanal
163 (59 mg, 0.440 mmol, 1.10 eq) and anhydrous MgSO4 (112 mg) in anhydrous
DCM:THF(5:1, 5 mL) was stirred for 15 hours under N2. The mixture was filtered
and concentrated under reduced pressure. The resulting material was dissolved
in EtOH (3 mL) and NaBH4 (20 mg, 0.529 mmol, 1.3 eq) added and stirred under
N2 at room temperature for 24 hours. The reaction mixture was cooled to 0°C
and hydrochloric acid (1 mL, 1M) added. The mixture was stirred briefly at room
temperature before adjusting the pH > 7 by addition of NaOH solution (2M) and
concentrated to dryness in vacuo. The resulting solid was triturated with CHCl3
(4 x 5 mL) and concentrated under reduced pressure to give a white crystalline
solid (118 mg) that was purified by column chromatography (10% MeOH(Sat. NH3)
in CHCl3) to give 161 as a colourless oil (38 mg, 25%).
OH
N
H
C13H27
161
1H NMR (CDCl3): δ 7.30-7.24 (m, 2H), 7.21-
7.15 (m, 3H), 3.81-3.75 (m, 1H), 3.03-2.94 (m,
1H), 2.79-2.53 (m, 5H), 1.85-1.75 (m, 2H),
1.64-1.56 (m, 1H), 1.54-1.18 (m, 26H), 0.93-
0.84 (m, 3H). 13C NMR (CDCl3): δ 142.0 (C), 128.50 (CH), 128.49 (CH), 126.0
(CH), 73.9 (CH), 49.26 (CH2), 49.18 (CH2), 38.1 (CH2), 35.1 (CH2), 33.7 (CH2),
32.1 (CH2), 31.6 (CH2), 29.93 (CH2), 29.84 (CH2), 29.83 (CH2), 29.80 (CH2),
29.79 (CH2), 29.5 (CH2), 25.8 (CH2), 22.8 (CH2), 14.3 (CH3) IR (ATR, cm-1)
3264.82, 2918.99, 2849.97, 1467.23, 1453.07, 1112.23, 1074.18, 910.37, 898.54,
742.04, 713.65, 696.87. HRMS (ESI) m/z C25H45NO [M+H]+ = 376.3574, found
= 376.3557.
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6.2.9 Hydroxyl methylation
(R/S)-3-Hydroxyhexadecanenitrile 166
NaBH4 (70 mg, 1.85 mmol, 1.4 eq) was added to a suspension of the ketonitrile
124 (324 mg, 1.29 mmol) in EtOH (10 mL) and petroleum spirit (2 mL) at 0°C.
The reaction mixture left to warm to room temperature for 15 hours, then cooled
to 0°C. Saturated NH4Cl solution (1 mL) was added and the reaction mixture
was concentrated under reduced pressure. The residue was diluted in CHCl3 (25
mL) and washed with hydrochloric acid (1 M, 25 mL). The aqueous phase was
extracted with CHCl3 (25 mL). The combined organic extracts were washed with
brine (25 mL) and dried over a mixture of K2CO3 and MgSO4. The filtrate was
concentrated under reduced pressure to give a light yellow semi solid that was
purified by column chromatography (DCM) to give 166 as colourless wax (231
mg, 71 %).
C13H27
OH
CN
166
Melting range: 44 - 47°C. 1H NMR (CDCl3): δ 3.94-3.93 (m,
1H), 2.52 (dd, J = 17.1, 5.5 Hz, 2H), 2.13 (d, J = 5.2 Hz,
1H), 1.60-1.25 (m, 24H), 0.87 (t, J = 6.5 Hz, 3H). 13C NMR
(CDCl3): δ 117.8 (C), 68.0 (CH), 36.7 (CH2), 32.1 (CH2), 29.81
(CH2), 29.78 (CH2), 29.75 (CH2), 29.66 (CH2), 29.61 (CH2), 29.48 (CH2), 29.45
(CH2), 26.2 (CH2), 25.5 (CH2), 22.8 (CH2), 14.2 (CH3). IR (ATR, cm-1): 3372,
2912, 2848, 2265, 1471, 1100, 1079, 717. HRMS (ESI) m/z C16H31NO [M+H]+
= 254.2478, found = 254.2475.
3-Methoxyhexadecanenitrile 168
Ag2O (500 mg, 2.16 mmol) was added to a solution of 166 (198 mg, 0.781 mmol)
in MeI (5 mL) and stirred in a sealed vessel for 5 days at room temperature.
The reaction mixture was concentrated under a stream of nitrogen and dispersed
in DCM (25 mL) and filtered. The filtrate was washed with water (25 mL),
dried over magnesium sulphate and concentrated under reduced pressure to give
168 as a light yellow oil (199 mg, 95%) that was used in the following step
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without further purification. An analytically pure sample was obtained by column
chromatography (5% EtOAc in PS).
C13H27
O
CN
168
1H NMR (CDCl3): δ 3.45-3.40 (m, 4H), 2.51 (t, J = 5.3 Hz,
2H), 1.40-1.26 (m, 24H), 0.88 (t, J = 6.9 Hz, 3H). 13C NMR
(CDCl3): δ 117.7 (C), 77.0 (CH), 57.5 (CH3), 34.0 (CH2),
32.1 (CH2), 29.81 (CH2), 29.78 (CH2), 29.75 (CH2), 29.68
(CH2), 29.63 (CH2), 29.60 (CH2), 29.49 (CH2), 25.1 (CH2), 22.8 (CH2), 22.5
(CH2), 14.2 (CH3). IR (ATR, cm-1): 2922, 2853, 2250, 1465, 1105, 722. HRMS
(ESI) m/z C17H33NO [M+H]+ = 268.2635, found = 268.2623.
3-Methoxyhexadecan-1-amine 167
NaBH4(230 mg, 6.08 mmol) was added to a solution of crude 168 (153 mg,
0.572 mmol) and CoCl2.6H2O (320 mg, 1.17 mmol) in EtOH (2 mL) at 0°C. The
solution was left to stir at this temperature for 2 hours and allowed to warm to
room temperature for 1 hour. Hydrochloric acid (3M, 10 mL) was added dropwise
and stirred until the black precipitate dissolved. Ammonia solution (30%) was
added to the reaction mixture until pH > 7 and extracted with CHCl3 (3 x 25 mL).
The combined extracts were washed with brine (3 x 25 mL), dried over anhydrous
MgSO4 and concentrated under reduced pressure to give a pink oil (146 mg) that
was purified by column chromatography (10:1:89 MeOH:NH3(aq):CHCl3) to give
167 as a yellow oil (50 mg, 32%).
C13H27
O
NH2
167
1H NMR (CDCl3): δ 3.30 (s, 3H), 3.23 (quintet, J = 5.9 Hz,
1H), 2.78 (t, J = 7.02 Hz, 2H), 1.69 (s, 3H), 1.61 (td, J =
7.0, 6.1 Hz, 2H), 1.51-1.39 (m, 3H), 1.29 (dd, J = 14.8, 7.2
Hz, 20H), 0.86 (t, J = 6.9 Hz, 3H). 13C NMR (CDCl3): δ
79.6 (CH), 56.5 (CH3), 39.0 (CH2), 37.4 (CH2), 33.6 (CH2), 32.1 (CH2), 29.99
(CH2), 29.82 (CH2), 29.80 (CH2), 29.78 (CH2), 29.77 (CH2), 29.75 (CH2), 29.5
(CH2), 25.3 (CH2), 22.8 (CH2), 14.2 (CH3). IR (ATR, cm-1) 2921.2, 2852.1,
1570.8, 1465.6, 1316.1, 819.0, 720.8. HRMS (ESI) m/z C17H37NO [M+H]+ =
272.2948, found = 272.2948.
171
6.3 Chapter 3 experimental
6.3.1 Phenyl analogues
3-Hydroxy-3-(phenylethynyl)hexadecanenitrile 181
A solution of n-BuLi (1.5 mL, 2.4 mmol, 1.3 eq) was added dropwise to a stirred
solution of phenyl acetylene (270 mg, 1.54 mmol, 1.4 eq) in anhydrous THF (3.5
mL) at -84°C. The mixture was allowed to warm to room temperature before it
was added dropwise to a suspension (previously stirred for 2 hours) of anhydrous
cerium chloride (1.02 g CeCl3.7H2O progressively heated to 140°C under Hi-Vac
overnight, 2.74 mmol, 1.5 eqv) in THF (8 mL) at -84°C. After 30 min, a solution
of the ketonitrile 124 (454 mg, 1.81 mmol, 1 eq) in anhydrous THF (5 mL)
was added dropwise. The reaction mixture was held at -84°C for 5 hours before
addition of sat. NH4Cl (5 mL) and stirred overnight. The reaction mixture was
concentrated under reduced pressure and hydrochloric acid (1M, 50 mL) added.
The mixture was extracted with CHCl3 (3 x 50 mL). The combined extracts
were washed with brine (50 mL) and dried over a mixture of anhydrous K2CO3
and MgSO4. The filtrate was concentrated under reduced pressure to give a crude
yellow semi solid (803 mg) which was purified by column chromatography (75-100
% DCM in PS) to give 181 as a light yellow oil (217 mg, 34 %).
C13H27
CN
OH
181
1H NMR (CDCl3): δ 7.46-7.30 (m, 5H), 2.86 (d, J = 16.4
Hz, 1H), 2.82 (d, J = 16.4 Hz, 1H), 2.59 (s, 1H), 1.89-1.85
(m, 2H), 1.64-1.57 (m, 3H), 1.40-1.26 (m, 19H), 0.88 (t, J =
6.9 Hz, 3H).13C NMR (CDCl3): δ 132.0 (CH), 129.1 (CH),
128.5 (CH), 121.7 (C), 116.7 (C), 88.5 (C), 86.5 (C), 69.0 (C),
41.6 (CH2), 32.5 (CH2), 32.1 (CH2), 29.82 (CH2), 29.79 (CH2),
29.76 (CH2), 29.67 (CH2), 29.59 (CH2), 29.57 (CH2), 29.49 (CH2), 24.5 (CH2),
22.8 (CH2), 14.3 (CH3). HRMS (ESI): Molecular ion not found. IR (ATR, cm-1):
3423, 2922, 2853, 2258, 1490, 1465, 1378, 1071, 756, 691.
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3-Hydroxy-3-phenethylhexadecanenitrile 189
A solution of the propargyl alcohol 181 (53 mg, 0.15 mmol) in EtOAc (1.5 mL)
was degassed before the addition of Pd/C (22 mg, 41 wt%). The stirred reaction
mixture was exposed to a hydrogen atmosphere for 2.5 hours. The reaction was
filtered though celite and concentrated under reduced pressure to give 189 as a
clear oil (51 mg, 96%) that did not require further purification.
C13H27
CN
OH
189
1H NMR (CDCl3): δ 7.32-7.28 (m, 2H), 7.23-7.19 (m, 3H), 2.69
(dd, J = 9.8, 7.2 Hz, 2H), 2.56 (s, 2H), 1.93 (td, J = 8.6, 4.2
Hz, 2H), 1.77 (s, 1H), 1.71-1.67 (m, 2H), 1.34-1.24 (m, 22H),
0.89 (t, J = 6.9 Hz, 3H). 13C NMR (CDCl3): δ 141.3 (C), 128.7
(CH), 128.4 (CH), 126.3 (CH), 117.6 (C), 73.1 (C), 41.0 (CH2),
39.4 (CH2), 32.1 (CH2), 29.99 (CH2), 29.82 (CH2), 29.79 (CH2),
29.75 (CH2), 29.68 (CH2), 29.63 (CH2), 29.50 (CH2), 29.49 (CH2), 29.39 (CH2),
23.7 (CH2), 22.8 (CH2), 14.3 (CH3). IR (ATR, cm-1): 3444, 2917, 2848, 2256,
1468, 1460, 751, 698. HRMS (ESI): Molecular ion not found.
1-Amino-3-(phenethyl)hexadecan-3-ol 175
A solution of the nitrile 189 (65 mg, 0.182 mmol) in anhydrous THF (1 mL) was
added dropwise to a cooled suspension of LiAlH4 (11 mg, 0.448 mmol) in THF
(0.5 mL) at -10°C. The reaction mixture was warmed to room temperature for 1
hour and cooled on a ice bath. Water (100 µl), potassium hydroxide (10%, 100
µl) and water (100 µl) were added and stirred for 30 min. The reaction mixture
was diluted with CHCl3, dried over magnesium sulphate and filtered. The filtrate
was concentrated under reduced pressure and purified by column chromatography
(10:2:88 MeOH:TEA:CHCl3) to give 175 as a yellow oil (32 mg, 49%).
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C13H27 NH2
OH
175
1H NMR (CDCl3): δ 7.29-7.15 (m, 5H), 3.03 (t, J = 6.1
Hz, 2H), 2.86-2.56 (m, 6H), 1.85-1.70 (m, 2H), 1.66-1.60
(m, 2H), 1.60-1.49 (m, 2H), 1.37-1.14 (m, 21H), 0.90-0.84
(m, 3H). 13C NMR (CDCl3): δ 143.1 (C), 128.5 (CH), 125.8
(CH), 74.8 (C), 41.5 (CH2), 39.4 (CH2), 32.1 (CH2), 30.5
(CH2), 30.2 (CH2), 29.84 (CH2), 29.82 (CH2), 29.81 (CH2),
29.5 (CH2), 24.1 (CH2), 22.8 (CH2), 14.3 (CH3). IR (ATR, cm-1) 2922, 2852, 1603,
1496, 1455, 743, 697. HRMS (ESI) m/z C24H43NO [M+H]+ = 362.3417, found
= 362.3418.
6.3.2 2,4-Dichlorophenyl analogues
2,4-Dichlorophenylacetelyene 191
Pyridine (28 mL, 34.6 mmol) was added dropwise to PCl5 (8.11 g, 38.9 mmol) in
an ice bath under N2 and the mixture was allowed to warm to room temperature.
2,4-Dichloroacetophenone (7.25 g, 38.4 mmol) was added and immediately placed
on a preheated oil bath at 150°C for 12.5 min and cooled to 0°C. HCl (150 mL,
3M) was added and the reaction mixture was extracted with DCM (3 x 100
mL). The extracts were washed with brine (100 mL) and dried over anhydrous
MgSO4. Silica was added and filtered though celite. The clear yellow solution
was concentrated to give a yellow solid (4.37 g). This was recrystallised from
petroleum spirit (25 mL) at -40°C and washed with ice cold petroleum spirit (5
x 5 mL) and dried under reduced pressure to give 191 as small brown crystals
(2.65 g, 40%, 90% pure).
ClCl
191
1H NMR (CDCl3): δ 7.45 (dd, J = 8.3, 0.3 Hz, 1H), 7.43 (dd, J
= 2.1, 0.3 Hz, 1H), 7.21 (dd, J = 8.3, 2.1 Hz, 1H), 3.40 (s, 1H).
13C NMR (CDCl3): δ 137.2 (C), 135.4 (C), 134.7 (CH), 129.5
(CH), 127.1 (C), 120.8 (C), 83.5 (CH), 79.4 (C). (Matches116)
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3-((2,4-Dichlorophenyl)ethynyl)-3-hydroxyhexadecanenitrile 193
A solution of n-BuLi (1.45 mL, 1.6M) was added dropwise to a stirred solution
of 191 (422 mg, 2.47 mmol) in anhydrous THF (4 mL) at -84°C. The solution
was allowed to warm to room temperature and added dropwise to a suspension
(previously stirred for 2 hours at room temp) of anhydrous cerium chloride (1.264
g CeCl3.7H2O progressively heated to 140°C under high vacuum overnight, 3.39
mmol) in anhydrous THF (10 mL) at -84°C. After 40 min at this temperature, a
solution of the ketonitrile 124 (510 mg, 2.03 mmol) in anhydrous THF (5 mL) was
added and the reaction mixture stirred for 4 hours before addition of sat. NH4Cl
(10 mL). The reaction mixture was allowed to warm to room temperature and
concentrated under reduced pressure. Water (50 mL) was added and extracted
with DCM (3 x 75 mL). The combined extracts were washed with brine (50 mL)
and dried over MgSO4. The filtrate was concentrated under reduced pressure
to give a crude light yellow semisolid (761 mg) which was purified by column
chromatography (75-100% DCM in PS) to give 193 as a yellow oil (423 mg, 49
%).
C13H27
OH
CN
Cl
Cl
193
1H NMR (CDCl3): δ 7.43-7.40 (m, 2H), 7.22 (dd, J = 8.4,
2.1 Hz, 1H), 2.91-2.81 (m, 2H), 2.61 (s, 1H), 1.91-1.87 (m,
2H), 1.64-1.60 (m, 3H), 1.40-1.26 (m, 19H), 0.88 (t, J = 6.9
Hz, 3H). 13C NMR (CDCl3): δ 137.2 (C), 135.7 (C), 134.3
(CH), 129.5 (CH), 127.2 (CH), 120.3 (C), 116.5 (C), 94.6
(C), 82.3 (C), 69.2 (C), 41.6 (CH2), 32.3 (CH2), 32.1 (CH2),
29.82 (CH2), 29.80 (CH2), 29.75 (CH2), 29.64 (CH2), 29.58
(CH2), 29.53 (CH2), 29.50 (CH2), 24.5 (CH2), 22.8 (CH2), 14.3 (CH3). IR (ATR,
cm-1) 3423, 2923, 2853, 2259, 1584, 1547, 1474, 1379, 1101, 1059, 868, 820, 772,
721. HRMS (ESI): Molecular ion not found.
3-(2,4-Dichlorophenethyl)-3-hydroxyhexadecanenitrile 194
A solution of the propargyl alcohol 193 (256 mg, 0.606 mmol) in EtOAc (2.5 mL)
was degassed under reduced pressure before addition of 10% Pd/C (32 mg, 12.5%
wt). The reaction mixture was stirred under a hydrogen atmosphere for 15h at
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room temperature. A nitrogen atmosphere was introduced and the suspension
was filtered though celite. The filtrate was concentrated under reduced pressure
to give 194 as a yellow oil (256 mg, 99%) that did not require further purification.
C13H27
OH
CN
Cl
Cl
194
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
1H NMR (CDCl3): δ 7.37 (m, 1H), 7.20-7.17 (m, 2H), 2.79-
2.75 (m, 2H), 2.58 (s, 2H), 1.87-1.83 (m, 2H), 1.81 (s, 1H),
1.34-1.24 (m, 24H), 0.88 (t, J = 6.9 Hz, 3H). 13C NMR
(CDCl3): δ 137.5 (C), 134.5 (C), 132.8 (C), 131.3 (CH),
129.5 (CH), 127.5 (CH), 117.4 (C), 73.0 (C), 39.3 (CH2),
39.1 (CH2), 32.1 (CH2), 29.97 (CH2), 29.82 (CH2), 29.79
(CH2), 29.75 (CH2), 29.67 (CH2), 29.62 (CH2), 29.50 (CH2), 29.36 (CH2), 27.5
(CH2), 23.8 (CH2), 22.8 (CH2), 14.3 (CH3). IR (ATR, cm-1) 3466, 2920, 2851,
2254, 1470, 1455, 1049, 864, 827, 567. HRMS (ESI): Molecular ion not found.
1-Amino-3-(2,4-dichlorophenethyl)hexadecan-3-ol 190
A solution of 194 (154 mg, 0.361 mmol) in anhydrous THF (1 mL) was added
dropwise to a suspension of LiAlH4 (16 mg, 0.421 mmol) in anhydrous THF
(1 mL) in a salt/ice bath. After 5 min, the solution was allowed to warm to
room temperature for 30 min before being quenched with water (5 drops), KOH
(10%, 5 drops) and water (5 drops). The mixture was stirred for 20 min before
addition of DCM (70 mL) and then filtered. The filtrate was dried over MgSO4
and concentrated under reduced pressure to give a yellow oil (119 mg) which was
purified by column chromatography (10:2.5:87.5 MeOH:TEA:CHCl3) to give the
amine 190 as a yellow oil (19 mg, 12 %).
C13H27
OH
Cl
Cl
NH2
190
1H NMR (CDCl3): δ 7.34-7.32 (m, 1H), 7.19-7.12 (m, 2H),
3.09 (m, 1H), 2.70 (m, 2H), 1.74-1.68 (m, 4H), 1.57-1.56
(m, 2H), 1.28 (m, 23H), 0.88 (t, J = 6.9 Hz, 3H). 13C
NMR (CDCl3): δ 139.0 (C), 134.5 (C), 132.2 (C), 131.3
(CH), 129.3 (CH), 127.3 (CH), 74.9 (C), 39.29 (CH2), 39.14
(CH2), 37.7 (CH2), 37.4 (CH2), 32.1 (CH2), 31.1 (CH2),
30.5 (CH2), 29.87 (CH2), 29.85 (CH2), 29.84 (CH2), 29.82
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(CH2), 29.5 (CH2), 27.7 (CH2), 24.1 (CH2), 22.8 (CH2), 14.3 (CH3). IR (ATR,
cm-1) 3325, 2923, 2852, 1652, 1587, 1561, 1472, 1382, 1102, 1050, 865, 817, 721.
HRMS (ESI) m/z C25H41Cl2NO [M+H]+ = 430.2638 , found = 430.2654.
1-((2,4-Dichlorobenzyl)amino)hexadecan-3-ol 196
Amixture of 1-aminohexadecan-3-ol 109 (98 mg, 0.381 mmol), 2,4-dichlorobenzaldehyde
(71 mg, 0.405 mmol, 1.06 eq) and anhydrous MgSO4 (103 mg) in anhydrous
DCM:THF (5:1, 5 mL) was stirred for 20 hours under nitrogen at room tem-
perature. The reaction mixture was filtered and the filtrate concentrated under
reduced pressure. The residue was dissolved in dry EtOH (6 mL) and NaBH4
(21 mg, 0.555 mmol, 1.45 eq) added and stirred for 72 hours under N2 at room
temperature. HCl (1M) was added and the reaction mixture was stirred briefly
at room temperature before adjusting the pH > 7 by addition of NaOH (2M) and
concentration to dryness under reduced pressure. The resulting material was trit-
urated with CHCl3, filtered and the filtrate concentrated under reduced pressure
to give a mixture of a clear oil and white crystalline solid (129 mg). The mixture
was triturated with petroleum spirit (4 x 2 mL) and remaining solid (71 mg)
was further purified by column chromatography (4% MeOH(Sat. NH3) in CHCl3)
to give 196 as a colourless powder (41 mg, 26%).
C13H27
OH HN
Cl
Cl
196
Melting range: 59 - 60°C. 1H NMR (CDCl3): δ 7.38
(d, J = 2.1 Hz, 1H), 7.33 (d, J = 8.2 Hz, 1H), 7.22
(dd, J = 8.2, 2.1 Hz, 1H), 3.91 (d, J = 13.9 Hz,
1H), 3.86 (d, J = 13.8 Hz, 1H), 2.99 (d, J = 1.4
Hz, 1H), 2.79 (d, J = 3.5 Hz, 1H), 1.40-1.37 (m,
5H), 1.31-1.25 (m, 24H), 0.88 (t, J = 6.8 Hz, 3H). 13C NMR (CDCl3): δ 134.74
(C), 134.67 (C), 134.0 (C), 131.4 (CH), 129.6 (CH), 127.4 (CH), 73.4 (CH), 50.4
(CH2), 48.1 (CH2), 37.9 (CH2), 34.9 (CH2), 32.1 (CH2), 29.88 (CH2), 29.84 (CH2),
29.83 (CH2), 29.80 (CH2), 29.77 (CH2), 29.5 (CH2), 25.7 (CH2), 22.8 (CH2), 14.3
(CH3). IR (ATR, cm-1) 3266, 2957, 2917, 2848, 1594, 1565, 1468, 1095, 1042,
1020, 867, 836, 723. HRMS (ESI) m/z C23H39Cl2NO [M+H]+ = 416.2481, found
= 416.2669.
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3,5-Dichloro-2-(((3-hydroxyhexadecyl)amino)methyl)phenol 197
Amixture of 1-aminohexadecan-3-ol 109 (102 mg, 0.397 mmol), 2,4-dichlorosalicaldehyde
(76 mg, 0.398 mmol) and anhydrous MgSO4 (144 mg) in anhydrous DCM:THF
(5:1, 2.2 mL) was stirred for 48 hours in a sealed vessel at room temperature. The
reaction mixture was filtered and the filtrate concentrated under reduced pres-
sure. The residue was dissolved in dry EtOH (4 mL) and NaBH4 added (16 mg,
0.422 mmol) added and stirred for 4 hours under N2 at room temperature. HCl
(1M) was added and the reaction mixture was stirred briefly at room temperature
before adjusting the pH > 7 by addition of NaOH (2M) and concentration to dry-
ness under reduced pressure. The resulting material was triturated with CHCl3,
filtered and the filtrate concentrated under reduced pressure to give a clear oil
(129 mg). The oil was purified by column chromatography (6-8% MeOH(Sat. NH3)
in CHCl3) to give 197 as a white powder (59 mg, 34%).
C13H27
OH HN
Cl
ClHO
197
Melting range: 117 - 119°C. 1H NMR (DMSO-
d6 ): δ 6.82 (d, J = 2.1 Hz, 1H), 6.62 (d, J = 2.1
Hz, 1H), 3.99 (s, 2H), 3.46-3.43 (m, 1H), 2.64 (m,
2H), 1.54-1.44 (m, 2H), 1.31-1.18 (m, 24H), 0.87-
0.83 (m, 3H). 13C NMR (DMSO-d6): δ 162.2 (C),
133.0 (C), 132.4 (C), 119.1 (C), 117.0 (CH), 115.0 (CH), 68.0 (CH), 47.4 (CH2),
45.0 (CH2), 37.3 (CH2), 35.8 (CH2), 31.3 (CH2), 29.10 (CH2), 29.01 (CH2), 28.98
(CH2), 28.7 (CH2), 25.1 (CH2), 22.1 (CH3). IR (ATR, cm-1): 3089, 2916, 2851,
1571, 1536, 1411, 1267, 966, 816. HRMS (ESI) m/z C23H40Cl2NO2 [M+H]+ =
432.2431, found = 432.2411.
6.3.3 4’-Fluorobiphenyl analogues
1-(4’-Fluorobiphenyl-2-yl)ethanone 204
Pd(OAc)2 (113 mg, 0.503 mmol, 8.5 mol%) was added to a stirred mixture of
2-bromoacetophenone (802 µl, 5.91 mmol), 4-fluorophenylboronic acid (1.02 g,
7.31 mmol, 1.23 eqv), K2CO3 (2.04 g, 14.8 mmol, 2.50 eqv) and TBAB (1.97
g, 6.11 mmol, 1.03 eqv) in water (10 mL) and heated at 70°C under N2 for 15
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h. The reaction mixture was allowed to cool, diluted with water (50 mL) and
extracted with EtOAc (1 x 50 mL). The extract was washed with water (3 x 10
mL) before back extracting the combined washings with EtOAc (1 x 50 mL). The
combined extracts were dried over anhydrous MgSO4 and concentrated under
reduced pressure to give a black residue (1.48 g) that was purified by column
chromatography (50 - 100% DCM in petroleum spirt) to yield 204 as a yellow oil
(1.12 g, 88%). The NMR spectra match those reported.119
F O
replacemen
204
1H NMR (CDCl3): δ 7.55 (ddd, J = 7.6, 1.5, 0.5 Hz, 1H),
7.51 (td, J = 7.5, 1.5 Hz, 1H), 7.43 (dd, J = 7.5, 1.3 Hz,
1H), 7.35 (ddd, J = 7.6, 1.3, 0.5 Hz, 1H), 7.32-7.29 (m,
2H), 7.14-7.10 (m, 2H), 2.06 (s, 3H). 13C NMR (CDCl3):
δ 204.6 (C), 164.0 (C), 161.6 (C), 140.9 (C), 139.5 (C), 136.9 (C), 130.9 (CH),
130.62 (CH), 130.54 (CH), 130.44 (CH), 128.1 (CH), 127.7 (CH), 115.9 (CH),
115.7 (CH), 30.6 (CH3) IR (ATR, cm-1) 1685, 1606, 1597, 1512, 1474, 1443, 1355,
1268, 1222, 1159, 837.5, 820, 763.
2-Ethynyl-4’-fluoro-1,1’-biphenyl 201
The acetophenone 204 (1.10 g, 5.12 mmol) was added to a mixture of PCl5 (1.07 g,
5.13 mmol, 1.00 eq) in pyridine (10mL, 124 mmol, 24 eq). The mixture was heated
using microwave irritation (0 - 400 W) for 20 min at 110°C. The dark red to brown
solution was poured into a ice cold HCl solution (3M, 150 mL) and extracted with
petroleum spirit (3 x 80 mL). The combined extracts were washed with brine (100
mL), dried over anhydrous MgSO4. The filtrate was concentrated to give a golden
oil (622 mg) that was purified by column chromatography (petroleum spirits) to
give 201 as a colourless oil (503 mg, 54%).
F
201
1H NMR (CDCl3): δ 7.62 (d, J = 7.7 Hz, 1H), 7.58-7.53 (m,
2H), 7.43-7.29 (m, 3H), 7.15-7.09 (m, 2H), 3.05 (s, 1H). 13C
NMR (CDCl3): δ 163.8 (C), 161.4 (C), 143.5 (C), 136.37
(C), 136.34 (C), 134.0 (CH), 131.08 (CH), 131.00 (CH),
129.6 (CH), 129.2 (CH), 127.3 (CH), 120.6 (C), 115.2 (CH), 115.0 (CH), 83.1
(CH), 80.5 (C). IR (ATR, cm-1) 3287, 3060, 2105, 1607, 1511, 1476 1442, 1220,
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1158, 835, 757, 650, 618, 562.
3-((4’-Fluoro-[1,1’-biphenyl]-2-yl)ethynyl)-3-hydroxy
hexadecanenitrile 205
A solution of n-BuLi (1.4 mL, 1.6M, 2.24 mmol, 1.11 eq) was added dropwise
to a solution of the alkyne 201 (463 mg, 2.36 mmol) in anhydrous THF (3 mL)
at -84°C. The solution was warmed to room temperature and added dropwise to
a suspension (previously stirred for 2 hours at room temperature) of anhydrous
cerium chloride (962 mg CeCl3.7H2O progressively heated to 140°C under Hi-
Vac overnight, 2.58 mmol) in anhydrous THF (8 mL) at -84°C and held at this
temperature for 30 min. A solution of the ketonitrile 124 (508 mg, 2.02 mmol)
in anhydrous THF (5 mL) was added and the reaction mixture was held at -84°C
for 4 hours before addition of sat. NH4Cl (10 mL). The reaction mixture was
left to warm to room temperature and concentrated under reduced pressure. The
reaction mixture was dissolved in HCl (1 M, 75 mL) and extracted with DCM (3 x
50 mL). The combined extracts were washed with brine (150 mL) and dried over
a combination of anhydrous K2CO3 and MgSO4. The filtrate was concentrated
under reduced pressure to give a light yellow semi solid (932 mg) that was purified
using column chromatography (DCM) to give 205 as a light yellow oil (198 mg,
22%).
C13H27
OH
CN
F
205
1H NMR (CDCl3): δ 7.56 (m, 1H), 7.53-7.48 (m, 2H), 7.43-
7.30 (m, 3H), 7.15-7.09 (m, 2H), 2.71 (d, J = 16.4 Hz, 1H),
2.67 (d, J = 16.4 Hz, 1H), 1.75-1.67 (m, 2H), 1.40-1.19 (m,
23H), 0.90-0.86 (m, 3H). 13C NMR (CDCl3): δ 163.8 (C),
161.4 (C), 143.5 (C), 136.46 (C), 136.43 (C), 133.4 (CH),
131.08 (CH), 131.00 (CH), 129.55 (CH), 129.42 (CH), 127.4
(CH), 120.2 (C), 116.6 (C), 115.2 (CH), 115.0 (CH), 91.4 (C), 86.0 (C), 69.0 (C),
41.6 (CH2), 32.3 (CH2), 32.1 (CH2), 29.84 (CH2), 29.80 (CH2), 29.77 (CH2),
29.70 (CH2), 29.61 (CH2), 29.58 (CH2), 29.51 (CH2), 24.4 (CH2), 22.8 (CH2),
14.3 (CH3). IR (ATR, cm-1) 3432, 2923, 2853, 2258, 1606, 1514, 1479, 1223,
1159, 1094, 837, 759. HRMS (ESI): Molecular ion not found.
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3-(2-(4’-Fluoro-[1,1’-biphenyl]-2-yl)ethyl)-3-hydroxy
hexadecanenitrile 208
A stirred solution of the alkyne 205 (176 mg, 0.394 mmol) was dissolved in EtOAc
(3 mL) and degassed prior to addition of Pd/C (5%w/w, 20 mg). The mixture
was stirred under a hydrogen atmosphere (x 3) for 15 hours at room temperature
and filtered though celite. The filtrate was concentrated under reduced pressure
to give 208 as a white waxy solid (172 mg, 96 %) that did not require further
purification.
F
C13H27
OH
CN
208
1H NMR (CDCl3): δ 7.32-7.23 (m, 5H), 7.18 (d, J
= 7.4, 1H), 7.14-7.09 (m, 2H), 2.62 (dd, J = 10.2,
7.0 Hz, 2H), 2.36 (s, 2H), 1.69 (m, 2H), 1.48-1.43
(m, 2H), 1.31-1.18 (m, 21H), 1.09-1.07 (m, 2H),
0.90-0.87 (m, 3H). 13C NMR (CDCl3): δ 163.4 (C),
161.0 (C), 140.9 (C), 138.8 (C), 137.57 (C), 137.53 (C), 130.92 (CH), 130.84 (CH),
130.4 (CH), 129.6 (CH), 128.1 (CH), 126.4 (CH), 117.4 (C), 115.5 (CH), 115.2
(CH), 72.9 (C), 40.7 (CH2), 38.9 (CH2), 32.1 (CH2), 29.97 (CH2), 29.84 (CH2),
29.81 (CH2), 29.76 (CH2), 29.73 (CH2), 29.59 (CH2), 29.51 (CH2), 29.3 (CH2),
27.3 (CH2), 23.5 (CH2), 22.8 (CH2), 14.3 (CH3). IR (ATR, cm-1) 3476, 2922,
2852, 2252, 1512, 1482, 1469, 1220, 1159, 837, 766, 724. HRMS (ESI): Molecular
ion not found.
1-Amino-3-(2-(4’-fluoro-[1,1’-biphenyl]-2-yl)ethyl)hexadecan-3-ol 199
NaBH4 (127 mg, 3.36 mmol) was added to a solution of crude nitrile 208 (153
mg, mmol) and CoCl2.6H2O (179 mg, 0.653 mmol) in EtOH (3 mL) at 0°C. The
reaction mixture was stirred for 1 hour at room temperature before addition of
HCl solution (1M, 10mL). The mixture was made alkaline by addition of con-
centrated ammonia solution (5 mL) and concentrated to dryness under reduced
pressure. The residue was triturated with chloroform (5 x 20 mL) and the filtrate
concentrated to give a crude brown oil (107 mg) that was purified by column
chromatography (5-10% MeOH, 1% TEA in CHCl3) to give 199 as a waxy white
solid (19 mg, 12%).
181
F
C13H27
OH
NH2
199
1H NMR (CDCl3): δ 7.32-7.03 (m, 8H), 2.97-2.83
(m, 2H), 2.63-2.46 (m, 2H), 1.66-1.41 (m, 4H),
1.39-1.08 (m, 23H), 1.01-0.91 (m, 2H), 0.92-0.84
(m, 3H). 13C NMR (CDCl3): 163.3 (C), 160.9 (C),
140.9 (C), 140.3 (C), 137.90 (C), 137.86 (C), 130.97
(CH), 130.89 (CH), 130.2 (CH), 129.7 (CH), 127.9 (CH), 125.9 (CH), 115.2 (CH),
115.0 (CH), 74.9 (C), 40.9 (CH2), 38.9 (CH2), 37.5 (CH2), 37.1 (CH2), 32.1 (CH2),
30.4 (CH2), 29.92 (CH2), 29.87 (CH2), 29.85 (CH2), 29.83 (CH2), 29.82 (CH2),
29.5 (CH2), 27.6 (CH2), 23.7 (CH2), 22.8 (CH2), 14.3 (CH3). HRMS (ESI) m/z
C30H46FNO [M+H]+ = 456.3636, found = 456.3633. IR (ATR, cm-1): 3150.0,
3140, 2923, 2853, 1512, 1221, 1157, 1091, 1091, 1008, 837. 759.
6.3.4 4’-Fluoro-2,4-dichlorobiphenyl analogues
2,4-Dichlorobenzaldehyde O-methyl oxime 209120
2,4-Dichlorobenzaldehyde (1.31 g, 7.49 mmol) was added to a solution of methoxy
amine hydrochloride (0.75 g, 8.98 mmol, 1.2 eq) and pyridine (2.4 mL, 2.35 g, 29.8
mmol, 4.0 eq) in dry DCM (15 mL). The solution was stirred at room temperature
for 2 hours and concentrated to dryness. The reaction mixture was filtered though
a plug of silica and the residue washed with DCM until the filtrate was no longer
active under UV to TLC. The filtrate was concentrated under reduced pressure to
give 2,4-dichlorobenzaldehyde-O-methyloxime 209 as a colourless crystalline solid
(1.48 g, 97 %, 96:4 E:Z). The NMR spectra were identical to those reported.120
Cl
Cl
N
OMe
209
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
1H NMR (CDCl3): δ 8.41 (s, 1H), 7.83 (d, J = 8.5 Hz, 1H),
7.39 (d, J = 2.1 Hz, 1H), 7.24 (ddd, J = 8.5, 2.1, 0.7 Hz, 1H),
4.00 (s, 3H). 13C NMR (CDCl3): δ 144.8, 136.2, 134.4, 129.8,
128.8, 128.0, 127.6, 62.5.
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2-Bromo-4,6-dichlorobenzaldehyde O-methyl oxime120
2,4-Dichlorobenzaldehyde O-methyloxime 209 (5.95 g, 29.2 mmol), NBS (10.57
g, 59.4 mmol, 2.0 eq), acetic acid (1.68 mL, 29.37, 1.0 eq), silver trifluoroacetate
(657 mg, 2.97 mmol, 0.10 eq) and palladium acetate (660 mg, 2.94 mmol, 0.10
eq) were suspended in DCE (60 mL) and heated in a sealed vessel at 120°C for
24 hours. The reaction mixture was allowed to cool and filtered. The residue
was washed with DCM (200 mL). The combined filtrates were washed with water
(2 x 100 mL). The aqueous phase was back extracted with DCM (50 mL). The
combined extracts were washed with brine (1 x 50mL), dried over anhydrous
MgSO4 and concentrated under reduced pressure onto silica. The crude/silica
mixture was subjected to column chromatography (10 - 25% DCM in PS) to
give 2-bromo-4,6-dichlorobenzaldehyde O-methyl oxime as colourless crystalline
solid (5.56 g, 67 %, 308:309, E:Z, 2:1). he NMR spectra were identical to those
reported.120
Cl
Cl
N
O
Br Cl
Cl
N
Br
O
E Z308 309
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
1H NMR (CDCl3) (E ): δ 8.15 (s, 1H), 7.56 (d,
J = 2.0 Hz, 1H), 7.41 (d, J = 2.0 Hz, 1H),
4.02 (s, 3H). 13C NMR (CDCl3): δ 145.1 (CH),
135.55 (C), 135.47 (C), 131.8 (CH), 129.43
(CH), 129.30 (C), 124.6 (C), 62.7, (CH3).1H
NMR (CDCl3): (Z ) δ 7.52 (d, J = 1.9 Hz,
1H), 7.39 (d, J = 1.9 Hz, 1H), 7.36 (s, 1H), 3.94 (s, 3H). 13C NMR (CDCl3):
δ 142.4 (CH), 135.7 (C), 134.3 (C), 130.95 (CH), 130.91 (C), 128.6 (CH), 122.8
(C), 62.6 (CH3). (Matches120)
3,5-Dichloro-4’-fluoro-[1,1’-biphenyl]-2-carbaldehyde O-methyl oxime 212
A mixture of 2-bromo-4,6-dichlorobenzaldehyde O-methyl oxime (141 mg, 0.5
mmol, 2:1 308:309), 4-fluorophenylboronic acid (85 mg, 0.607 mmol, 1.2 eqv),
K2CO3 (211 mg, 1.526 mmol, 3.1 eqv), TBAB (155 mg, 0.481 mmol, 1 eqv),
Pd(OAc)2 (16 mg, 14 mol%) in water (2.5 mL) was stirred at 70°C for 15 hours.
The reaction mixture was allowed to cool, diluted with EtOAc (10 mL) and
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washed with water (3 x 10 mL). The aqueous phase was back extracted with
EtOAc (5 mL) and the combined extracts were dried over anhydrous MgSO4.
The filtrate was concentrated under reduced pressure to give a brown solid (160
mg) that was purified by column chromatography (10% DCM in PS) to give 212
as a colourless oil (29 mg, 19 %).
Cl
Cl
N
O
F
212
1H NMR (CDCl3): δ 8.02 (s, 1H), 7.48 (d, J = 2.1
Hz, 1H), 7.28-7.23 (m, 3H), 7.13-7.09 (m, 2H), 3.79
(s, 3H). 13C NMR (CDCl3): δ 163.9 (C), 161.4 (C),
145.1 (CH), 144.3 (C), 135.18 (C), 135.12 (C), 135.08
(C), 134.97 (C), 131.36 (CH), 131.28 (CH), 129.3 (CH),
129.1 (CH), 127.5 (C), 115.4 (CH), 115.2 (CH), 62.2 (CH3). HRMS (ESI) m/z
C14H10Cl2FNO [M+H]+ = 298.0196, found = 298.0190.
2-Bromo-4,6-dichlorobenzaldehyde 214120
A solution the 2-bromo-4,6-dichlorobenzaldehyde O-methyl oxime (298 mg, 1.06
mmol), p-toluenesulfonic acid (385 mg, 2.24 mmol, 2.1 eq) and formaldehyde
(1.2 mL, 35% in water, 420 mg, 14 mmol) in THF:H2O (10:1, 4.1 mL) was
heated under microwave irradiation (0 - 400 W) at 100°C for 1h. The crude
reaction mixture was concentrated on to a small amount of silica and purified
using column chromatography (35 % DCM in PS) to give 214 as yellow crystals
(273 mg, 100%).
Cl
Cl
O
Br
214
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
1H NMR (CDCl3): δ 10.32 (t, J = 0.3 Hz, 1H), 7.63
(dd, J = 1.9, 0.3 Hz, 1H), 7.47 (dd, J = 2.0, 0.3 Hz,
1H).13C NMR (CDCl3): δ 189.0, 139.5, 137.6, 133.1,
130.6, 130.0, 125.6.
2-(4’-Fluorophenyl)-4,6-dichlorobenzaldehyde 210
A mixture of 6-bromo-2,4-dichlorobenzaldehyde 214 (4.45 g, 17.69 mmol), 4-
fluorophenylboronic acid (2.72 g, 19.44 mmol, 1.10), TBAB (0.379 g, 1.798 mmol,
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0.102 eq), K2CO3 (3.01 g, 21.81 mmol, 1.232 eq) and Pd(OAc)2 (226 mg, 1.518
mmol, 8.6 mol%) was stirred under N2 at room temperature. After 16 hours, a
second addition of Pd(OAc)2 (115 mg) was required after monitoring the reaction
by NMR showed a incomplete reaction. The reaction mixture was left to stir at
room temperature for a total of 130 hours before concentrating under a stream
of nitrogen. The residues were dissolved in toluene (150 mL) and washed with
water (75 mL). The aqueous phase was extracted with toluene (50 mL) and the
combined organic phases washed with HCl (1M, 100 mL), NaHCO3 (5%, 100 mL)
and brine (100 mL) before being dried with anhydrous MgSO4. The filtrate was
concentrated under a stream of nitrogen overnight to give a yellow/brown solid
(4.64 g) that was purified by column chromatography (20-35% DCM in PS) to
yield 210 as a yellow solid (3.38 g, 67%).
Cl
Cl
OF
210
1H NMR (CDCl3): δ 10.05 (s, 1H), 7.51 (d, J
= 2.0 Hz, 1H), 7.28 (d, J = 2.0 Hz, 1H), 7.28-
7.23 (m, 2H), 7.16-7.12 (m, 2H). Matches80 13C
NMR (CDCl3): δ 189.8 (CH), 164.4 (C), 161.9 (C),
146.5 (C), 138.6 (C), 136.3 (C), 133.04 (C), 133.01
(C), 131.25 (CH), 131.17 (CH), 130.30 (C), 130.17
(CH), 130.02 (CH), 115.9 (CH), 115.7 (CH).
3,5-Dichloro-2-(2,2-dibromovinyl)-4’-fluoro-1,1’-biphenyl 221
A solution of the aldehyde 210 (3.63 g, 13.45 mmol) and CBr4 (9.41 g, 28.37
mmol, 2.1 eq) in anhydrous DCM (30 mL) was added dropwise to a stirred
solution of triethyl phosphite (9.6 mL, 56.0 mmol, 4.2 eq) in anhydrous DCM
(3.5 mL) at -45°C. The temperature was maintained for 90 min and TLC showed
consumption of 210. The reaction mixture was poured onto an iced saturated
NaHCO3 solution and extracted with DCM (2 x 50 mL). The combined extracts
were washed with NaHCO3 (Sat. 1 x 60 mL, 5% 1 x 60 mL) and brine (1 x 60
mL) before being concentrated under reduced pressure. The resulting material
was purified using column chromatography (PS) to give 221 as a colourless oil
(3.78 g, 64%).
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Cl
F
Br
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1H NMR (CDCl3): δ 7.44 (d, J = 2.1 Hz, 1H),
7.30-7.26 (m, 2H), 7.24 (d, J = 2.1 Hz, 1H), 7.22
(s, 1H), 7.14-7.09 (m, 2H). 13C NMR (CDCl3): δ
164.1 (C), 161.6 (C), 143.4 (C), 134.91 (C), 134.88
(C), 134.6 (C), 134.0 (CH), 132.5 (C), 130.81 (CH),
130.73 (CH), 128.8 (CH), 128.5 (CH), 115.7 (CH),
115.5 (CH), 96.4 (C). HRMS (ESI): Molecular ion not found. IR (ATR, cm-1):
1603, 1576, 1546, 1508, 1435, 1380, 1224, 1158, 1096, 1055, 886, 824.
3,5-Dichloro-2-ethynyl-4’-fluoro-1,1’-biphenyl 206
A solution of 221 (3.73 g, 8.79 mmol) in dry toluene (25 mL) was added dropwise
to a solution of potassium tert-amylate (5 mL, 25 % in Tol.) at 0°C over 25 min.
The reaction mixture was stirred at 0°C for 90 min before addition of methanol
(1.8 mL). A sample was removed and a aqueous workup isolated the intermediate
222. Dimethyl phosphite (1.1 mL, 12.0 mmol, 1.4 eqv) and potassium tert-
amylate (4.9 mL, 8.44 mmol, 1.0 eqv) were sequentially added and the reaction
mixture held at 0°C for 45 min before being poured onto saturated NH4Cl solution
(35 mL). The reaction mixture was diluted with toluene (60 mL) and washed with
water (2 x 30 mL), NaHCO3 solution (saturated 2 x 30 mL, 5% 2 x 30 mL) and
brine (2 x 30 mL). The organic phase was dried over MgSO4 and concentrated
under reduced pressure to give a light blue solid (2.31 g) that was purified by
column chromatography (PS) to give 206 as a colourless solid (2.23 g, 96%).
Cl
Cl
F
R
R= H
R= Br
206
222
.206: Melting range: 105 - 106 °C. 1H NMR (CDCl3 ): δ
7.53-7.48 (m, 2H), 7.44 (d, J = 2.1 Hz, 1H), 7.24 (d, J =
2.1 Hz, 1H), 7.15-7.09 (m, 2H), 3.37 (s, 1H). 13C NMR
(CDCl3): δ 164.2 (C), 161.8 (C), 146.7 (C), 138.5 (C),
134.85 (C), 134.66 (C), 134.62 (C), 131.03 (CH), 130.95
(CH), 128.2 (CH), 119.5 (C), 115.4 (CH), 115.2 (CH), 87.1
(C), 78.7 (CH). HRMS (ESI): Molecular ion not found. IR
(ATR, cm-1): 3285, 1601, 1577, 1543, 1507, 1431, 1410,
1382, 1220, 1159, 1101, 1054, 847, 828, 695.
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222: 1H NMR (CDCl3): δ 7.55-7.48 (m, 2H), 7.47-7.43 (m, 1H), 7.26-7.25 (m,
1H), 7.22-7.12 (m, 2H). 13C NMR (CDCl3): δ 164.3 (C), 161.8 (C), 146.7 (C),
138.6 (C), 134.66 (C), 134.57 (C), 134.54 (C), 130.92 (CH), 130.84 (CH), 128.15
(CH), 128.10 (CH), 120.0 (C), 115.5 (CH), 115.3 (CH), 75.8 (C), 59.7 (C).
3-((3,5-Dichloro-4’-fluoro-[1,1’-biphenyl]-2-yl)ethynyl)-
3-hydroxyhexadecanenitrile 207
n-BuLi (3.55 mL, 1.6M, 5.70 mmol) was added to a solution of 206 (1.51 g, 5.70
mmol) in THF (12 mL) at -84°C and allowed to warm to room temperature.
After 5 min, the solution was added dropwise to a suspension (previously stirred
for 2 hours at room temp) of anhydrous cerium chloride (2.30 g CeCl3.7H2O
progressively heated to 140°C for 2 hours, 6.18 mmol) in anhydrous THF (18
mL) at -84°C under N2. After 30 min, a solution of the ketonitrile 124 (1.21 g,
4.75 mmol) in THF (5 mL) was added and reaction mixture was held at -84°C
for 4 hours before dropwise addition of saturated NH4Cl solution (10 mL). The
reaction mixture was allowed to warm to room temperature and concentrated
under a stream of nitrogen. The residue was dissolved in DCM (100 mL) and
washed with hydrochloric acid (1M, 100 mL). The washings were back extracted
with DCM (2 x 50 mL). The combined extracts were washed with brine (200
mL) before being dried over anhydrous MgSO4 and concentrated under reduced
pressure. The resulting residue was purified by column chromatography (75 -
100% DCM in PS) to give 207 as a light blue oil (1.33 g, 65%).
Cl
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F
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1H NMR (CDCl3): δ 7.50-7.45 (m, 2H), 7.44 (d,
J = 2.1 Hz, 1H), 7.25 (d, J = 2.1 Hz, 1H),
7.17-7.12 (m, 2H), 2.69 (d, J = 0.7 Hz, 2H),
1.75-1.71 (m, 2H), 1.39-1.26 (m, 23H), 0.88 (t, J
= 6.9 Hz, 3H).13C NMR (CDCl3): δ 164.3 (C),
161.8 (C), 146.5 (C), 138.2 (C), 135.2 (C), 134.69
(C), 134.66 (C), 131.02 (CH), 130.94 (CH), 128.26
(CH), 128.14 (CH), 119.2 (C), 116.3 (C), 115.6 (CH), 115.4 (CH), 97.7 (C), 81.7
(C), 69.2 (C), 41.4 (CH2), 32.1 (CH2), 29.83 (CH2), 29.80 (CH2), 29.75 (CH2),
29.66 (CH2), 29.58 (CH2), 29.53 (CH2), 29.50 (CH2), 24.3 (CH2), 22.8 (CH2),
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14.3 (CH3). IR (ATR, cm-1): 3432, 2923, 2853, 2261, 1605, 1510, 1226, 1159,
1059, 836, 786. HRMS (ESI): Molecular ion not found.
Z -3-(2-(3,5-Dichloro-4’-fluoro-[1,1’-biphenyl]-2-yl)vinyl)-
3-hydroxyhexadecanenitrile 223
A solution of 207 (460 mg, 0.891 mmol) in EtOAc (3 mL) was degassed under
reduced pressure and placed under N2 (x 3). Pd/C (97 mg, 10%) was added
and a hydrogen atmosphere introduced (x 3). The reaction mixture was rapidly
stirred for 4 days and placed under a nitrogen atmosphere. The reaction mixture
was filtered though celite and the filtrate concentrated under reduced pressure to
give 223 as a golden oil (458 mg, 99%) that did not require further purification.
F
C13H27HO
CN
Cl
H
H
Cl
223
1H NMR (CDCl3): δ 7.41 (dd, J = 9.6, 2.1 Hz, 1H),
7.34-7.29 (m, 2H), 7.22 (apparent t, J = 2.2 Hz,
1H), 7.15-7.07 (m, 2H), 6.47 (d, J = 12.5 Hz, 1H),
5.53 (apparent d, J = 28.2, 12.5 Hz, 1H), 2.48-2.39
(m, 1H), 1.69 (s, 1H), 1.61-1.02 (m, 26H), 0.89 (td,
J = 6.8, 2.4 Hz, 3H), 0.78-0.72 (m, 1H). 13C NMR
(CDCl3): δ 163.9 (C), 161.42 (C), 161.40 (C), 143.2 (C), 142.7 (C), 136.02 (C),
135.98 (C), 135.77 (C), 135.74 (C), 135.3 (CH), 135.0 (CH), 134.08 (C), 134.04
(C), 133.87 (C), 133.77 (C), 133.4 (C), 131.56 (CH), 131.48 (CH), 131.32 (CH),
131.23 (CH), 128.48 (CH), 128.44 (CH), 128.2 (CH), 128.0 (CH), 126.6 (CH),
126.3 (CH), 116.90 (C), 116.78 (C), 115.78 (CH), 115.59 (CH), 115.56 (CH),
115.38 (CH), 74.6 (C), 40.7 (CH2), 40.0 (CH2), 32.1 (CH2), 29.88 (CH2), 29.83
(CH2), 29.79 (CH2), 29.78 (CH2), 29.70 (CH2), 29.60 (CH2), 29.56 (CH2), 29.50
(CH2), 28.5 (CH2), 23.5 (CH2), 23.1 (CH2), 22.8 (CH2), 14.3 (CH3). IR (ATR,
cm-1): 3467, 2923, 2852, 2252, 1605, 1510, 1378, 1225, 1159, 1102, 1053, 840, 816.
HRMS (ESI): Molecular ion not found.
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3-(2-(3,5-Dichloro-4’-fluoro-[1,1’-biphenyl]-2-yl)ethyl)-
3-hydroxyhexadecanenitrile 224
A solution of 223 (884 mg, 1.71 mmol) in EtOAc (8 mL) was degassed under
reduced pressure and placed under N2 (x 3). 10% Pd/C (1.02 g) was added. The
reaction mixture was heated at reflux under H2 for 3 hours and allowed to cool.
A N2 atmosphere was introduced and the reaction mixture filtered though celite.
The filtrate was concentrated under reduced pressure to give an oil (717 mg) that
was purified by column chromatography (Column 1: 10% EtOAc in PS, Column
2: 75 - 100% DCM in PS) to give the starting material (515 mg) and 224 as a
colourless oil (44 mg, 5%).
F C13H27
OH
CN
Cl
Cl
224
1H NMR (CDCl3): δ 7.40 (d, J = 2.2 Hz, 1H),
7.25-7.21 (m, 2H), 7.16-7.11 (m, 2H), 7.10 (d, J =
2.2 Hz, 1H), 2.67 (td, J = 8.7, 6.9 Hz, 2H), 2.37
(d, J = 3.7 Hz, 2H), 1.67-1.63 (m, 2H), 1.55 (s,
2H), 1.49-1.43 (m, 2H), 1.32-1.21 (m, 19H), 1.11-
1.06 (m, 2H), 0.88 (t, J = 6.9 Hz, 3H). 13C NMR
(CDCl3): δ 163.8 (C), 161.3 (C), 144.2 (C), 135.76
(C), 135.73 (C), 135.62 (C), 135.4 (C), 132.2 (C), 130.67 (CH), 130.59 (CH),
129.10 (CH), 128.92 (CH), 117.3 (C), 115.8 (CH), 115.6 (CH), 72.8 (C), 38.6
(CH2), 38.1 (CH2), 32.1 (CH2), 29.95 (CH2), 29.83 (CH2), 29.79 (CH2), 29.74
(CH2), 29.71 (CH2), 29.57 (CH2), 29.50 (CH2), 29.3 (CH2), 24.7 (CH2), 23.5
(CH2), 22.8 (CH2), 14.3 (CH3). IR (ATR, cm-1): 3485, 2923, 2852, 2251, 1605,
1552, 1508, 1390, 1222, 1158, 862, 839. HRMS (ESI): Molecular ion not found.
1-Amino-3-(2-(3,5-dichloro-4’-fluoro-[1,1’-biphenyl]-2-yl)ethyl)
hexadecan-3-ol 229
NaBH4 (20 mg, 0.528 mmol) was added to a solution of 224 (20 mg, 0.038
mmol) and CoCl2.6H2O (22 mg, 0.080 mmol) in EtOH (0.5 mL) at 0°C. The
reaction mixture was held at this temperature for 1 hour and then allowed to
warm to room temperature for 1 hour. HCl (1M, 0.5 mL) was added and stirred
at room temperature until the reaction mixture became clear. Concentrated NH3
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solution (1 mL) and water (4 mL) were added and the mixture extracted with
CHCl3 (5 x 3 mL). The combined extracts were dried over anhydrous MgSO4 and
concentrated under reduced pressure to give an oil (18 mg) that was purified by
column chromatography (3 - 5 % MeOH, 1% NH3(aq) in CHCl3) to afford 229 as
a colourless oil (9 mg, 45%).
F C13H27
OH
NH2
Cl
Cl
229
1H NMR (CDCl3): δ 7.37 (d, J = 2.2 Hz, 1H), 7.26-
7.20 (m, 2H), 7.10 (m, 2H), 7.07 (d, J = 2.2 Hz,
1H), 2.92-2.77 (m, 4H), 2.73-2.52 (m, 3H), 1.57-
1.38 (m, 5H), 1.38-1.08 (m, 24H), 1.08-0.92 (m,
3H), 0.93-0.85 (m, 3H). 13C NMR (CDCl3): δ 163.7
(C), 161.3 (C), 144.1 (C), 137.2 (C), 136.14 (C),
136.11 (C), 135.4 (C), 131.5 (C), 130.82, 130.74,
128.96, 128.78, 115.63, 115.54, 115.3, 74.7 (C), 39.1 (CH2), 38.19 (CH2), 38.12
(CH2), 37.6 (CH2), 32.1 (CH2), 30.5 (CH2), 29.87 (CH2), 29.85 (CH2), 29.84
(CH2), 29.82 (CH2), 29.78 (CH2), 29.5 (CH2), 25.2 (CH2), 23.5 (CH2), 22.9 (CH2),
14.3 (CH3). IR (ATR, cm-1): 3349, 2922, 2851, 1605, 1508, 1390, 1221, 1159, 838.
HRMS (ESI) m/z C30H44Cl2FNO [M+H]+ = 524.2857, found = 524.2860.
1-(((3,5-Dichloro-4’-fluoro-[1,1’-biphenyl]-2-yl)methyl)amino)
hexadecan-3-ol 235
A mixture of the amine 109 (98 mg, 0.381 mmol), benzaldehyde 210 (110 mg,
0.409 mmol, 1.1 eq) and MgSO4 (126 mg) was suspended in anhydrous DCM (2
mL) and stirred for 48 hours in a sealed vessel at 50 °C. The filtrate was concen-
trated under reduced pressure and dissolved in EtOH (4 mL). NaBH4 (15 mg)
was added and stirred for 3 hours before addition of saturated NH4Cl solution.
K2CO3 solution (5%) was added until pH > 7 and extracted with CHCl3 (3 x 25
mL). The extracts were dried with anhydrous MgSO4 and concentrated under re-
duced pressure to give a crude colourless oil (148 mg) that was purified by column
chromatography (1% MeOH (Sat. NH3) in CHCl3) to give 235 as a colourless oil
(50 mg, 26%).
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C13H27
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N
H
Cl Cl
F
235
1H NMR (CDCl3): δ 7.41 (ad, J = 2.0 Hz, 1H),
7.34-7.29 (m, 2H), 7.17-7.11 (m, 3H), 3.77-3.66
(m, 3H), 2.82 (m, 1H), 2.58 (m, 1H), 1.60-
1.53 (m, 1H), 1.47-1.15 (m, 27H), 0.91-0.83 (m,
3H). 13C NMR (CDCl3): δ 164.0 (C), 161.5
(C), 145.0 (C), 136.2 (C), 135.3 (C), 133.6 (C),
133.1 (C), 130.88 (CH), 130.80 (CH), 129.2
(CH), 128.9 (CH), 115.8 (CH), 115.5 (CH), 73.3 (CH), 48.4 (CH2), 47.9 (CH2),
37.8 (CH2), 35.0 (CH2), 32.1 (CH2), 29.90 (CH2), 29.83 (CH2), 29.80 (CH2),
29.79 (CH2), 29.5 (CH2), 25.7 (CH2), 22.8 (CH2), 14.3 (CH3). IR (ATR, cm-1):
3239, 3341, 2915, 2849, 1606, 1509, 1471, 1225, 1090, 836. HRMS (ESI) m/z
C29H42FNO [M+H]+ = 510.2700, found = 510.2683.
6.3.5 Fluvastatin analogues
2-Bromo-4´-fluoroacetophenone 239
Method A
Bromine (17.5 g, 109.5 mmol) was added to a solution of 4’-fluoroacetophenone
(15.01 g, 108 mmol) in CHCl3 (150 mL) and stirred for 1.5h at room temperature.
The reaction mixture was washed with 2% sodium metabisulphite solution (150
mL), sat. NaHCO3 solution (150 mL) and water (100 mL). The organic phase
was dried with anhydrous MgSO4 and concentrated under reduced pressure to
give a semi solid (23.1 g). 1H NMR analysis on the crude showed a mixture
of mono-brominated product, di-brominated product and the starting material
(84:9:7). The crude material was purified by column chromatography in batches
(20-50 % DCM in PS) to give a colourless solid (18.1 g, 77 %). The NMR spectra
were identical to those reported.179
F
O
Br
239
Melting point: 48.9°C (Lit. 48-49133). 1H NMR (400HMz,
CDCl3) 8.05 – 8.00 (2 H, m), 7.2 – 7.14 (2 H, m), 4.41 (2 H,
s). 13C NMR (CDCl3): δ 190.0, 166.3, 131.8, 130.5, 116.2,
30.5. IR (ATR, cm-1) 2954, 1693, 1593, 1503, 1411, 1392,
1300, 1281, 1235, 1194, 1156, 1100, 995, 820.
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Method B135
A solution of bromine (11.74 g, 73.4 mmol) in anhydrous Et2O (5 mL) was added
to a mixture of 4’-fluoroacetophenone (9.95 g, 72.0 mmol) and AlCl3 (200 mg,
1.5 mmol, 2 mol%) in anhydrous Et2O (15 mL) in an ice bath. The light yellow
reaction mixture was concentrated under reduced pressure which formed crude
yellow solid on cooling. The solid was triturated with portions of water and
petroleum spirit yielding a off white solid (12.96 g, 79%, mp 46.0 – 47.0°C) that
did not require further purification and had spectral data identical to the material
isolated above.
N -Isopropylanaline 98136
Zinc powder (65.2 g, 0.997 mol) was slowly added to a solution of aniline (23.5
mL, 24.0 g, 0.257 mol) and acetone (20.5 mL, 16.1 g, 0.277 mol) in acetic acid
(200 mL). The reaction mixture was heated at 70°C for 3.5h and allowed to
cool. Methanol (100 mL) was added and the reaction mixture was filtered though
celite. The residue was washed with methanol and the filtrate concentrated under
reduced pressure. The residue was dissolved in CHCl3 (150 mL) and neutralised
by addition of ammonia solution (25%, approx. 100 mL). The aqueous phase was
extracted with CHCl3 (150 mL). The combined organic phases were washed with
water (150 mL), dried over anhydrous MgSO4 and concentrated under reduced
pressure to give 98 as a yellow oil (33.06 g, 95%, 97% pure) that did not require
further purification.
NH
98
1H NMR (CDCl3): δ 7.30-7.23 (m, 2H), 6.81-6.76 (m, 1H),
6.70-6.67 (m, 2H), 3.72 (septet, J = 6.3 Hz, 1H), 3.50 (bs,
1H), 1.30 (d, J = 6.3 Hz, 6H). 13C NMR (CDCl3): δ 147.5
(C), 129.3 (CH), 117.0 (CH), 113.3 (CH), 44.2 (CH), 23.0
(CH3).
1-(4-Fluorophenyl)-2-(isopropyl(phenyl)amino)ethanone 240
Method A131
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A solution of 2-bromo-4’-fluoroacetophenone 239 (4.72 g, 21 mmol) and N -
isopropyl aniline 98 (5.89 g, 43.5 mmol) in absolute EtOH (140 mL) was heated
under at reflux for 20 hours, cooled and concentrated under reduced pressure.
The residue was dissolved in CHCl3 (80 mL) and washed with saturated Na2CO3
solution (2 x 50 mL) and water (50 mL). The aqueous washings were combined
and extracted with CHCl3 (3 x 100 mL). The combined organic extracts were
dried over anhydrous MgSO4 and concentrated under reduced pressure to give a
brown crude material (8.9 g) that was purified by column chromatography (5%
EtOAc in PS) to give 240 a yellow solid (5.52 g, 73 %). The NMR spectra
matched those reported.137
F
O
N
240
1H NMR (CDCl3): 8.11 – 8.07 (m, 2H), 7.22 – 7.15 (m,
4H), 6.72 (t, J = 7.3, 1H), 6.64 (d, J = 8.0, 1H), 4.60
(s, 2H), 4.24 (septet, 1H), 1.21 (d, J = 6.6 Hz, 6H). 13C
NMR (CDCl3): δ 195.7, 167.3, 164.8, 148.7, 131.99, 131.96,
130.76, 130.66, 129.4, 117.3, 116.1, 115.9, 113.2, 51.5, 48.5,
20.2.
Method B
A solution of N -isopropylaniline 98 (6.22 g, 46.0 mmol), DIPEA (8.86 g, 68.55
mmol) and 2-bromo-4’-fluoroacetophenone 239 (10.0 g, 46.11 mmol) in dry EtOH
(80 mL) was heated under reflux for 6.5h and allowed to cooled. The reaction
mixture was concentrated under reduced pressure and the residue dissolved in
DCM (300 mL) and washed with saturated Na2CO3 solution (2 x 300 mL). The
combined washings were extracted with DCM (40 mL) and the combined extracts
were dried over anhydrous MgSO4 and concentrated under reduced pressure. 240
was isolated as a brown semi crystalline solid (13.1g, >100%) that was used in
the following step without further purification.
3-(4-Fluorophenyl)-1-isopropyl-1H -indole 96
Method A
Zinc chloride (110 g, 807 mmol, 27 eq) was dried by carefully heating with a
heatgun under reduced pressure directly before addition to a mixture of crushed
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molecular sieves (4A, approx. 25g) and purified 240 (8.15 g, 30 mmol) in an-
hydrous EtOH (280mL). The reaction mixture was heated under reflux for 15h
and allowed to cooled before being filtered through celite. The filtrate was con-
centrated under reduced pressure, dissolved in DCM (200 mL) and washed with
water (700 mL). The aqueous washing was extracted with DCM (3 x 100 mL) and
filtered though celite. The organic phase was dried over anhydrous MgSO4 and
concentrated under reduced pressure to give a 96 as white solid (7.7 g, Quant.)
that did not require further purification.
Method B
Zinc chloride (165 g, 1.21 mol) was dried by carefully heating with a heatgun
under reduced pressure then added to a solution of crude 240 (13.1g, 48 mmol)
in anhydrous EtOH (350 mL). The mixture was heated for 13 hours, allowed
to cool and concentrated under reduced pressure. The resulting residue was
poured onto HCl (700 mL, 1M) and extracted with DCM (2 x 300 mL). The
combined organic extracts were washed with HCl (500 mL, 1M) and brine (250
mL). The organic phase was dried over MgSO4 and absorbed onto silica under
reduced pressure. The material was filtered though silica and washed with 25%
DCM in PS until the filtrate was free from UV activity to TLC. The filtrate was
concentrated under reduced pressure to give 96 as pale yellow solid (8.06 g, 68%)
which did not require further purification.
N
F
96
Melting Point: 93.9 – 96°C (lit: 94.5 – 95.50°C137) 1H NMR
(CDCl3): δ 7.91 (m, 1H), 7.66-7.62 (m, 2H), 7.46 (d, J =
8.3 Hz, 1H), 7.38 (s, 1H), 7.32 – 7.28 (m, 1H), 7.24 - 7.20
(m, 1H), 7.19-7.14 (m, 2H), 4.75 (septet, J = 6.7 Hz, 1H),
1.60 (d, J = 6.7 Hz, 6H). 13C NMR (CDCl3): δ 162.7 (C),
160.2 (C), 136.4 (C), 132.1 (C), 128.92 (CH), 128.84 (CH),
126.3 (C), 121.9 (CH), 121.4 (CH), 120.1 (CH), 119.8 (CH),
116.1 (C), 115.8 (CH), 115.6 (CH), 109.9 (CH), 47.2 (CH), 23.0 (CH3). IR (ATR,
cm-1) 2973, 1600, 1552, 1498, 1459, 1415, 1402, 1370, 1203, 1149, 1131, 1093, 1014,
845, 834, 806, 750.
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3-(4-Fluorophenyl)-1-isopropyl-1H -indole-2-carbaldehyde 238139
Phosphorous oxychloride (4.4 mL, 47.0 mmol, 2.0 eqv) was added dropwise to
DMF (4.0 mL, 51.6 mmol, 2.2 eqv) in an ice bath. The reaction mixture was
warmed to 80°C before addition of the indole 96 (6.02 g, 23.8 mmol) in DMF (6
mL) over 10 min. After 2h, DMF (10 mL) was added, cooled to room temperat-
ure, and transferred to a dropping funnel. The reaction mixture added dropwise
to a solution of sodium hydroxide (6 g) in water (120 mL) at 40°C. The reaction
mixture stirred overnight at room temperature. The aqueous phase was extrac-
ted with toluene (4 x 30 mL). The combined extracts were washed with water
(6 x 60 mL), brine (1 x 60 mL) and dried over anhydrous MgSO4. The filtrate
was concentrated under reduced pressure to give a golden oil (6.80 g) that was
purified by column chromatography (25-50 % DCM in PS) to give 238 as a white
solid (3.81 g, 57%).
N
F
O
238
Melting range: 95 - 97°C. 1H NMR (CDCl3): δ 9.81
(s, 1H), 7.67-7.64 (m, 2H), 7.50-7.45 (m, 2H), 7.41 (m,
1H), 7.23-7.15 (m, 3H), 5.95-5.90 (m, 1H), 1.70 (d, J =
7.0 Hz, 6H). 13C NMR (CDCl3): δ 183.7 (CH), 163.9
(C), 161.5 (C), 138.0 (C), 132.77 (CH), 132.69 (CH),
132.1 (C), 130.7 (C), 128.27 (C), 128.24 (C), 127.07
(CH), 126.93 (C), 122.2 (CH), 120.9 (CH), 115.8 (CH), 115.5 (CH), 113.3 (CH),
48.1 (CH), 21.5 (CH3). (Matches137) IR (ATR, cm-1) 2966, 1661, 1603, 1529,
1495, 1458, 1379, 1352, 1339, 1321, 1217, 1150, 1119, 903, 841, 752.
2-(2,2-Dibromovinyl)-3-(4-fluorophenyl)-1-isopropyl-1H-indole 241 124
A solution of 238 (1.27 g, 4.5 mmol) and carbon tetrabromide (3.12 g, 9.4 mmol,
2.1 eqv) in DCM (10 mL) was added dropwise over a period of 20 min to a solution
of triethyl phosphite (3.2 mL, 18.7 mmol, 4.2 eqv) in DCM (3 mL) at -45°C and
held at this temperature for 3.5 hours. The reaction mixture was poured onto
saturated NaHCO3 solution (30 mL). The resulting mixture was extracted with
DCM (2 x 20 mL). The combined organic extracts were washed with NaHCO3
solution (5%, 3 x 50 mL) and brine (1 x 50 mL) and dried over anhydrous MgSO4.
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The filtrate was concentrated under reduced pressure to give a yellow oil and solid
(4.78 g) that was purified by column chromatography (0 - 15% DCM in PS) to
give 241 as a white solid (1.36 g, 89%).
N
F
Br
Br
241
1H NMR (CDCl3): δ 7.75 (d, J = 8.0 Hz, 1H), 7.60
(d, J = 8.4 Hz, 1H), 7.57 (s, 1H), 7.50-7.46 (m, 2H),
7.30 (ddd, J = 8.5, 7.2, 1.1 Hz, 1H), 7.21-7.16 (m,
3H), 4.72 (sept, J = 7.0 Hz, 1H), 1.71 (d, J = 7.0 Hz,
6H). 13C NMR (CDCl3): δ 162.9 (C), 160.4 (C), 135.4
(C), 131.10 (C), 131.07 (C), 130.79 (CH), 130.71 (CH),
129.5 (CH), 127.6 (C), 122.6 (CH), 120.11 (CH), 119.99
(CH), 116.0 (C), 115.7 (CH), 115.5 (CH), 111.8 (CH), 98.8 (C), 48.8 (CH), 22.1
(CH3).
2-Ethynyl-3-(4-fluorophenyl)-1-isopropyl-1H -indole 237 124
A solution of potassium tert-amylate (5.8 mL, 11.4 mmol, 1.08 eqv, 25% in tolu-
ene) was added over 20 mins to a solution of 241 (4.61 g, 10.6 mmol) in toluene
(50 mL) at 0°C. After TLC showed consumption of the starting material, meth-
anol (2.1 mL, 51.1 mmol) and dimethyl phosphite (1.26 mL, 13.7 mmol, 1.30 eqv)
were respectively added followed by dropwise addition of potassium tert-amylate
(5.6 mL, 11.0 mmol, 1.04 eqv, 25% in toluene) over 20 min. Cold saturated NH4Cl
solution (15 mL) was added after 20 min and the reaction mixture was concen-
trated under reduced pressure. The residue was dissolved in petroleum spirit and
filtered though silica. The silica was washed with petroleum spirit until the eluent
no longer show UV activity to TLC plates. The filtrate was concentrated under
reduced pressure and recrystallised from petroleum spirit overnight at -20°C. The
crystals were washed with cold petroleum spirit (2 x 5 mL) and dried under high
vacuum to give 237 (2.36 g, 81%) as grey/light violet needles.
196
N
F
237
1H NMR (CDCl3): δ 7.75-7.69 (m, 3H), 7.52 (dt, J =
8.5, 0.8 Hz, 1H), 7.29 (ddd, J = 8.4, 7.0, 1.3 Hz, 1H),
7.19-7.13 (m, 3H), 5.08 (septet, J = 7.0 Hz, 1H), 3.55
(s, 1H), 1.72 (d, J = 7.0 Hz, 6H). 13C NMR (CDCl3):
δ 163.1 (C), 160.6 (C), 135.4 (C), 130.91 (CH), 130.83
(CH), 130.24 (C), 130.21 (C), 126.4 (C), 123.6 (CH), 122.6 (C), 120.40 (CH),
120.33 (CH), 117.1 (C), 115.6 (CH), 115.3 (CH), 111.3 (CH), 85.9 (C), 76.4 (CH),
48.9 (CH), 21.8 (CH3). IR (ATR, cm-1): 3303, 2979, 2935, 2109, 1538, 1496, 1451,
1371, 1337, 1220, 1156, 838, 744, 665, 602. HRMS (ESI) m/z C19H16FN [M+H]+
= 277.1340, found = 278.1340.
3-((3-(4-Fluorophenyl)-1-isopropyl-1H -indol-2-yl)ethynyl)-
3-hydroxyhexadecanenitrile 247
A solution of n-BuLi (2.8 mL, 1.6M, 4.09 mmol, 2.0 eqv) was added dropwise
to a solution of the alkyne 237 (1.24 g, 4.46 mmol, 2.2 eqv) in anhydrous THF
(20 mL) at -84°C. The solution was allowed to warm to room temperature and
added dropwise to a suspension (previously stirred for 2 hours at room temp)
of anhydrous cerium chloride (1.8 g CeCl3.7H2O progressively heated to 140°C
under Hi-Vac for at least 2 hours, 4.84 mmol, 2.4 eqv) in anhydrous THF (15 mL)
at -84°C and held at this temperature for 40 min. A solution of the ketonitrile
124 (935 mg, 2.02 mmol) in anhydrous THF (15 mL) was added and the reaction
mixture was held at -84°C for 4 hours before addition of saturated NH4Cl solution
(10 mL). The reaction mixture was left to warm to room temperature and con-
centrated under reduced pressure. HCl (1 M, 75 mL) was added and extracted
with DCM (3 x 75 mL). The combined organic extracts were washed with brine
(200 mL) and dried over a combination of K2CO3 and MgSO4. The filtrate was
concentrated under reduced pressure to give a residue that was purified using
column chromatography (DCM) to give 247 as a colourless oil (1.40 g, 87 %).
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NF
OH
C13H27
CN
247
1H NMR (CDCl3): δ 7.76-7.74 (m, 1H), 7.72-7.68 (m,
2H), 7.54 (d, J = 8.5 Hz, 1H), 7.31 (ddd, J = 8.4, 7.1,
1.3 Hz, 1H), 7.21-7.15 (m, 3H), 5.09 (septet, J = 7.0
Hz, 1H), 2.84-2.82 (m, 3H), 1.86 (dd, J = 9.0, 7.6 Hz,
2H), 1.76 (d, J = 7.0 Hz, 6H), 1.37-1.31 (m, 22H), 0.94-
0.91 (m, 3H). 13C NMR (CDCl3): δ 163.1 (C), 160.6
(C), 135.6 (C), 130.88 (CH), 130.80 (CH), 130.16 (C),
130.13 (C), 126.3 (C), 123.7 (CH), 122.7 (C), 120.47 (CH), 120.29 (CH), 116.60
(C), 116.40 (C), 115.6 (CH), 115.4 (CH), 111.3 (CH), 96.6 (C), 79.1 (C), 69.4
(C), 48.9 (CH), 41.7 (CH2), 32.2 (CH2), 32.0 (CH2), 29.80 (CH2), 29.75 (CH2),
29.74 (CH2), 29.65 (CH2), 29.59 (CH2), 29.46 (CH2), 24.6 (CH2), 22.8 (CH2),
21.8 (CH3), 14.2 (CH3). IR (ATR, cm-1): 3439, 2923, 2853, 2256, 2218, 1607,
1540, 1502, 1454, 1347, 1336, 1224, 1156, 1096, 837, 742. HRMS (ESI) m/z
C35H45FN2O [M+H]+ = 529.3589, found = 529.3590.
3-(2-(3-(4-Fluorophenyl)-1-isopropyl-1H -indol-2-yl)ethyl)-
3-hydroxyhexadecanenitrile 249
A solution of 247 (1.18 g, 2.22 mmol) in EtOAc (10 mL) was degassed under
reduced pressure and placed under N2 (x 3). 10 %w/w Pd/C (130 mg, 11 %wt)
was added, a H2 atmosphere introduced and heated under reflux overnight. The
reaction mixture was allowed to cool, placed under a N2 atmosphere and filtered
though celite. The filtrate concentrated under reduced pressure and the resulting
residue purified by column chromatography (DCM) to give 249 as a colourless
oil (881 mg, 74%).
C13H27
N
F
OH
CN
249
1H NMR (CDCl3): δ 7.59-7.57 (m, 1H), 7.52-7.50 (m,
1H), 7.42-7.37 (m, 2H), 7.15 (s, 3H), 7.10-7.06 (m, 1H),
4.73-4.66 (m, 1H), 2.93-2.87 (m, 2H), 2.47 (s, 2H),
1.91-1.80 (m, 2H), 1.78-1.70 (m, 6H), 1.61-1.51 (m,
2H), 1.38-1.12 (m, 23H), 0.92-0.86 (m, 3H). 13C NMR
(CDCl3): δ 162.9 (C), 160.4 (C), 135.5 (C), 134.3 (C),
131.61 (CH), 131.54 (CH), 128.5 (C), 121.1 (CH), 119.5
(CH), 119.1 (CH), 117.4 (C), 115.7 (CH), 115.5 (CH), 113.6 (C), 112.0 (CH), 72.9
198
(C), 47.4 (CH), 39.06 (CH2), 38.94 (CH2), 32.0 (CH2), 29.92 (CH2), 29.79 (CH2),
29.75 (CH2), 29.72 (CH2), 29.67 (CH2), 29.60 (CH2), 29.46 (CH2), 29.2 (CH2),
23.7 (CH2), 22.8 (CH2), 21.6 (CH3), 19.4 (CH2), 14.2 (CH3). IR (ATR, cm-1):
3485, 2925, 2854, 2255, 1558, 1505, 1462, 1350, 1221, 1155, 1093, 839, 817, 740,
727. HRMS (ESI) m/z C35H49FN2O [M+H]+ = 533.3902, found = 533.3905.
1-Amino-3-(2-(3-(4-fluorophenyl)-1-isopropyl-1H -indol-2-yl)ethyl)
hexadecan-3-ol 116
NaBH4 (243 mg, 6.42 mmol) was added to a solution of 249 (320 mg, 0.601 mmol)
and CoCl2.6H2O (335 mg, 1.22 mmol) in EtOH (5 mL) at 0°C. After 1 hour at
0°C, the reaction mixture was allowed to warm to room temperature for 1 hour
before addition of HCl (3M, 6 mL). Conc NH3(aq) (10 mL) and water (10 mL) were
added and the resulting mixture extracted with CHCl3 (3 x 30 mL). The combined
organic extracts were dried over anhydrous MgSO4 and concentrated under a
stream of nitrogen to give an oil that was purified by column chromatography
(2-4% MeOH, 1% NH3(aq) in CHCl3) to give 116 as a colourless oil (214 mg,
66%).
C13H27
N
F
OH
NH2
116
1H NMR (CDCl3): δ 7.58 (d, J = 8.2 Hz, 1H), 7.53
(dd, J = 7.9, 0.5 Hz, 1H), 7.45-7.41 (m, 2H), 7.19-
7.06 (m, 4H), 4.80 (septet, J = 7.0 Hz, 1H), 3.00-
2.80 (m, 7H), 1.80-1.65 (m, 9H), 1.57-1.44 (m, 5H),
1.37-1.15 (m, 20H), 0.91 (t, J = 6.8 Hz, 3H).13C
NMR (CDCl3): δ 162.8 (C), 160.3 (C), 137.6 (C),
134.2 (C), 132.04 (C), 132.01 (C), 131.64 (CH),
131.57 (CH), 128.7 (C), 120.7 (CH), 119.3 (CH), 118.9 (CH), 115.5 (CH), 115.3
(CH), 113.1 (C), 111.9 (CH), 74.8 (C), 47.2 (CH), 40.0 (CH2), 39.1 (CH2), 38.1
(CH2), 37.8 (CH2), 32.1 (CH2), 30.5 (CH2), 29.86 (CH2), 29.83 (CH2), 29.81
(CH2), 29.5 (CH2), 24.3 (CH2), 22.8 (CH2), 21.68 (CH3), 21.64 (CH3), 19.4
(CH2), 14.3 (CH3). HRMS (ESI) m/z C35H53FN2O [M+H]+ = 537.4215, found
= 537.4213. IR (ATR, cm-1): 3272, 3053, 2922, 2852, 1608, 1557, 1505, 1461,
1349, 1215, 1155, 940, 838, 815, 740.
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3-(N-Methyl-N -phenylamino)acrolein 99140
A solution of N -methylformanilide (9.1 mL, 9.96 g, 73.7 mmol) and butyl vinyl
ether (10.3 mL, 8.01 g, 80.0 mmol) in acetonitrile (10 mL) was added dropwise
to a stirred solution of oxalyl chloride (10.1 g, 79.6 mmol) in acetonitrile (5
mL) at -10°C. The solution was allowed to warm to room temperature over 80
min. The reaction mixture was cooled in a ice bath before dropwise addition of
Na2CO3 solution (20 %, approx 50 mL) until the pH > 7. The reaction mixture
was diluted with water (100 mL) and extracted with toluene (3 x 70 mL). The
combined organic extracts were washed with water (2 x 50 mL). The organic
phase was dried with MgSO4 and concentrated under reduced pressure to give a
black viscous crude (10.9 g) that was distilled under reduced pressure to give 99
as a brown oil (5.4 g, 50 %). The NMR spectra matched reported values.140
N O
99
1H NMR (CDCl3): δ 9.27 (d, J = 8.1 Hz, 1H), 7.55 (d,
J = 13.1 Hz, 1H), 7.43-7.38 (m, 2H), 7.25-7.22 (m, 1H),
7.20-7.16 (m, 3H), 5.47 (dd, J = 13.0, 8.1 Hz, 1H), 3.33 (s,
3H).13C NMR (CDCl3): δ 190.3, 156.4, 146.1, 129.7, 125.5,
120.6, 105.6, 37.4
3-(3-(4-Fluorophenyl)-1-isopropyl-1H -indol-2-yl)
acrylaldehyde 100131,140
A solution of freshly distilled 3-(N -Methyl-N -phenylamino)acrolein 99 (10.5 g,
65.1 mmol) in dry acetonitrile (15 mL) was added over 45 min to a solution of
freshly distilled phosphorus oxychloride (10.38 g, 67.7 mmol) in acetonitrile (25
mL) at -5°C. After 75 min at this temperature a solution of 1-(isopropyl)-3-(4’-
fluorophenyl)-indole 100 (6.33 g, 25.0 mmol) in dry acetonitrile (50 mL) was
added rapidly and the reaction mixture was heated under reflux for 3 h. The
reaction mixture was allowed to cool to room temperature before addition of
water (50 mL). The reaction mixture was heated to 55°C for 3 h. The reaction
mixture was cooled, diluted with water (500 mL) and extracted with toluene (2
x 150 mL). The combined organic phases were washed with water (2 x 200 mL)
and dried over anhydrous MgSO4. The filtrate was concentrated under reduced
200
pressure and the residue purified by column chromatography (15% EtOAc in PS)
to give 100 as yellow solid (6.05 g, 79%).
N
O
F
100
Melting point: 132°C (lit:129 - 130°C140)1H NMR (CDCl3):
δ 9.59 (d, J = 7.6 Hz, 1H), 7.64-7.54 (m, 3H), 7.43-7.39
(m, 2H), 7.34 (m, 1H), 7.23-7.19 (m, 2H), 7.15 (m, 1H),
6.34 (dd, J = 16.2, 7.6 Hz, 1H), 5.00 (septet, J = 7.0
Hz, 1H), 1.76 (d, J = 7.0 Hz, 6H). 13C NMR (CDCl3):
δ 193.4 (CH), 163.6 (C), 161.1 (C), 141.1 (CH), 137.6 ,
132.05 (CH), 131.97 (CH), 130.5 (C), 130.06 (C), 130.03
(C), 129.7 (CH), 128.4 (C), 124.7 (CH), 122.8 (C), 121.1 (CH), 120.7 (CH), 116.1
(CH), 115.9 (CH), 112.6 (CH), 48.3 (CH), 21.9 (CH3). IR (ATR, cm-1) 2975,
1658, 1613, 1602, 1541, 1492, 1450, 1371, 1340, 1209, 1120, 1104, 1089, 1012,
1004, 956, 839, 739, 604.
3-(3-(4-Fluorophenyl)-1-isopropyl-1H -indol-2-yl)propanal 251
A mixture of the propenal 100 (1250 mg, 4.0 mmol), KOAc (approx. 5 mg) and
water (25 μl) in EtOAc (12.5 mL) was degassed under reduced pressure and a
replaced with a N2 atmosphere (x 3). Pd/C (38 mg, 3 %wt, 10 %Pd) was added
and a H2 atmosphere introduced. After 36 hours at room temperature, a N2
atmosphere was introduced and the reaction mixture was filtered though celite.
The filtrate was concentrated under reduced pressure and the residue was purified
by column chromatography (50% DCM in PS) to give 251 as a yellow solid (906
mg, 72 %).
N
O
F
251
Melting range: 86 - 87°C. 1H NMR (400 MHz; CDCl3): δ
9.73 (s, 1H), 7.58 (d, J = 8.3 Hz, 1H), 7.51 (dt, J = 7.9, 0.6
Hz, 1H), 7.39-7.35 (m, 2H), 7.22-7.08 (m, 4H), 4.62 (septet,
J = 7.0 Hz, 1H), 3.17 (t, J = 7.9 Hz, 2H), 2.71 (t, J =
7.9 Hz, 2H), 1.73 (d, J = 7.0 Hz, 6H). 13C NMR (CDCl3):
δ 200.4 (CH), 163.0 (C), 160.5 (C), 134.6 (C), 134.4 (C),
131.66 (CH), 131.58 (CH), 131.45 (C), 131.42 (C), 128.6
(C), 121.3 (CH), 119.6 (CH), 119.2 (CH), 115.8 (CH), 115.6 (CH), 114.2 (C),
201
111.9 (CH), 47.5 (CH), 44.4 (CH2), 21.7 (CH3), 17.7(CH2). IR (ATR, cm-1):
2964, 2934, 1717, 1602, 1558, 1503, 1462, 1340, 1216, 1154, 1103, 1067, 836, 814,
749. HRMS (ESI) m/z C20H20FNO [M+H]+ = 310.1602, found = 310.1608.
1-((3-(3-(4-Fluorophenyl)-1-isopropyl-1H-indol-2-yl)
propyl)amino)hexadecan-3-ol 250
A mixture of 1-aminohexadecan-3-ol 109 (99 mg, 0.389 mmol), the aldehyde 251
(126 mg, 0.409 mmol) and MgSO4 (114 mg) in a dry DCM/THF mixture (5:1,
3 mL) was stirred at 50°C for 20 hours. The reaction mixture was filtered and
concentrated under reduced pressure. NaBH4 (20 mg, 0.528 mmol, 1.35 eq) was
added to a solution of the residue in EtOH (4 mL) at 0°C. The reaction mixture
was stirred overnight at room temperature before addition of with saturated
NH4Cl (1 mL). The reaction mixture was stirred for 1 hour and diluted with
NaHCO3 solution (5%, 20 mL). The resulting mixture was extracted with CHCl3
(3 x 15 mL). The organic extracts were washed with water (30 mL) and brine
(30 mL) before drying over K2CO3. The colourless oil (218 mg) was purified by
column chromatography (2% MeOH(Sat. NH3) in CHCl3) to give 250 as a colourless
oil (36 mg, 23%).
C13H27
OH HN
N
F
250
1H NMR (C6H6): δ 7.69-7.66 (m, 1H), 7.44
(m, 1H), 7.33-7.30 (m, 2H), 7.24-7.17 (m, 2H),
7.03-6.99 (m, 2H), 4.33 (septet, J = 7.0 Hz,
1H), 3.77 (bs, 1H), 2.64 (s, 2H), 2.48 (dt, J =
11.8, 4.4 Hz, 1H), 2.37-2.31 (m, 1H), 2.24-2.19
(m, 1H), 2.12 (m, 1H), 1.67-1.59 (m, 2H), 1.54-
1.25 (m, 35H), 0.91 (m, 3H). 13C NMR (C6D6): δ 163.2 (C), 160.8 (C), 136.1
(C), 134.9 (C), 132.57 (C), 132.54 (C), 132.03 (CH), 131.96 (CH), 129.3 (C),
121.5 (CH), 119.9 (CH), 119.7 (CH), 115.9 (CH), 115.7 (CH), 114.0 (C), 112.2
(CH), 73.2 (CH), 49.1 (CH2), 48.9 (CH2), 47.4 (CH), 38.7 (CH2), 35.9 (CH2),
32.4 (CH2), 30.8 (CH2), 30.41 (CH2), 30.31 (CH2), 30.25 (CH2), 30.23 (CH2),
30.17 (CH2), 29.9 (CH2), 26.3 (CH2), 23.2 (CH2), 22.9 (CH2), 21.38 (CH3), 21.36
(CH3), 14.4 (CH3). IR (ATR, cm-1): 3292, 2922, 2852, 1557, 1505, 1460, 1350,
1220, 1155, 1102, 835, 815, 741. HRMS (ESI) m/z C36H55FN2O [M+H]+ =
202
551.4371, found = 551.4347.
1-(((3-(4-Fluorophenyl)-1-isopropyl-1H-indol-2-yl)methyl)
amino)hexadecan-3-ol 117
Amixture of 1-aminohexadecan-3-ol 109 (102 mg, 0.396 mmol), the aldehyde 238
(113 mg, 0.402 mmol, 1.0 eq) and MgSO4 (150 mg) were suspended in anhydrous
DCM (2 mL) and stirred for 48h at 50°C in a sealed vessel. The reaction mixture
was filtered and concentrated under reduced pressure. NaBH4 (15 mg, 0.389
mmol) was added to a solution of the residue in anhydrous EtOH (4 mL) at 0°C.
The reaction mixture was allowed to warm to room temperature over 2 hours
before addition of saturated NH4Cl (1 mL). The reaction mixture was diluted
with K2CO3 solution (5 %) and extracted with CHCl3 (3 x 25 mL). The combined
organic extracts were dried over anhydrous MgSO4 and the filtrate concentrated
under reduced pressure to give a clear oil (196 mg). The oil was purified by column
chromatography (1% MeOH(Sat. NH3) in CHCl3) to give 117 as a colourless oil (54
mg, 26%).
C13H27
OH HN
N
F
117
1H NMR (Toluene-d8): δ 7.64 (d, J = 7.8, 1H),
7.42 (d, J = 8.1 Hz, 1H), 7.22-7.17 (m, 3H), 7.16-
7.08 (m, 2H), 7.01-6.92 (m, 3H), 4.71 (7, J = 7.0
Hz, 1H), 3.66-3.60 (m, 2H), 3.55 (ad, J = 13.0 Hz,
1H), 2.56 (m, J = 4.0 Hz, 1H), 2.43 (m, J = 3.9 Hz,
1H), 1.54-1.41 (m, 8H), 1.39-1.19 (m, 24H), 0.93-
0.89 (t, J = 6.9 Hz, 3H). 13C NMR (Toluene-d8): δ
163.3 (C), 160.9 (C), 137.4 (C), 135.1 (C), 133.4 (C), 131.91 (CH), 131.84 (CH),
122.1 (CH), 120.1 (CH), 119.9 (CH), 115.71 (CH), 115.55 (C), 115.50 (CH), 112.4
(CH), 72.9 (CH), 48.9 (CH2), 47.8 (CH), 44.4 (CH2), 38.6 (CH2), 36.3 (CH2), 32.4
(CH2), 30.42 (CH2), 30.33 (CH2), 30.29 (CH2), 30.22 (CH2), 29.9 (CH2), 26.2
(CH2), 23.2 (CH2), 21.42 (CH3), 21.39 (CH3), 14.4 (CH3). HRMS (ESI) m/z
C34H51FN2O [M+H]+ = 523.4058, found = 523.4040. IR (ATR, cm-1): 3423,
2915, 2848, 1559, 1506, 1457, 1356, 1223, 1156, 837, 733.
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6.4 Chapter 4 experimental
6.4.1 Chain analogues; position 5 alkene
1,2-Dibromodecane 270
A solution of bromine (5.5 mL, 17.1 g, 107 mmol) in dry DCM (75 mL) was added
dropwise over 90 min to a solution of 1-decene (15.05 g, 107 mmol) in anhydrous
DCM (125 mL) at 0 °C under N2. The reaction mixture was allowed to warm
to room temperature for 45 min. Bromine (approx 1-2 mL) was added to the
colourless reaction mixture dropwise until an orange colour was sustained for >
10 min. Sodium metabisulfite solution (5%) was added dropwise to the reaction
mixture until colourless. Anhydrous MgSO4 was added and the reaction mixture
was filtered. The filtrate was concentrated to give 270 as a light yellow oil (31.2
g, 97 %). The NMR spectra matched those reported.147
Br
Br
C8H17
270
1H NMR (CDCl3): δ 4.20-4.14 (m, 1H), 3.85 (dd, J = 10.2,
4.5 Hz, 1H), 3.63 (dd, J = 10.1, 9.8 Hz, 1H), 2.13 (m, 1H),
1.83-1.74 (m, 1H), 1.59-1.24 (m, 12H), 0.89 (t, J = 6.9
Hz, 3H).13C NMR (CDCl3): δ 53.3, 36.5, 36.2, 32.0, 29.50,
29.34, 29.0, 26.9, 22.8, 14.2.
1-Decyne 267
1,2-dibromodecane (15.86 g, 52.8 mmol) and Aliquot 336 (0.3 mL, 0.265 g, 0.656
mmol) were placed in a round bottom flask (50 mL). Powdered KOH (12 g, 210
mmol) was added. The flask was set up for a vacuum distillation with a 10 cm
fractionation column under reduced pressure (approx 40- 60 mm Hg) and the
flask placed in a preheated oil bath (150°C) to obtain a biphasic distillate. Water
was pipetted from biphasic colourless distillate obtained. The remaining distillate
was diluted with DCM (approx 25 mL) and dried over anhydrous MgSO4. The
solution was carefully concentrated to give 267 as a colourless liquid (6.84 g,
94%) with a distinctive odour. The NMR spectra matched those reported.149
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C8H17
267
1H NMR (CDCl3): δ 2.18 (td, J = 7.1, 2.7 Hz, 2H), 1.93
(t, J = 2.7 Hz, 1H), 1.56-1.49 (m, 2H), 1.42-1.35 (m, 2H),
1.32-1.24 (m, 8H), 0.90-0.86 (m, 3H). 13C NMR (CDCl3):
δ 84.9 (CH), 68.2 (C), 32.0 (CH2), 29.33 (CH2), 29.23 (CH2), 28.9 (CH2), 28.7
(CH2), 22.8 (CH2), 18.6 (CH2), 14.2 (CH3). IR (ATR, cm-1) 3314, 2925, 2856,
2120, 1466, 624.
Ethyl 4-iodobutyrate 271
A suspension of ethyl 4-bromobutyrate (5.07 g, 26.0 mmol) in acetone (20 mL)
was stirred with NaI (9.54 g, 63.6 mmol, 2.4 eqv) for 84h before being concen-
trated under reduced pressure. The material was triturated with 10% EtOAc in
petroleum spirit (4 x 50 mL) and the filtrate was concentrated under reduced
pressure to give 271 as a colourless oil (1.53 g, 62 %) that did not require further
purification. The NMR spectra matched those reported.153
O
O
I
271
1H NMR (CDCl3): δ 4.16 (q, J = 7.1 Hz, 2H), 3.26 (t, J
= 6.8 Hz, 2H), 2.46 (t, J = 7.2 Hz, 2H), 2.15 (tt, J = 7.2,
6.8 Hz, 2H), 1.28 (t, J = 7.1 Hz, 3H). 13C NMR (CDCl3):
δ 172.5, 60.7, 35.0, 28.6, 14.4, 5.6.
4-Bromobutyric acid 276152
A solution of γ-butyrolactone (4.87 g, 56.6 mmol), HBr (32 mL, 48%) and conc.
H2SO4 (7.6 mL) was slowly heated to reflux for 6 hours. The reaction mixture was
poured onto water (150 mL) and extracted with Et2O (3 x 50 mL). The combined
organic extracts were washed with brine (50 mL), dried over anhydrous MgSO4
and concentrated under reduced pressure to give 4-bromobutyric acid 276 as a
light yellow oil (6.80 g, 72%) that did not require further purification.
OH
O
Br
276
1H NMR (CDCl3): δ 3.48 (t, J = 6.4 Hz, 2H), 2.58 (t, J
= 7.2 Hz, 2H), 2.18 (m, 2H). 13C NMR (CDCl3): δ 178.8,
32.50, 32.31, 27.5.
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4-Iodobutyric acid 310
A suspension of 4-bromobutyric acid (1.98 g, 11.9 mmol) and NaI (4.61 g, 30.9
mmol) in acetone (8 mL) was stirred overnight. The resulting mixture was con-
centrated under reduced pressure and the residue was dissolved in Et2O (50 mL)
and washed with water (20 mL). The aqueous phase was back extracted with
Et2O (2 x 25 mL) and the combined organic extracts were washed with sodium
metabisulfite solution (5%, 10 mL) and brine (10 mL). The organic phase was
dried over anhydrous MgSO4 and concentrated under reduced pressure to give
310 as a colourless semi-solid (2.35 g, 92%) that did not require further purific-
ation. The NMR spectra matched those reported.154
OH
O
I
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1H NMR (CDCl3): δ 3.25 (t, J = 6.7 Hz, 2H), 2.52 (t, J
= 7.1 Hz, 2H), 2.14 (tt, J = 6.7, 7.1 Hz, 2H). 13C NMR
(CDCl3): δ 178.6, 34.6, 28.3, 5.2.
4-Bromobutan-1-ol 280
HBr (16 mL, 48 %, 141 mmol) was added dropwise to a stirred solution of conc.
H2SO4 (1 mL) in THF (14 mL, 172 mmol) at 0°C. The reaction mixture was
heated under reflux for 5h and cooled in a ice bath. The pH of the reaction
mixture was adjusted to > 7 by dropwise addition of a NaHCO3 solution (5%).
The reaction mixture was extracted with Et2O (3 x 75 mL). The combined or-
ganic extracts were dried over anhydrous MgSO4 and concentrated under reduced
pressure to give 280 as a colourless oil (6.72 g, 31%) that did not require further
purification. The NMR spectra matched those reported.162
Br OH
280
1H NMR (CDCl3): δ 3.61 (t, J = 6.4 Hz, 2H), 3.41 (t,
J = 6.7 Hz, 2H), 1.93-1.87 (m, 2H), 1.69-1.64 (m, 2H).
13C NMR (CDCl3): δ 61.7, 33.8, 31.1, 29.2.
2-(4-Bromobutoxy)tetrahydro-2H -pyran 281
A solution of 4-bromobutanol 280 (2.02 g, 13.2 mmol), 3,4-dihydro-2H -pyran
(1.30 mL, 1.20 g, 14.2 mmol) and p-TsOH (14 mg, 0.081 mmol, 3 mol%) in DCM
206
(15 mL) was stirred overnight at room temperature. The reaction mixture was
concentrated under reduced pressure and purified by column chromatography (0
- 20% EtOAc in PS) to give 281 as a colourless oil (795 mg, 25 %). The NMR
spectra matched those reported.160
Br O O
281
1H NMR (CDCl3): δ 4.55 (m, 1H), 3.83 (m, 1H), 3.75
(m, 1H), 3.51-3.37 (m, 4H), 1.99-1.92 (m, 2H), 1.83-
1.66 (m, 5H), 1.58-1.47 (m, 5H).13C NMR (CDCl3): δ
98.9, 66.6, 62.4, 33.8, 30.8, 29.9, 28.5, 25.6, 19.7. IR
(ATR, cm-1) 2940, 2869, 1440, 1352, 1246, 1201, 1134, 1118, 1075, 1032, 986, 904,
868, 813.
2-(Tetradec-5-yn-1-yloxy)tetrahydro-2H -pyran 311
A solution of n-BuLi (6.5 mL, 1.3M in hexane) was added dropwise to a stirred
solution of 1-decyne (1.26 g, 9.11 mmol, 2.12 eqv) and HMPA (1.5 mL, 8.60
mmol, 2.0 eqv) in THF (15 mL) at -84°C. After 30 min at this temperature, a
solution of the bromide 281 (1.02 g, 4.28 mmol, 1.0 eqv) in THF (5 mL) was
added. The reaction mixture was heated under reflux for 3 h before cooling in
a ice bath. Water (5 mL) was added and the reaction mixture was concentrated
under a stream of nitrogen overnight. The reaction mixture was dissolved in
toluene (100 mL) and washed with brine (2 x 100 mL), water (2 x 100 mL) and
brine (2 x 100 mL) before drying over anhydrous MgSO4 and concentrated under
reduced pressure. The crude residue was purified by column chromatography
(2:1:97 EtOAc:TEA:PS) to give 311 as a colourless oil (1.05 g, 83%).
O O
C8H17
311
1H NMR (400 MHz; CDCl3): δ 4.56 (dd, J = 4.1, 2.8
Hz, 1H), 3.84 (td, J = 7.5, 3.6 Hz, 1H), 3.73 (dt, J =
9.7, 6.6 Hz, 1H), 3.51-3.46 (m, 1H), 3.39 (dt, J = 9.7,
6.4 Hz, 1H), 2.17 (s, 2H), 2.11 (s, 2H), 1.82 (dd, J =
8.8, 3.5 Hz, 1H), 1.73-1.65 (m, 3H), 1.60-1.42 (m, 8H),
1.38-1.26 (m, 10H), 0.87 (t, J = 6.9 Hz, 3H).13C NMR (CDCl3): δ 98.9 (CH),
80.6 (C), 79.9 (C), 67.2 (CH2), 62.4 (CH2), 32.0 (CH2), 30.9 (CH2), 29.34 (CH2),
29.28 (CH2), 29.26 (CH2), 29.07 (CH2), 29.02 (CH2), 26.1 (CH2), 25.6 (CH2),
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22.8 (CH2), 19.8 (CH2), 18.89 (CH2), 18.75 (CH2), 14.2 (CH3). IR (ATR, cm-1)
2925, 2855, 1455, 1440, 1352, 1201, 1076, 1110, 1034, 1021, 906, 869, 815. HRMS
(ESI) m/z C19H34O2 [M+H]+ = 295.2632, found = 295.2632.
2-(Z -Tetradec-5-en-1-yloxy)tetrahydro-2H -pyran 283
NaBH4 (218 mg, 0.741 mmol) was added to a stirred solution of Ni(OAc)2.4H2O
(189 mg, 0.759 mmol) in EtOH (5 mL) under a H2 atmosphere. The stirred solu-
tion was left for 15 min at room temperature before addition of freshly distilled
ethylenediamine (220 μl, 0.951 mmol) followed by a solution of the alkyne 311
in EtOH (5 mL). The reaction mixture was stirred for 90 min before addition of
Et2O (50 mL). The reaction mixture was filtered though a plug of silica and the
residue was washed with Et2O (2 x 20 mL). The combined filtrates were dried
over anhydrous MgSO4 and concentrated under reduced pressure to give 283 as
a colourless oil (179 mg, 80%) that did not require further purification.
O O
C8H17
283
1H NMR (CDCl3): δ 5.35 (s, 2H), 4.57 (dd, J = 4.1, 2.9
Hz, 1H), 3.89-3.83 (m, 1H), 3.73 (dt, J = 9.6, 6.8 Hz,
1H), 3.51-3.46 (m, 1H), 3.38 (dt, J = 9.6, 6.6 Hz, 1H),
2.06-2.00 (m, 4H), 1.70 (d, J = 3.0 Hz, 1H), 1.62-1.49
(m, 6H), 1.44-1.39 (m, 2H), 1.34-1.26 (m, 13H), 0.87
(dt, J = 4.3, 2.5 Hz, 3H). 13C NMR (CDCl3): δ 130.4 (CH), 129.6 (CH), 98.9
(CH), 67.6 (CH2), 62.4 (CH2), 32.0 (CH2), 30.9 (CH2), 29.9 (CH2), 29.66 (CH2),
29.53 (CH2), 29.47 (CH2), 29.45 (CH2), 27.4 (CH2), 27.1 (CH2), 26.6 (CH2), 25.7
(CH2), 22.8 (CH2), 19.8 (CH2), 14.2 (CH3). IR (ATR, cm-1): 2923, 2854, 1455,
1201, 1137, 1119, 1034, 1021, 869, 815, 721. HRMS (ESI) m/z C19H36O2 [M+H]+
= 297.2788, found = 297.2788.
Tetradec-5-ynoic acid 286
Jones reagent (1.3M, 50 mL, 65 mmol) was added dropwise to a solution of
the protected alcohol 311 (3.05 g 10.37 mmol) in acetone (50 mL) at 0°C. The
reaction was left to warm to room temperature overnight and concentrated under
reduced pressure. The residue was diluted with H2O (250 mL) and extracted
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with EtOAc (3 x 100 mL). The extracts were washed with sodium bisulfide (1 x
100 mL, 1%), HCl (150 mL, 1M) and brine (150 mL) to give crude 286 as a light
green oil (2.38 g, quant.) that was used in the next step without purification.
OH
C8H17
O
286
1H NMR (CDCl3): δ 2.52-2.44 (m, 2H), 2.27-2.20 (m,
2H), 2.17-2.10 (m, 2H), 1.85-1.77 (m, 2H), 1.51-1.41
(m, 2H), 1.41-1.21 (m, 10H), 0.91-0.85 (m, 3H). 13C
NMR (CDCl3): δ 180.1 (C), 81.6 (C), 78.6 (C), 33.0
(CH2), 32.0 (CH2), 29.32 (CH2), 29.23 (CH2), 29.16
(CH2), 29.00 (CH2), 24.1 (CH2), 22.8 (CH2), 18.8 (CH2), 18.3 (CH2), 14.2 (CH3).
IR (ATR, cm-1): 2926, 2955, 1708, 1414, 1242, 935. HRMS (ESI) m/z C14H24O2
[M+H]+ = 225.1849, found = 225.1848.
Propyl tetradec-5-ynoate 285
A mixture of crude 286 (2.38 g, 10.6 mmol), 1-bromopropane (5.20 g, 42.2 mmol,
4.0 eqv), TBAI (390 mg, 1.06 mmol, 0.1 eqv), K2CO3 (6.70 g, 48.48 mmol, 4.5
eqv) in acetone (25 mL) was heated under reflux for 3 hours and allowed to cool to
room temperature and diluted with water (500 mL). The mixture was acidified
with HCl solution (1M) and extracted with DCM (3 x 100 mL). The extracts
were washed with brine (150 mL), dried over anhydrous MgSO4 and concentrated
under reduced pressure to give a crude brown oil with white crystals (2.53 g). The
crude material was purified by column chromatography (4% EtOAc in PS) to give
285 as a light yellow oil (2.45 g, 90% over two steps).
O
C8H17
O
285
1H NMR (CDCl3): δ 4.01 (t, J = 6.7 Hz, 2H), 2.40 (dd,
J = 8.5, 6.5 Hz, 2H), 2.19 (tt, J = 6.9, 2.4 Hz, 2H),
2.10 (tt, J = 7.0, 2.4 Hz, 2H), 1.81-1.74 (m, 2H), 1.67-
1.58 (m, 2H), 1.46-1.41 (m, 2H), 1.35-1.21 (m, 11H),
0.92 (t, J = 7.4 Hz, 3H), 0.87-0.84 (m, 3H). 13C NMR
(CDCl3): δ 173.5 (C), 81.3 (C), 78.9 (C), 66.0 (CH2), 33.3 (CH2), 32.0 (CH2),
29.33 (CH2), 29.24 (CH2), 29.20 (CH2), 29.0 (CH2), 24.5 (CH2), 22.8 (CH2), 22.1
(CH2), 18.8 (CH2), 18.4 (CH2), 14.2 (CH3), 10.5 (CH3). IR (ATR, cm-1) 2926,
2855, 1736, 1457, 1205, 1157, 1062, 723. HRMS (ESI) m/z C17H30O2 [M+H]+ =
209
267.2319, found = 267.2320.
Propyl Z -tetradec-5-enoate 287
NaBH4 (157 mg, 4.15 mmol, 1.1eqv) was added to a stirred solution of Ni(OAc)2.4H2O
(931 mg, 3.74 mmol, 1.0 eqv) in EtOH (25 mL) under a hydrogen atmosphere at
room temperature. After 20 min, freshly distilled ethylenediamine (1.08 mL, 16.2
mmol, 4.3 eqv) was added directly before the addition of the alkyne 285 (1.00
g, 3.78 mmol) in EtOH (5 mL). The hydrogen atmosphere was maintained for
90 min before the reaction mixture was diluted with Et2O (200 mL) and filtered
though a plug of silica. The residue was washed with Et2O (5 x 50 mL) and the
filtrate concentrated under reduced pressure to give a crude clear oil (1.02 g) that
was purified by column chromatography (30 - 50% DCM in PS) to yield 287 as
a colourless oil (495 mg, 49%).
O
O
C8H17
287
1H NMR (CDCl3): δ 5.43-5.37 (m, 1H), 5.35-5.29 (m,
1H), 4.03 (t, J = 6.7 Hz, 2H), 2.35-2.29 (m, 2H), 2.10-
2.04 (m, 2H), 2.01 (m, 2H), 1.72-1.59 (m, 4H), 1.34-
1.22 (m, 12H), 0.96-0.91 (m, 3H), 0.88 (t, J = 6.9 Hz,
3H). 13C NMR (CDCl3): δ 174.0 (C), 131.3 (CH), 128.5
(CH), 66.0 (CH2), 33.9 (CH2), 32.0 (CH2), 29.86 (CH2), 29.67 (CH2), 29.48 (CH2),
29.45 (CH2), 27.4 (CH2), 26.7 (CH2), 25.1 (CH2), 22.8 (CH2), 22.2 (CH2), 14.2
(CH3), 10.5 (CH3). IR (ATR, cm-1) 3006, 2956, 2924, 1737, 1458, 1458, 1238,
1156, 1063, 722. HRMS (ESI) m/z C17H32O2 [M+H]+ = 269.2475, found =
269.2479.
Z -3-Oxohexadec-7-enenitrile
A solution of anhydrous acetonitrile (200 μl, 3.83 mmol, 2.6 eqv) in THF (0.3
mL) was added dropwise to a solution of n-BuLi (2.2 mL, 3.52 mmol, 2.4 eqv)
in THF (2 mL) at -84°C and stirred for 30 min. A solution of the ester 287 (400
mg, 1.49 mmol) in THF (1 mL) was added dropwise and stirred for 45 min before
addition of sat. NH4Cl (3 mL). The reaction mixture was allowed to warm to
room temperature and diluted with EtOAc (50 mL). The mixture was washed
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with water (50 mL), HCl (1M, 50 mL) and brine (50 mL). The solution was dried
over anhydrous MgSO4 and concentrated under reduced pressure to give a yellow
solid (525 mg) that was purified by column chromatography (15 - 20 % EtOAc
in PS) to give 288 as a yellow oil (220 mg, 59%).
O
CN
C8H17
288
1H NMR (CDCl3): δ 5.43 (dtt, J = 10.8, 7.3, 1.6 Hz,
1H), 5.28 (dtt, J = 10.8, 7.3, 1.6 Hz, 1H), 3.43 (s,
2H), 2.64 (t, J = 7.3 Hz, 2H), 2.10 (m, 2H), 2.04-1.99
(m, 2H), 1.72 (m, 2H), 1.37-1.26 (m, 12H), 0.92-0.89
(m, 3H). 13C NMR (CDCl3): δ 197.5 (C), 131.9 (CH),
127.9 (CH), 113.9 (C), 41.6 (CH2), 32.11 (CH2), 32.03 (CH2), 29.82 (CH2), 29.65
(CH2), 29.46 (CH2), 29.44 (CH2), 27.4 (CH2), 26.3 (CH2), 23.4 (CH2), 22.8 (CH2),
14.2 (CH3). IR (ATR, cm-1) 3007, 2923, 2853, 2263, 1730, 1457, 1403, 1374, 1306,
1087, 722. HRMS (ESI) m/z C16H27NO [M+H]+ = 250.2165, found = 250.2166.
Z -1-Aminohexadec-7-en-3-ol
A solution of the ketonitrile 288 (124 mg, 0.497 mmol) in THF (2 mL) was added
to a stirred suspension of LiAlH4 (65 mg, 1.73, 3.5 eqv) in THF (1 mL) at 0°C.
The solution was allowed to warm to room temperature for 3 hours. The reaction
mixture was cooled in a ice bath and Sat. NH4Cl (1 mL) added dropwise. The
pH was adjusted to > 7 with Sat. Na2CO3 solution and the reaction mixture
was concentrated to dryness under reduced pressure. The reaction mixture was
triturated with CHCl3, filtered though celite and the filtrate concentrated under
reduced pressure to give a crude yellow oil (85 mg) that was purified by column
chromatography (10:1:89 MeOH:NH3(aq):CHCl3) to give 263 as a yellow oil (35
mg, 28%).
OH
NH2
C8H17
263
1H NMR (CDCl3): δ 5.39-5.31 (m, 2H), 3.83-3.77 (m,
1H), 3.16-3.11 (m, 1H), 2.91-2.82 (m, 1H), 2.91-2.64
(m, 4H), 2.09-1.96 (m, 4H), 1.65-1.17 (m, 17H), 0.91-
0.83 (m, 3H). 13C NMR (CDCl3): δ 130.3 (CH), 129.7
(CH), 72.9 (CH), 40.7 (CH2), 37.6 (CH2), 37.3 (CH2),
211
32.0 (CH2), 29.9 (CH2), 29.67 (CH2), 29.48 (CH2), 29.45 (CH2), 27.40 (CH2),
27.36 (CH2), 25.9 (CH2), 22.8 (CH2), 14.2 (CH3). IR (ATR, cm-1) 3352, 3329,
3290, 3005, 2922, 2853, 1567, 1458, 1320, 1077, 940, 821, 721. HRMS (ESI) m/z
C16H33NO [M+H]+ = 256.2635, found = 256.2633.
6.4.2 Chain analogues; C6 Phenoxy chain
1-Bromo-4-butoxybenzene 295
A suspension of 1-bromobutane (10 mL, 93.1 mmol), p-bromophenol (11.43 g,
66.06 mmol) and K2CO3 (10.82 g, 78.4 mmol) in acetone (125 mL) was heated
under reflux for 40 hours. The reaction mixture was allowed to cool to room
temperature, filtered and the filtrate concentrated under reduced pressure. The
resulting residue was purified by vacuum distillation (approx 25 mm Hg) to give
295 as a light yellow oil (11.5 g, 76 %). The NMR spectra match those repor-
ted.173
O
Br
295
1H NMR (CDCl3): δ 7.36 (ad, J = 9.1 Hz, 2H), 6.78
(ad, J = 9.1 Hz, 2H), 3.92 (t, J = 6.5 Hz, 2H), 1.76
(m, 2H), 1.49 (m, 2H), 0.98 (t, J = 7.4 Hz, 3H). 13C
NMR (CDCl3): δ 158.4, 132.3, 116.4, 112.7, 68.1, 31.4,
19.3, 14.0. IR (ATR, cm-1): 2958, 2933, 2872, 1590, 1577, 1487, 1473, 1284, 1240,
1170, 1070, 1001, 971, 818.
5-(4-Butoxyphenyl)pent-4-yn-1-ol 292
A mixture of the bromide 295 (2.504 g, 10.9 mmol), pent-4-yn-1-ol (2.808 g, 33.3
mmol, 3.1 eq), PdCl2(PPh3)2(383 mg, 0.539 mmol, 4.9 mol%), CuI (208 mg, 1.09
mmol, 10 mol%) and PPh3 (290 mg, 1.105 mmol, 10 mol%) in 1:4 NEt3:THF (70
mL) was heated under reflux for 15 hours under N2. The black reaction mixture
was allowed to cool and concentrated under reduced pressure. The residue was
dispersed in DCM (150 mL), filtered and the filtrate washed with hydrochloric
acid (1M, 4 x 100 mL) and brine (1 x 100 mL). The organic phase was dried
over anhydrous K2CO3 and concentrated under reduced pressure to give a crude
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yellow oil (3.3 g) which was purified by column chromatography (20% EtOAc
in PS) to give 292 as a golden oil (1.41 g, 56%) that contained a small PPh3
impurity.
O
OH
292
1H NMR (CDCl3): δ 7.32-7.29 (m, 2H), 6.81-
6.78 (m, 2H), 3.94 (t, J = 6.5 Hz, 2H), 3.83-
3.80 (m, 2H), 2.52 (m, 2H), 1.88-1.81 (m, 2H),
1.79-1.72 (m, 2H), 1.64 (s, 1H), 1.48 (m, 2H),
0.97 (t, J = 7.4 Hz, 3H). 13C NMR (CDCl3):
δ 158.9 (C), 133.0 (CH), 115.7 (C), 114.5 (CH), 87.7 (C), 81.1 (C), 67.8 (CH2),
62.1 (CH2), 31.6 (CH2), 31.4 (CH2), 19.4 (CH2), 16.2 (CH2), 14.0 (CH3). IR
(ATR, cm-1)3441, 3387, 2960, 2907, 2873, 2932, 1604, 1508, 1472, 1285, 1242,
1174, 1041, 1008, 922, 828. HRMS (ESI) m/z C15H20O2 [M+H]+ = 233.1536,
found 233.1527.
5-(4-Butoxyphenyl)pentan-1-ol 297
The alkyne 292 (1.39 g, 0.598 mmol) was dissolved in EtOAc (3 mL) and a
nitrogen atmosphere introduced (x 3). Pd/C (150 mg, 5%) was added and a
hydrogen atmosphere was introduced (x 3) stirred overnight at room temperature.
A nitrogen atmosphere was introduced and the reaction mixture filtered. The
filtrate was concentrated under reduced pressure to give 297 as a golden oil (1.25
g, 88%) that did not require further purification.
O
OH
297
1H NMR (CDCl3): δ 7.09-7.05 (m, 2H), 6.87-
6.80 (m, 2H), 3.95-3.92 (m, 2H), 3.65-3.62 (m,
2H), 2.56 (t, J = 7.6 Hz, 2H), 1.79-1.70 (m,
3H), 1.66-1.56 (m, 4H), 1.53-1.44 (m, 2H),
1.43-1.35 (m, 2H), 0.99-0.95 (m, 3H). 13C NMR (CDCl3): δ 157.4 (C), 134.6
(C), 129.3 (CH), 114.5 (CH), 67.8 (C), 63.1 (C), 35.1 (C), 32.8 (CH2), 31.62
(CH2), 31.56 (CH2), 25.5 (CH2), 19.4 (CH2), 14.0 (CH3). IR (ATR, cm-1) 3326,
2931, 2859, 1611, 1510, 1464, 1241, 1175, 1068, 1042, 974, 827, 699. HRMS (ESI)
m/z C15H24O2 [M+H]+ = 237.1849, found = 237.1839.
213
5-(4-Butoxyphenyl)pentanal 293
A solution of anhydrous DMSO (800 µl) in DCM (2 mL) was added dropwise
to a stirred solution of oxalyl chloride (450 µl, 5.35 mmol) in anhydrous DCM
(4 mL) at -84°C. The reaction mixture was held at this temperature for 20 min
before the dropwise addition of a solution of the alcohol 297 (1.01 g, 4.28 mmol)
in anhydrous DCM (2 mL). The reaction mixture required addition of anhydrous
DCM (5 mL) to ensure fluidity. The reaction mixture was stirred for a further 20
min at -84°C before the addition of triethylamine (3 mL). The reaction mixture
was left to progressively warm to room temperature and left for 30 min before
dilution with DCM (100 mL). The reaction mixture was washed with water (100
mL), hydrochloric acid (2 x 100 mL, 1M) and brine (1 x 100 mL) and dried over
anhydrous K2CO3. The filtrate was concentrated under reduced pressure and
the resulting yellow oil (933 mg) was subjected to column chromatography (5%
EtOAc in PS) to give the aldehyde 293 as a golden oil (668 mg, 67%).
O
O
293
1H NMR (CDCl3): δ 9.75 (t, J = 1.8 Hz, 1H),
7.08-7.05 (m, 2H), 6.84-6.80 (m, 2H), 3.94 (t,
J = 6.5 Hz, 2H), 2.58 (t, J = 7.1 Hz, 2H),
2.44 (m, 2H), 1.79-1.72 (m, 2H), 1.69-1.61 (m,
4H), 1.54-1.45 (m, 2H), 0.98 (t, J = 7.4 Hz, 3H). 13C NMR (CDCl3): δ 202.6
(CH), 157.5 (C), 133.9 (C), 129.3 (CH), 114.5 (CH), 67.8 (CH2), 43.9 (CH2), 34.8
(CH2), 31.5 (CH2), 31.2 (CH2), 21.7 (CH2), 19.4 (CH2), 14.0 (CH3). IR (ATR,
cm-1)2932, 2867, 1724, 1611, 1510, 1390, 1241, 1176, 827. HRMS (ESI) m/z
C15H22O2 [M-H]+ = 233.1547, found 233.1526.
5-(4-Butoxyphenyl)pentanoic acid 303
A solution of the aldehyde 293 (1.24 g, 5.29 mmol) and 2-methyl-2-butene (7.51
g, 107 mmol, 20 eqv) in 1:1 t-BuOH:THF (30 mL) was stirred with a solution of
sodium dihydrogen phosphate (7.07 g, 58.9 mmol, 11 eqv) and sodium chlorite
(1.47 g, 16.2 mmol, 3 eqv) in water (40 mL) overnight in a ice bath. The reaction
mixture was diluted with hydrochloric acid (250 mL, 1M) and extracted with
EtOAc (5 x 50 mL). The extracts were washed with sodium metabisulfite solution
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(50 mL, 1%) and brine (50 mL) and dried over anhydrous MgSO4. The filtrate
was concentrated under reduced pressure to give 303 as brown crystalline solid
(1.40 g, >100%) that was used in the following step without purification.
O
O
OH
303
1H NMR (CDCl3): δ 7.12-7.08 (m, 2H), 6.87-
6.83 (m, 2H), 3.97 (t, J = 6.5 Hz, 2H), 2.60
(t, J = 7.1 Hz, 2H), 2.39 (t, J = 7.1 Hz, 2H),
1.82-1.75 (m, 2H), 1.73-1.65 (m, 4H), 1.52-
1.47 (m, 1H), 1.35-1.30 (m, 2H), 1.03-0.99 (m, 3H). 13C NMR: δ 179.6 (C), 157.4
(C), 134.0 (C), 129.3 (CH), 114.5 (CH), 67.8 (CH2), 34.7 (CH2), 34.0 (CH2), 31.5
(CH2), 31.1 (CH2), 24.4 (CH2), 19.4 (CH2), 14.0 (CH3).
Propyl 5-(4-butoxyphenyl)pentanoate 302
A mixture of crude acid 303 (1.40 g, 5.59 mmol), 1-bromopropane (1.1 mL, 1.5
g, 12.1 mmol, 2 eqv), TBAI (215 mg, 0.582 mmol, 10 mol%) and K2CO3 (3.88
g, 28.0 mmol) in acetone (10 mL) was heated at reflux for 3 hours and then
allowed to cool to room temperature. The reaction mixture was concentrated
under reduced pressure and diluted with HCl (1M, until pH < 1) and extracted
with EtOAc (4 x 25 mL). The organic phase was washed with brine (50 mL),
dried over anhydrous MgSO4 and concentrated. The crude yellow oil (1.64 g)
was purified by column chromatography (5% EtOAc in PS) to give 302 as a clear
oil (1.23 g, 83% over 2-Steps)
O
O
O
302
1H NMR (CDCl3): δ 7.08-7.06 (m,
2H), 6.83-6.81 (m, 2H), 4.03 (m, 2H),
3.94 (t, J = 6.5 Hz, 2H), 2.57 (t, J =
7.2 Hz, 2H), 2.33 (dd, J = 9.3, 5.1 Hz,
2H), 1.79-1.72 (m, 2H), 1.69-1.60 (m, 6H), 1.52-1.46 (m, 2H), 0.98 (t, J = 7.2 Hz,
3H), 0.94 (t, J = 7.2 Hz, 3H). 13C NMR (CDCl3): δ 173.9 (C), 157.4 (C), 134.1
(C), 129.3 (CH), 114.5 (CH), 67.8 (CH2), 66.0 (CH2), 34.8 (CH2), 34.3 (CH2),
31.5 (CH2), 31.3 (CH2), 24.7 (CH2), 22.1 (CH2), 19.4 (CH2), 14.0 (CH3), 10.5
(CH3). IR (ATR, cm-1) 2960, 2934, 2873, 1733, 1612, 1511, 1463, 1511, 1463,
1241, 1175, 1067, 826. HRMS (ESI) m/z C18H28O3[M+H]+ = 293.2111, found
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= 293.2110.
7-(4-Butoxyphenyl)-3-oxoheptanenitrile 304
A solution of freshly distilled acetonitrile (270 μl, 212 mg, 5.17 mmol, 2.5 eqv) in
THF (3 mL) was added dropwise to a stirred solution of n-BuLi (3.0 mL, 1.6 M,
4.8 mmol, 2.3 eqv) in THF (5 mL) at -84°C. The reaction mixture was stirred at
this temperature for 30 min before dropwise addition of a solution of the ester
302 (604 mg, 2.06 mmol) in THF (3 mL). The reaction mixture was stirred at
-84°C for 10 min before addition of sat. NH4Cl solution. The reaction mixture
was allowed to warm to room temperature and diluted with HCl (1M, 30 mL).
The reaction mixture was extracted with DCM (3 x 30 mL) and the combined
extracts were washed with brine and dried over anhydrous MgSO4. The filtrate
was concentrated under reduced pressure to give a crude yellow oil (557 mg) that
was purified by column chromatography (15 - 20 % EtOAc in PS) to give 304 as
a white waxy solid (321 mg, 57%).
O
O
CN
304
Melting point: 63°C. 1H NMR (CDCl3): δ
7.08-7.04 (m, 2H), 6.84-6.80 (m, 2H), 3.94
(t, J = 6.5 Hz, 2H), 3.40 (s, 2H), 2.63-2.55
(m, 4H), 1.79-1.72 (m, 2H), 1.68-1.58 (m,
4H), 1.49 (m, 2H), 0.99-0.96 (m, 3H). 13C NMR (CDCl3): δ 197.5 (C), 157.5
(C), 133.7 (C), 129.3 (CH), 114.5 (CH), 113.9 (C) 67.8 (CH2), 42.1 (CH2), 34.7
(CH2), 32.0 (CH2), 31.5 (CH2), 30.8 (CH2), 22.9 (CH2), 19.3 (CH2), 13.9 (CH3).
IR (ATR, cm-1) 2936, 2871, 2261, 1711, 1611, 1510, 1239, 1176, 1037, 1007, 824,
817. HRMS (ESI) m/z C17H23NO2 [M+H]+ = 274.1802, found = 274.1797.
1-Amino-7-(4-butoxyphenyl)heptan-3-ol 120
A solution of the ketonitrile 304 (266 mg, 0.972 mmol) in THF (2 mL) was added
dropwise to a suspension of LiAlH4 (100 mg, 2.66 mmol) in THF (2 mL) in a ice
bath. The reaction mixture was left in the ice bath to warm to room temperature
over 3 hours. The reaction mixture was cooled to 0°C before addition of sat NH4Cl
solution, followed by 1M HCl. A solution of sat. Na2CO3 was added until pH >7
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and extracted with EtOAc (4 x 25 mL). The extracts were washed with brine,
dried over anhydrous MgSO4 and concentrated to give a yellow crude (252 mg)
that was purified by column chromatography (10:1:89 MeOH:NH3(aq):CHCl3) to
give 120 as a colourless power (20 mg, 12%).
O
OH
NH2
120
Melting point: 81°C. 1H NMR
(CDCl3): δ 7.07 (d, J = 8.4 Hz, 2H),
6.80 (d, J = 8.5 Hz, 2H), 3.93 (t, J =
6.5 Hz, 2H), 3.83-3.77 (m, 1H), 3.16-
3.10 (m, 1H), 2.87-2.80 (m, 1H), 2.55 (t, J = 7.7 Hz, 2H), 1.75 (m, 2H), 1.69-1.55
(m, 5H), 1.54-1.32 (m, 8H), 0.97 (t, J = 7.4 Hz, 3H). 13C NMR (CDCl3): δ 157.3
(C), 134.8 (C), 129.3 (CH), 114.4 (CH), 73.5 (CH), 67.8 (CH2), 41.2 (CH2), 37.9
(CH2), 37.7 (CH2), 35.2 (CH2), 32.0 (CH2), 31.6 (CH2), 25.4 (CH2), 19.4 (CH2),
14.0 (CH3). IR (ATR, cm-1) 3361, 3276, 2956, 2923, 2871, 1612, 1510, 1475, 1243,
1177, 1069, 1026, 970, 809. HRMS (ESI) m/z C17H29NO2 [M+H]+ = 280.2271,
found = 280.2275.
6.5 Biology
The assays were conducted by Prof. Sumalee Kamchonwongpaisan at the Na-
tional Centre for Genetic Engineering and Biotechnology, Thailand.
Trypanosome culture and testing compounds in vitro
Trypanosome brucei rhodesiense (STB900) was maintained continuously in MEM/EBSS
medium supplemented with 3 g/l Sodium bicarbonate, 4.5 g/l glucose, 25 mM
HEPES, pH 7.3, 0.05 mM bathocuproinedisulphonic acid disodium salt, 1.5 mM
L-cysteine, 1 mM hypoxanthine, 0.16 mM thymidine, 1 mM sodium pyruvate,
0.2 mM 2-mercaptoethanol, 1% MEM non-essential amino acid, and 15% heated
fetal bovine serum, in a 5% CO2 incubator. To assay anti-Tbr activity, a mod-
ified reported protocol was used.180 Briefly, 2 x 104 Trypanasome cells in 175 μl
culture media /well were incubated with 25 μl of varying concentrations of each
compound in a 96-well plate under the same culture condition. The compounds
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were dissolved in DMSO and the final concentration of DMSO in each well was
0.1% which causes no effect on parasite viability. Following 72-hour incubation,
20 µl Alamar Blue (a resazurin solution) was added in each well. The reaction
was further incubated at 37°C, 5% CO2 for 3 hours to allow irreversible reduction
of resazurin (violet colour) to resorufin (pink color) by viable trypanosome cells.
The fluorescence signals were measured by spectrofluorometer at ex530/em585
nm. The results were read as concentration of each compound that exhibit 50%
growth inhibition (IC50) from the dose-response curve established from the fluor-
escence signals at each concentration of compounds.
Parasite Culture and Antimalarial Testing in Vitro.
Two P. falciparum strains, TM4/8.2 (wild-type drug sensitive strain) and K1CB1
(multidrug resistant strain) were used in this study, these were generous gifts
from S. Thaithong, Department of Biology, Faculty of Science, Chulalongkorn
University. The parasites were maintained continuously in human erythrocytes
at 37°C under 3% CO2 in RPMI 1640 culture media (Gibco, USA) supplemented
with 25 mM HEPES (Sigma), pH 7.4, 2 g/L NaHCO3 and 10% human serum.
In vitro antimalarial activity was determined by using the [3H] hypoxanthine
incorporation method. 1.5% cell suspension of parasitized erythrocytes with 1%
parasitemia (200 µL) in each well was incubated with varying concentration of
compound (25 µL) under the same culture conditions for 24 h. Parasite survival
was determined by [3H] hypoxanthine incorporation assay. Briefly, 25 µL of
0.5 µCi [3H] hypoxanthine was added to each well, and the mixture was further
incubated for 18-20 h. Then the cells were lysed with water and the parasite DNA
was harvested onto 96-well microplates with built-in glass fiber filters (Unifilter
TM plates, Packard, USA). The filters in the plates were air-dried, and then 22 µL
of liquid scintillation fluid (Microscint, Packard) was added. The radioactivity on
the filters was then measured using microplate scintillation counter (TopCount,
Packard, USA). The IC50 of each compound was determined from dose-response
curve.181
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Cytotoxicity testing by sulforhodamine B (SRB) colorimetric assay.
African green monkey kidney fibroblast (VERO cells) and human epidermoid car-
cinoma (KB) cells were obtained from the bioassay laboratory, BIOTEC, NSTDA.
Vero cells were maintained continuously in MEM/EBSS medium supplemented
with 10% heated fetal bovine serum, 2.2 g/l Sodium bicarbonate, and 100 mM
sodium pyruvate. KB cells were maintained continuously in DMEM/low gluc-
ose medium supplemented with 10% heated fetal bovine serum, 3.7 g/l Sodium
bicarbonate, and 1%. Non-essential amino acid. Cytotoxicity was determined
by sulforhodamine B (SRB) assay. Briefly, 1.9 x 104 cells were incubated with
test compounds at 37°C, 5% CO2 for 72 hours. Then, the cells were fixed with
10% trichloroacetic acid at 4◦C for 45 minute, washed with water and dried at
room temperature overnight. Then the plate was stained with 0.057% (W/V)
sulforhodamine B, washed 4 times with 1% (V/V) acetic acid, and left dry at
room temperature overnight. Finally, 10X Tris-base was added to each well to
dissolve protein-bound dye. The optical density was determined by spectropho-
tometer at wavelength 510 nm. The IC50 value of each compound was determined
from the dose-response curve.182
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Figure A.1: 400 MHz 1H NMR of 111 in CDCl3
235
ppm 050100150
29.530.0
C13H27 O
O
111
Figure A.2: 100 MHz 13C NMR 111 in CDCl3
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Figure A.3: 400 MHz 1H NMR of 124 in CDCl3
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Figure A.4: 100 MHz 13C NMR of 124 in CDCl3
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Figure A.5: 400 MHz 1H NMR of 312 in CDCl3
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Figure A.6: 100 MHz 13C NMR of 312 in CDCl3
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Figure A.7: 400 MHz 1H NMR of 125 in CDCl3
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Figure A.8: 100 MHz 13C NMR of 125 in CDCl3
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Figure A.9: 400 MHz 1H NMR of 130 in CDCl3
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Figure A.10: 100 MHz 13C NMR of 130 in CDCl3
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Figure A.11: 400 MHz 1H NMR of 132 in CDCl3
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Figure A.12: 100 MHz 13C NMR of 132 in CDCl3
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Figure A.13: 400 MHz 1H NMR of 138 in CDCl3
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Figure A.14: 100 MHz 13C NMR 138 in CDCl3
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Figure A.15: 400 MHz 1H NMR of 133 in CDCl3
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Figure A.16: 100 MHz 13C NMR of 133 in CDCl3
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Figure A.17: 400 MHz 1H NMR of 143 in CDCl3
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Figure A.18: 100 MHz 13C NMR of 143 in CDCl3
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Figure A.19: 400 MHz 1H NMR of 144 in CDCl3
253
ppm 050100150200
130140150160170
29.530.0
O N
O
N
O
C13H27
144
Figure A.20: 100 MHz 13C NMR of 144 in CDCl3
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Figure A.21: 400 MHz 1H NMR of 148 in CDCl3
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Figure A.22: 100 MHz 13C NMR of 148 in CDCl3
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Figure A.23: 400 MHz 1H NMR of 108 in CDCl3
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Figure A.24: 100 MHz 13C NMR of 108 in CDCl3
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Figure A.25: 400 MHz 1H NMR of 149 in CDCl3
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Figure A.26: 100 MHz 13C NMR of 149 in CDCl3
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Figure A.27: 400 MHz 1H NMR of 150 in CDCl3
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Figure A.28: 100 MHz 13C NMR of 150 in CDCl3
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Figure A.29: 400 MHz 1H NMR of 113 in CDCl3
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Figure A.30: 100 MHz 13C NMR of 113 in CDCl3
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Figure A.31: 400 MHz 1H NMR of 112 in CDCl3
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Figure A.32: 100 MHz 13C NMR of 112 in CDCl3
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Figure A.33: 400 MHz 1H NMR of 155 in CDCl3
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Figure A.34: 100 MHz 13C NMR of 155 in CDCl3
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Figure A.35: 400 MHz 1H NMR of 153 in C6D6
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Figure A.36: 100 MHz 13C NMR of 153 in C6D6
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Figure A.37: 400 MHz 1H NMR of 158 in C6D6
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Figure A.38: 100 MHz 13C NMR of 158 in C6D6
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Figure A.39: 400 MHz 1H NMR of 159 in C6D6
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Figure A.40: 100 MHz 13C NMR of 159 in C6D6
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Figure A.41: 400 MHz 1H NMR of 159 in C6D6
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Figure A.42: 100 MHz 13C NMR of 159 in C6D6
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Figure A.43: 400 MHz 1H NMR of 114 in C6D6
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Figure A.44: 100 MHz 13C of 114 NMR in C6D6
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Figure A.45: 400 MHz 1H NMR of 161 in CDCl3
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Figure A.46: 100 MHz 13C NMR of 161 in CDCl3
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Figure A.47: 400 MHz 1H NMR of 164 in
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Figure A.48: 100 MHz 13C of 164 NMR in
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Figure A.49: 400 MHz 1H NMR of 162 in
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Figure A.50: 100 MHz 13C of 162 NMR in
284
2.94
23.7
0.964
1.99
1
ppm 0246810
0.964
1.99
1
2.53.03.54.0
C13H27
OH
CN
166
Figure A.51: 400 MHz 1H NMR of 166 in CDCl3
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Figure A.52: 100 MHz 13C NMR of 166 in CDCl3
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Figure A.53: 400 MHz 1H NMR of 168 in CDCl3
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Figure A.54: 100 MHz 13C NMR of 168 in CDCl3
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Figure A.55: 400 MHz 1H NMR of 167 in CDCl3
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Figure A.56: 100 MHz 13C NMR of 167 in CDCl3
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Figure A.57: 400 MHz 1H NMR of 181 in CDCl3
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Figure A.58: 100 MHz 13C NMR of 181 in CDCl3
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Figure A.59: 400 MHz 1H NMR of 189 in CDCl3
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Figure A.60: 100 MHz 13C NMR of 189 in CDCl3
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Figure A.61: 400 MHz 1H NMR of 175 in CDCl3
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Figure A.62: 100 MHz 13C NMR 175 in CDCl3
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Figure A.63: 400 MHz 1H NMR of 191 in CDCl3
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Figure A.64: 100 MHz 13C NMR of 191 in CDCl3
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Figure A.65: 400 MHz 1H NMR of 193 in CDCl3
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Figure A.66: 100 MHz 13C NMR of 193 in CDCl3
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Figure A.67: 400 MHz 1H NMR of 194 in CDCl3
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Figure A.68: 100 MHz 13C NMR of 194 in CDCl3
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Figure A.69: 400 MHz 1H NMR of 190 in CDCl3
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Figure A.70: 100 MHz 13C NMR of 190 in CDCl3
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Figure A.71: 400 MHz 1H NMR of 196 in CDCl3
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Figure A.72: 100 MHz 13C NMR of 196 in CDCl3
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Figure A.73: 400 MHz 1H NMR of 204 in CDCl3
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Figure A.74: 100 MHz 13C NMR of 204 in CDCl3
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Figure A.75: 400 MHz 1H NMR of 201 in CDCl3
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Figure A.76: 100 MHz 13C NMR 201 in CDCl3
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Figure A.77: 400 MHz 1H NMR of 205 in CDCl3
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Figure A.78: 100 MHz 13C NMR of 205 in CDCl3
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Figure A.79: 400 MHz 1H NMR of 208 in CDCl3
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Figure A.80: 100 MHz 13C NMR of 208 in CDCl3
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Figure A.81: 400 MHz 1H NMR of 199 in CDCl3
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Figure A.82: 100 MHz 13C NMR of 199 in CDCl3
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Figure A.83: 400 MHz 1H NMR of 209 in CDCl3
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Figure A.84: 100 MHz 13C NMR 209 in CDCl3
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Figure A.85: 400 MHz 1H NMR of 308 and 309 in CDCl3
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Figure A.86: 100 MHz 13C NMR of 308 and 309 in CDCl3
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Figure A.87: 400 MHz 1H NMR of 212 in CDCl3
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Figure A.88: 100 MHz 13C NMR of 212 in CDCl3
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Figure A.89: 400 MHz 1H NMR of 214 in CDCl3
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Figure A.90: 100 MHz 13C NMR of 214 in CDCl3
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Figure A.91: 400 MHz 1H NMR of 210 in CDCl3
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Figure A.92: 100 MHz 13C NMR of 210 in CDCl3
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Figure A.93: 400 MHz 1H NMR of 221 in CDCl3
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Figure A.94: 100 MHz 13C NMR 221 in CDCl3
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Figure A.95: 400 MHz 1H NMR of 222 in CDCl3
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Figure A.96: 100 MHz 13C NMR of 222 in CDCl3
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Figure A.97: 400 MHz 1H NMR of 206 in CDCl3
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Figure A.98: 100 MHz 13C NMR 206 in CDCl3
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Figure A.99: 400 MHz 1H NMR of 207 in CDCl3
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Figure A.100: 100 MHz 13C NMR of 207 in CDCl3
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Figure A.101: 400 MHz 1H NMR of 223 in CDCl3
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Figure A.102: 100 MHz 13C NMR of 223 in CDCl3
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Figure A.103: 400 MHz 1H NMR of 224 in CDCl3
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Figure A.104: 100 MHz 13C NMR of 224 in CDCl3
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Figure A.105: 400 MHz 1H NMR of 229 in CDCl3
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Figure A.106: 100 MHz 13C NMR of 229 in CDCl3
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Figure A.107: 400 MHz 1H NMR of 235 in C6D66
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Figure A.108: 100 MHz 13C NMR of 235 in C6D66
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Figure A.109: 400 MHz 1H NMR of 239 in CDCl3
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Figure A.110: 100 MHz 13C NMR of 239 in CDCl3
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Figure A.111: 400 MHz 1H NMR of 98 in CDCl3
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Figure A.112: 100 MHz 13C NMR of 98 in CDCl3
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Figure A.113: 400 MHz 1H NMR of 240 in CDCl3
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Figure A.114: 100 MHz 13C NMR of 240 in CDCl3
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Figure A.115: 400 MHz 1H NMR of 96 in CDCl3
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Figure A.116: 100 MHz 13C NMR of 96 in CDCl3
350
6.36
1.04
3.2
1.09
2.17
2.14
1.06
ppm 0246810
3.2
1.09
2.17
2.14
7.27.47.6
N
O
238
Figure A.117: 400 MHz 1H NMR 238 in CDCl3
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Figure A.118: 100 MHz 13C NMR of 238 in CDCl3
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Figure A.119: 400 MHz 1H NMR of 241 in CDCl3
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Figure A.120: 100 MHz 13C NMR of 241 in CDCl3
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Figure A.121: 400 MHz 1H NMR of 237 in CDCl3
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Figure A.122: 100 MHz 13C NMR of 237 in CDCl3
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Figure A.123: 400 MHz 1H NMR of 247 in CDCl3
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Figure A.124: 100 MHz 13C NMR of 247 in CDCl3
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Figure A.125: 400 MHz 1H NMR of 249 in CDCl3
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Figure A.126: 100 MHz 13C NMR of 249 in CDCl3
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Figure A.127: 400 MHz 1H NMR of 116 in CDCl3
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Figure A.128: 100 MHz 13C NMR 116 in CDCl3
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Figure A.129: 400 MHz 1H NMR of 100 in CDCl3
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Figure A.130: 100 MHz 13C NMR of 100 in CDCl3
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Figure A.131: 400 MHz 1H NMR of 251 in CDCl3
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Figure A.132: 100 MHz 13C NMR of 251 in CDCl3
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Figure A.133: 400 MHz 1H NMR of 250 in C6D66
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Figure A.134: 100 MHz 13C NMR of 250in C6D66
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Figure A.135: 400 MHz 1H NMR of 117 in C6D5CD3
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Figure A.136: 100 MHz 13C NMR 117 in C6D5CD3
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Figure A.137: 100 MHz 1H NMR in CDCl3 of 270
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Figure A.138: 100 MHz 13C NMR in CDCl3 of 270
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Figure A.139: 100 MHz 1H NMR in CDCl3 of 267
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Figure A.140: 100 MHz 13C NMR in CDCl3 of 267
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Figure A.141: 400 MHz 1H NMR in CDCl3 of 271
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Figure A.142: 100 MHz 13C NMR in CDCl3 of 271
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Figure A.143: 400 MHz 1H NMR in CDCl3 of 276
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Figure A.144: 100 MHz 13C NMR in CDCl3 of 276
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Figure A.145: 400 MHz 1H NMR in CDCl3 of 310
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Figure A.146: 100 MHz 13C NMR in CDCl3 of 310
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Figure A.147: 400 MHz 1H NMR in CDCl3 of crude 280
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Figure A.148: 100 MHz 13C NMR in CDCl3 of crude 280
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Figure A.149: 400 MHz 1H NMR in CDCl3 of 281
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Figure A.150: 100 MHz 13C NMR in CDCl3 of 281
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Figure A.151: 400 MHz 1H NMR in CDCl3 of 311
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Figure A.152: 100 MHz 13C NMR in CDCl3 of 311
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Figure A.153: 400 MHz 1H NMR in CDCl3 of 311
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Figure A.154: 100 MHz 13C NMR in CDCl3 of 311
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Figure A.155: 400 MHz 1H NMR in CDCl3 of 286
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Figure A.156: 100 MHz 13C NMR in CDCl3 of 286
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Figure A.157: 100 MHz 1H NMR in CDCl3 of 285
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Figure A.158: 100 MHz 1H NMR in CDCl3 of 285
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Figure A.159: 400 MHz 1H NMR in CDCl3 of 287
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Figure A.160: 100 MHz 13C NMR in CDCl3 of 287
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Figure A.161: 400 MHz 1H NMR in CDCl3 of 288
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Figure A.162: 100 MHz 13C NMR in CDCl3 of 288
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Figure A.163: 400 MHz 1H NMR in CDCl3 of 121
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Figure A.164: 100 MHz 13C NMR in CDCl3 of 121
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Figure A.165: 400 MHz 1H NMR spectra of 295 in CDCl3
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Figure A.166: 100 MHz 13C NMR spectra of 295 in CDCl3
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Figure A.167: 400 MHz 1H NMR spectra of 292 in CDCl3
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Figure A.168: 100 MHz 13C NMR spectra of 292 in CDCl3
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Figure A.169: 400 MHz 1H NMR spectra of 297 in CDCl3
403
ppm 050100150200
O
OH
297
Figure A.170: 100 MHz 13C NMR spectra of 297 in CDCl3
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Figure A.171: 400 MHz 1H NMR spectra of 293 in CDCl3
405
ppm 050100150200
30
x
x
x x
O
O
293
Figure A.172: 100 MHz 13C NMR spectra of 293 in CDCl3
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Figure A.173: 400 MHz 1H NMR spectra of 303 in CDCl3
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Figure A.174: 100 MHz 13C NMR spectra 303 in CDCl3
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Figure A.175: 400 MHz 1H NMR spectra of 302 in CDCl3
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Figure A.176: 100 MHz 13C NMR spectra 302 in CDCl3
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Figure A.177: 400 MHz 1H NMR spectra of 304 in CDCl3
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Figure A.178: 100 MHz 13C NMR spectra 304 in CDCl3
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Figure A.179: 400 MHz 1H NMR spectra of 120 in CDCl3
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Figure A.180: 100 MHz 13C NMR spectra 120 in CDCl3
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